Cancer Research and Treatment

Original Articles

Long-term Clinical Efficacy of Radiotherapy for Patients with Stage I-II Gastric Extranodal Marginal Zone B-Cell Lymphoma of Mucosa-Associated Lymphoid Tissue: A Retrospective Multi-institutional Study: Jae Uk Jeong, Hyo Chun Lee, Jin Ho Song, Keun Yong Eom, Jin Hee Kim, Yoo Kang Kwak, Woo Chul Kim, Sun Young Lee, Jin Hwa Choi, Kang Kyu Lee, Jong Hoon Lee; Received July 16, 2024 Accepted October 1, 2024 Published online October 4, 2024; DOI: https://doi.org/10.4143/crt.2024.651 [Epub ahead of print]

Abstract PDF Supplementary Material PubReader ePub: Purpose
This study aimed to evaluate long-term treatment outcomes in patients with localized gastric mucosa-associated lymphoid tissue (MALT) lymphoma treated with radiotherapy (RT).
Materials and Methods
A total of 229 patients who received RT in 10 tertiary hospitals between 2010 and 2019 were included in this multicenter analysis. Response after RT was based on esophagogastroduodenoscopy after RT. Locoregional relapse-free survival (LRFS) and disease-free survival (DFS), and overall survival (OS) were evaluated.
Results
After a median follow-up time of 93.2 months, 5-year LRFS, DFS, and OS rates were 92.8%, 90.4%, and 96.1%, respectively. LRFS, DFS, and OS rates at 10 years were 90.3%, 87.7%, and 92.8%, respectively. Of 229 patients, 228 patients (99.6%) achieved complete remission after RT. Five-year LRFS was significantly lower in patients with stage IIE than in those with stage IE (77.4% vs. 94.2%, p=0.047). Patients with age ≥ 60 had significantly lower LRFS than patients with age < 60 (89.3% vs. 95.1%, p=0.003). In the multivariate analysis, old age (≥ 60 years) was a poor prognostic factor for LRFS (hazard ratio, 3.72; confidence interval, 1.38 to 10.03; p=0.009). Grade 2 or higher gastritis was reported in 69 patients (30.1%). Secondary malignancies including gastric adenocarcinoma, malignant lymphoma, lung cancer, breast cancer, and prostate cancer were observed in 11 patients (4.8%) after RT.
Conclusion
Patients treated with RT for localized gastric MALT lymphoma showed favorable 10-year outcomes. Radiation therapy is an effective treatment without an increased risk of secondary cancer. The toxicity for RT to the stomach is not high.

660 View
62 Download

Breast cancer

Locoregional Recurrence in Adenoid Cystic Carcinoma of the Breast: A Retrospective, Multicenter Study (KROG 22-14): Sang Min Lee, Bum-Sup Jang, Won Park, Yong Bae Kim, Jin Ho Song, Jin Hee Kim, Tae Hyun Kim, In Ah Kim, Jong Hoon Lee, Sung-Ja Ahn, Kyubo Kim, Ah Ram Chang, Jeanny Kwon, Hae Jin Park, Kyung Hwan Shin; Cancer Res Treat. 2025;57(1):150-158. Published online July 12, 2024; DOI: https://doi.org/10.4143/crt.2024.201

Abstract PDF PubReader ePub: Purpose
This study aims to evaluate the treatment approaches and locoregional patterns for adenoid cystic carcinoma (ACC) in the breast, which is an uncommon malignant tumor with limited clinical data.
Materials and Methods
A total of 93 patients diagnosed with primary ACC in the breast between 1992 and 2022 were collected from multi-institutions. All patients underwent surgical resection, including breast-conserving surgery (BCS) or total mastectomy (TM). Recurrence patterns and locoregional recurrence-free survival (LRFS) were assessed.
Results
Seventy-five patients (80.7%) underwent BCS, and 71 of them (94.7%) received post-operative radiation therapy (PORT). Eighteen patients (19.3%) underwent TM, with five of them (27.8%) also receiving PORT. With a median follow-up of 50 months, the LRFS rate was 84.2% at 5 years. Local recurrence (LR) was observed in five patients (5.4%) and four cases (80%) of the LR occurred in the tumor bed. Three of LR (3/75, 4.0%) had a history of BCS and PORT, meanwhile, two of LR (2/18, 11.1%) had a history of mastectomy. Regional recurrence occurred in two patients (2.2%), and both cases had a history of PORT with (n=1) and without (n=1) irradiation of the regional lymph nodes. Partial breast irradiation (p=0.35), BCS (p=0.96) and PORT in BCS group (p=0.33) had no significant association with LRFS.
Conclusion
BCS followed by PORT was the predominant treatment approach for ACC of the breast and LR mostly occurred in the tumor bed. The findings of this study suggest that partial breast irradiation might be considered for PORT in primary breast ACC.

1,239 View
121 Download

Hematologic malignancy

Assessment of Bone Marrow Involvement in Extranodal NK/T-Cell Lymphoma: Positron Emission Tomography versus Bone Marrow Biopsy, and the Significance of Minimal Involvement by EBV+ Cells (KROG 18-09): Tae Hoon Lee, Hyun Ju Kim, Jong Hoon Lee, Jeongshim Lee, Jin Hee Kim, Dongryul Oh, Keun-Yong Eom; Cancer Res Treat. 2024;56(2):688-696. Published online December 11, 2023; DOI: https://doi.org/10.4143/crt.2023.1049

Abstract PDF PubReader ePub: Purpose
This study aims to investigate the diagnostic significance of positron emission tomography/computed tomography (PET/CT) in assessing bone marrow (BM) involvement through a comparison of PET/CT findings with BM biopsy in extranodal natural killer/T-cell lymphoma.
Materials and Methods
The medical records of 193 patients were retrospectively reviewed. Patients were categorized as having early-stage (PET-ES) or advanced-stage (PET-AS) disease based on PET/CT results. The BM involvement was classified into three groups according to BM biopsy: gross BM involvement, minimal BM involvement (defined as the presence of a limited number of Epstein-Barr virus–positive cells in BM), and no involvement. Calculations of the accuracy of PET/CT in detecting BM involvement and analysis of the clinical outcomes (progression-free survival [PFS] and overall survival [OS]) according to the BM biopsy status were performed.
Results
PET/CT exhibited a sensitivity of 64.7% and a specificity of 96.0% in detecting gross BM involvement. For detecting any (both gross and minimal) BM involvement, the sensitivity was 30.4%, while the specificity was 99.0%. Only one patient (0.7%) demonstrated gross BM involvement among the PET-ES group. Survival outcomes of the PET-ES group with minimal BM involvement (3-year PFS, 55.6%; OS, 77.0%) were closer to those of the PET-ES group with no BM involvement (3-year PFS, 62.2%; OS, 80.6%) than to those of the PET-AS group (3-year PFS, 20.1%; OS, 29.9%).
Conclusion
PET/CT exhibits high specificity, but moderate and low sensitivity in detecting gross and minimal BM involvement, respectively. The clinical significance of minimal BM involvement for patients in the PET-ES group may be limited.

2,829 View
112 Download

Gastrointestinal cancer

Risk Factors for Distant Metastasis in Extrahepatic Bile Duct Cancer after Curative Resection (KROG 1814): Younghee Park, Tae Hyun Kim, Kyubo Kim, Jeong Il Yu, Wonguen Jung, Jinsil Seong, Woo Chul Kim, Jin Hwa Choi, Ah Ram Chang, Bae Kwon Jeong, Byoung Hyuck Kim, Tae Gyu Kim, Jin Hee Kim, Hae Jin Park, Hyun Soo Shin, Jung Ho Im, Eui Kyu Chie; Cancer Res Treat. 2024;56(1):272-279. Published online July 31, 2023; DOI: https://doi.org/10.4143/crt.2023.616

Abstract PDF PubReader ePub: Purpose
Risk factors predicting distant metastasis (DM) in extrahepatic bile duct cancer (EHBDC) patients treated with curative resection were investigated.
Materials and Methods
Medical records of 1,418 EHBDC patients undergoing curative resection between Jan 2000 and Dec 2015 from 14 institutions were reviewed. After resection, 924 patients (67.6%) were surveilled without adjuvant therapy, 297 (21.7%) were treated with concurrent chemoradiotherapy (CCRT) and 148 (10.8%) with CCRT followed by chemotherapy. To exclude the treatment effect from innate confounders, patients not treated with adjuvant therapy were evaluated.
Results
After a median follow-up of 36.7 months (range, 2.7 to 213.2 months), the 5-year distant metastasis-free survival (DMFS) rate was 57.7%. On multivariate analysis, perihilar or diffuse tumor (hazard ratio [HR], 1.391; p=0.004), poorly differentiated histology (HR, 2.014; p < 0.001), presence of perineural invasion (HR, 1.768; p < 0.001), positive nodal metastasis (HR, 2.670; p < 0.001) and preoperative carbohydrate antigen (CA) 19-9 ≥ 37 U/mL (HR, 1.353; p < 0.001) were significantly associated with inferior DMFS. The DMFS rates significantly differed according to the number of these risk factors. For validation, patients who underwent adjuvant therapy were evaluated. In patients with ≥ 3 factors, additional chemotherapy after CCRT resulted in a superior DMFS compared with CCRT alone (5-year rate, 47.6% vs. 27.7%; p=0.001), but the benefit of additional chemotherapy was not observed in patients with 0-2 risk factors.
Conclusion
Tumor location, histologic differentiation, perineural invasion, lymph node metastasis, and preoperative CA 19-9 level predicted DM risk in resected EHBDC. These risk factors might help identifying a subset of patients who could benefit from additional chemotherapy after resection.

3,267 View
190 Download

Breast cancer

The Pattern of Care for Brain Metastasis from Breast Cancer over the Past 10 Years in Korea: A Multicenter Retrospective Study (KROG 16-12): Jae Sik Kim, Kyubo Kim, Wonguen Jung, Kyung Hwan Shin, Seock-Ah Im, Hee-Jun Kim, Yong Bae Kim, Jee Suk Chang, Jee Hyun Kim, Doo Ho Choi, Yeon Hee Park, Dae Yong Kim, Tae Hyun Kim, Byung Ock Choi, Sea-Won Lee, Suzy Kim, Jeanny Kwon, Ki Mun Kang, Woong-Ki Chung, Kyung Su Kim, Ji Ho Nam, Won Sup Yoon, Jin Hee Kim, Jihye Cha, Yoon Kyeong Oh, In Ah Kim; Cancer Res Treat. 2022;54(4):1121-1129. Published online December 31, 2021; DOI: https://doi.org/10.4143/crt.2021.1083

Abstract PDF Supplementary Material PubReader ePub

Purpose
We aimed to investigate manifestations and patterns of care for patients with brain metastasis (BM) from breast cancer (BC) and compared their overall survival (OS) from 2005 through 2014 in Korea.
Materials and Methods
We retrospectively reviewed 600 BC patients with BM diagnosed between 2005 and 2014. The median follow-up duration was 12.5 months. We categorized the patients into three groups according to the year when BM was initially diagnosed (group I [2005-2008], 98 patients; group II [2009-2011], 200 patients; and group III [2012-2014], 302 patients).
Results
Over time, the median age at BM diagnosis increased by 2.2 years (group I, 49.0 years; group II, 48.3 years; and group III, 51.2 years; p=0.008). The percentage of patients with extracranial metastasis was 73.5%, 83.5%, and 86.4% for group I, II, and III, respectively (p=0.011). The time interval between BC and BM was prolonged in patients with stage III primary BC (median, 2.4 to 3 years; p=0.029). As an initial brain-directed treatment, whole-brain radiotherapy alone decreased from 80.0% in 2005 to 41.1% in 2014. Meanwhile, stereotactic radiosurgery or fractionated stereotactic radiotherapy alone increased from 13.3% to 34.7% during the same period (p=0.005). The median OS for group I, II, and III was 15.6, 17.9, and 15.0 months, respectively, with no statistical significance.
Conclusion
The manifestations of BM from BC and the pattern of care have changed from 2005 to 2014 in Korea. However, the OS has remained relatively unchanged over the 10 years.

Citations

Citations to this article as recorded by

Comparison of initial and sequential salvage brain-directed treatment in patients with 1–4 vs. 5–10 brain metastases from breast cancer (KROG 16–12)
Jae Sik Kim, Kyubo Kim, Wonguen Jung, Kyung Hwan Shin, Seock-Ah Im, Hee-Jun Kim, Yong Bae Kim, Jee Suk Chang, Jee Hyun Kim, Doo Ho Choi, Yeon Hee Park, Dae Yong Kim, Tae Hyun Kim, Byung Ock Choi, Sea-Won Lee, Suzy Kim, Jeanny Kwon, Ki Mun Kang, Woong-Ki C
Breast Cancer Research and Treatment.2023; 200(1): 37. CrossRef

6,572 View
186 Download
1 Web of Science
1 Crossref

Postmastectomy Radiation Therapy for Node-Negative Breast Cancer of 5 cm or Larger Tumors: A Multicenter Retrospective Analysis (KROG 20-03): Kyubo Kim, Jinhong Jung, Haeyoung Kim, Wonguen Jung, Kyung Hwan Shin, Ji Hyun Chang, Su Ssan Kim, Won Park, Jee Suk Chang, Yong Bae Kim, Sung Ja Ahn, Ik Jae Lee, Jong Hoon Lee, Hae Jin Park, Jihye Cha, Juree Kim, Jin Hwa Choi, Taeryool Koo, Jeanny Kwon, Jin Hee Kim, Mi Young Kim, Shin-Hyung Park, Yeon-Joo Kim; Cancer Res Treat. 2022;54(2):497-504. Published online August 25, 2021; DOI: https://doi.org/10.4143/crt.2021.933

Abstract PDF PubReader ePub

Purpose
To evaluate the role of postmastectomy radiation therapy (PMRT) in patients with node-negative breast cancer of 5cm or larger tumors undergoing mastectomy
Materials and Methods
Medical records of 274 patients from 18 institutions treated with mastectomy between January 2000 and December 2016 were retrospectively reviewed. Among these, 202 patients underwent PMRT, while 72 did not. Two hundred and forty-one patients (88.0%) received systemic chemotherapy, and 172 (62.8%) received hormonal therapy. Patients receiving PMRT were younger, more likely to have progesterone receptor-positive tumors, and received adjuvant chemotherapy more frequently compared with those without PMRT (p <0.001, 0.018, and <0.001, respectively). Other characteristics were not significantly different between the two groups.
Results
With a median follow-up of 95 months (range, 1-249), there were 9 locoregional recurrences, and 20 distant metastases. The 8-year locoregional recurrence-free survival rates were 98.0% with PMRT and 91.3% without PMRT (p=0.133), and the 8-year disease-free survival (DFS) rates were 91.8% with PMRT and 73.9% without PMRT (p=0.008). On multivariate analysis incorporating age, histologic grade, lymphovascular invasion, hormonal therapy, chemotherapy, and PMRT, the absence of lymphovascular invasion and the receipt of PMRT were associated with improved DFS (p=0.025 and 0.009, respectively).
Conclusion
Locoregional recurrence rate was very low in node-negative breast cancer of 5cm or larger tumors treated with mastectomy regardless of the receipt of PMRT. However, PMRT was significantly associated with improved DFS. Further investigation is needed to confirm these findings.

Citations

Citations to this article as recorded by

Outcomes with and without postmastectomy radiotherapy for pT3N0‐1M0 breast cancer: An institutional experience
Xinxin Rao, Xuanyi Wang, Kairui Jin, Yilan Yang, Xu Zhao, Zhe Pan, Weiluo Lv, Zhen Zhang, Li Zhang, Xiaoli Yu, Xiaomao Guo
Cancer Medicine.2024;[Epub] CrossRef
The effect of radiotherapy on patients with pathological stage IIB breast cancer after breast-conserving surgery or mastectomy: A cohort study
Yi-Ying Pan, Tzu-Yu Lai, Cheng-Ying Shiau, Ling-Ming Tseng, I-Chun Lai, Yu-Ming Liu, Pin-I Huang
Journal of the Chinese Medical Association.2024; 87(2): 202. CrossRef
Post-mastectomy radiation therapy after breast reconstruction: from historic dogmas to practical expert agreements based on a large literature review of surgical and radiation therapy considerations
Yazid Belkacemi, Meena S. Moran, Burcu Celet Ozden, Yazan Masannat, Fady Geara, Mohamed Albashir, Nhu Hanh To, Kamel Debbi, Mahmoud El Tamer
Critical Reviews in Oncology/Hematology.2024; 200: 104421. CrossRef
Impact of the 21-gene recurrence score testing on chemotherapy selection and clinical outcomes in T3N0 luminal breast cancer
Ke Liu, Jia-Yi Li, Guan-Qiao Li, Zhen-Yu He, San-Gang Wu
Expert Review of Anticancer Therapy.2024; 24(12): 1283. CrossRef
Post-Mastectomy Radiation Therapy: Applications and Advancements
Jessica L. Thompson, Steven G. Allen, Cecilia Pesavento, Corey W. Speers, Jacqueline S. Jeruss
Current Breast Cancer Reports.2022; 14(3): 75. CrossRef

7,193 View
204 Download
5 Crossref

Effect of Postoperative Radiotherapy after Primary Tumor Resection in De Novo Stage IV Breast Cancer: A Multicenter Retrospective Study (KROG 19-02): Yeon Joo Kim, Yeon-Joo Kim, Yong Bae Kim, Ik Jae Lee, Jeanny Kwon, Kyubo Kim, Jihye Cha, Myungsoo Kim, In Young Jo, Jung Hoon Kim, Jaehyeon Park, Jin Hee Kim, Juree Kim, Kyung Hwan Shin, Su Ssan Kim; Cancer Res Treat. 2022;54(2):478-487. Published online July 12, 2021; DOI: https://doi.org/10.4143/crt.2021.632

Abstract PDF Supplementary Material PubReader ePub

Purpose
This study aimed to investigate the impact of postoperative radiotherapy (PORT) in de novo metastatic breast cancer (dnMBC) patients undergoing planned primary tumor resection (PTR) and to identify the subgroup of patients who would most benefit from PORT.
Materials and Methods
This study enrolled 426 patients with dnMBC administered PTR alone or with PORT. The primary and secondary outcomes were overall and progression-free survival (OS and PFS), respectively.
Results
The median follow-up time was 53.7 months (range, 3.1 to 194.4). The 5-year OS and PFS rates were 73.2% and 32.0%, respectively. For OS, clinical T3/4 category, triple-negative breast cancer (TNBC), postoperative chemotherapy alone were significantly poor prognostic factors, and administration of PORT failed to show its significance. Regarding PFS, PORT was a favorable prognostic factor (hazard ratio, 0.64; 95% confidence interval, 0.50 to 0.82; p < 0.001), in addition to T1/2 category, ≤ 5 metastases, and non-TNBC. According to the multivariate analyses of OS in the PORT group, we divided the patients into three groups (group 1, T1/2 and non-TNBC [n=193]; group 2, T3/4 and non-TNBC [n=171]; and group 3, TNBC [n=49]), and evaluated the effect of PORT. Although PORT had no significance for OS in all subgroups, it was a significant factor for good prognosis regarding PFS in groups 1 and 2, not in group 3.
Conclusion
PORT was associated with a significantly better PFS in patients with dnMBC who underwent PTR. Patients with clinical T1/2 category and non-TNBC benefited most from PORT, while those with TNBC showed little benefit.

Citations

Citations to this article as recorded by

Letter to the editor for the article“Tumor margin irregularity degree is an important preoperative predictor of adverse pathology for clinical T1/2 renal cell carcinoma and the construction of predictive model”
Yaping Miao, Lexin Wang, Ping Chen, Jiaan Lu, Guanhu Yang, Hao Chi
World Journal of Urology.2024;[Epub] CrossRef
The prognostic differences and the effect of postmastectomy radiotherapy between post‐chemotherapy ypT1‐2ypN1 and de novo pT1‐2N1 breast cancer
Tian Yang, Xiaorong Zhong, Jun Wang, Zhongzheng Xiang, Yuanyuan Zeng, Siting Yu, Zelei Dai, Ningyue Xu, Ting Luo, Lei Liu
Cancer Medicine.2023; 12(7): 8112. CrossRef
Impact of high dose radiotherapy for breast tumor in locoregionally uncontrolled stage IV breast cancer: a need for a risk-stratified approach
Nalee Kim, Haeyoung Kim, Won Park, Won Kyung Cho, Tae Gyu Kim, Young-Hyuck Im, Jin Seok Ahn, Yeon Hee Park, Ji-Yeon Kim
Radiation Oncology.2023;[Epub] CrossRef
Machine learning predicts the prognosis of breast cancer patients with initial bone metastases
Chaofan Li, Mengjie Liu, Jia Li, Weiwei Wang, Cong Feng, Yifan Cai, Fei Wu, Xixi Zhao, Chong Du, Yinbin Zhang, Yusheng Wang, Shuqun Zhang, Jingkun Qu
Frontiers in Public Health.2022;[Epub] CrossRef
Factors Influencing Prognosis in Patients with De Novo Stage IV Breast Cancer: A Systematic Review and Meta-Analysis
Meilin Zhang, Zining Jin, Yingying Xu, Bo Chen, Jian Song, Muyao Li, Feng Jin, Ang Zheng
SSRN Electronic Journal .2022;[Epub] CrossRef

7,529 View
172 Download
4 Web of Science
5 Crossref

CNS cancer

Influence of Concurrent and Adjuvant Temozolomide on Health-Related Quality of Life of Patients with Grade III Gliomas: A Secondary Analysis of a Randomized Clinical Trial (KNOG-1101 Study): Grace S. Ahn, Kihwan Hwang, Tae Min Kim, Chul Kee Park, Jong Hee Chang, Tae-Young Jung, Jin Hee Kim, Do-Hyun Nam, Se-Hyuk Kim, Heon Yoo, Yong-Kil Hong, Eun-Young Kim, Dong-Eun Lee, Jungnam Joo, Yu Jung Kim, Gheeyoung Choe, Byung Se Choi, Seok-Gu Kang, Jeong Hoon Kim, Chae-Yong Kim; Cancer Res Treat. 2022;54(2):396-405. Published online July 6, 2021; DOI: https://doi.org/10.4143/crt.2021.393

Abstract PDF Supplementary Material PubReader ePub

Purpose
The KNOG-1101 study showed improved 2-year PFS with temozolomide during and after radiotherapy compared to radiotherapy alone for patients with anaplastic gliomas. This trial investigates the effect of concurrent and adjuvant temozolomide on health-related quality of life (HRQoL).
Materials and Methods
In this randomized, open-label, phase II trial, 90 patients with World Health Organization grade III glioma were enrolled across multiple centers in South Korea between March 2012 to February 2015 and followed up through 2017. The European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30 (EORTC QLQ-C30) and 20-item EORTC QLQ-Brain Neoplasm (QLQ-BN20) were used to compare HRQoL between patients assigned to concurrent chemoradiotherapy with temozolomide followed by 6 cycles of adjuvant temozolomide (arm A) and radiotherapy (RT) alone (arm B).
Results
Of the 90 patients in the study, 84 patients (93.3%) completed the baseline HRQoL questionnaire. Emotional functioning, fatigue, nausea and vomiting, dyspnea, constipation, appetite loss, diarrhea, seizures, itchy skin, drowsiness, hair loss, and bladder control were not affected by the addition of temozolomide. All other items did not differ significantly between arm A and arm B throughout treatment. Global health status particularly stayed consistent at the end of adjuvant temozolomide (p=0.47) and at the end of RT (p=0.33).
Conclusion
The addition of concurrent and adjuvant temozolomide did not show negative influence on HRQoL with improvement of progression-free survival for patients with anaplastic gliomas. The absence of systematic and clinically relevant changes in HRQoL suggests that an overall long-term net clinical benefit exists for concurrent and adjuvant temozolomide.

Citations

Citations to this article as recorded by

Achievements of international rare cancers networks and consortia in the neuro-oncology field
Vincenzo Di Nunno, Enrico Franceschi, Ahmed Idbaih
Current Opinion in Oncology.2024; 36(6): 554. CrossRef
Prevalence and management of sleep disturbance in adults with primary brain tumours and their caregivers: a systematic review
Jason A. Martin, Nicolas H. Hart, Natalie Bradford, Fiona Naumann, Mark B. Pinkham, Elizabeth P. Pinkham, Justin J. Holland
Journal of Neuro-Oncology.2023; 162(1): 25. CrossRef
Prolonged use of temozolomide leads to increased anxiety and decreased content of aggrecan and chondroitin sulfate in brain tissues of aged rats
Anastasia Strokotova, Dmitry Sokolov, Olga Molodykh, Elena Koldysheva, Evgenii Kliver, Victor Ushakov, Maxim Politko, Nadezhda Mikhnevich, Galina Kazanskaya, Svetlana Aidagulova, Elvira Grigorieva
Biomedical Reports.2023;[Epub] CrossRef

8,161 View
164 Download
4 Web of Science
3 Crossref

The Role of Postoperative Radiotherapy in Intracranial Solitary Fibrous Tumor/Hemangiopericytoma: A Multi-institutional Retrospective Study (KROG 18-11): Joo Ho Lee, Seung Hyuck Jeon, Chul-Kee Park, Sung-Hye Park, Hong In Yoon, Jong Hee Chang, Chang-Ok Suh, Su Jeong Kang, Do Hoon Lim, In Ah Kim, Jin Hee Kim, Jung Ho Im, Sung-Hwan Kim, Chan Woo Wee, Il Han Kim; Cancer Res Treat. 2022;54(1):65-74. Published online March 24, 2021; DOI: https://doi.org/10.4143/crt.2021.142

Abstract PDF Supplementary Material PubReader ePub

Purpose
This study aimed to evaluate the role of postoperative radiotherapy (PORT) in intracranial solitary fibrous tumor/hemangiopericytoma (SFT/HPC).
Materials and Methods
A total of 133 patients with histologically confirmed HPC were included from eight institutions. Gross total resection (GTR) and subtotal resection (STR) were performed in 86 and 47 patients, respectively. PORT was performed in 85 patients (64%). The prognostic effects of sex, age, performance, World Health Organization (WHO) grade, location, size, Ki-67, surgical extent, and PORT on local control (LC), distant metastasis-free survival (DMFS), progression-free survival (PFS), and overall survival (OS) were estimated by univariate and multivariate analyses.
Results
The 10-year PFS, and OS rates were 45%, and 71%, respectively. The multivariate analysis suggested that PORT significantly improved LC (p < 0.001) and PFS (p < 0.001). The PFS benefit of PORT was maintained in the subgroup of GTR (p=0.001), WHO grade II (p=0.001), or STR (p < 0.001). In the favorable subgroup of GTR and WHO grade II, PORT was also significantly related to better PFS (p=0.028). WHO grade III was significantly associated with poor DMFS (p=0.029). In the PORT subgroup, the 0-0.5 cm margin of the target volume showed an inferior LC to a large margin with 1.0-2.0 cm (p=0.021). Time-dependent Cox proportion analysis showed that distant failures were significantly associated with poor OS (p=0.003).
Conclusion
This multicenter study supports the role of PORT in disease control of intracranial SFT/HPC, irrespective of the surgical extent and grade. For LC, PORT should enclose the tumor bed with sufficient margin.

Citations

Citations to this article as recorded by

Does Adjuvant Radiotherapy Enhance Survival in Intracranial Solitary Fibrous Tumor Patients?
Sakhr Alshwayyat, Haya Kamal, Tala Abdulsalam Alshwayyat, Mustafa Alshwayyat, Mesk Alkhatib, Ayah Erjan
World Neurosurgery.2025; 194: 123545. CrossRef
Application and effect evaluation of microsurgical resection combined with intensity-modulated radiation therapy in the treatment of intracranial solitary fibrous tumor/hemangiopericytoma
Jingcheng Jiang, Xiaoqin Qu, Han Wang, Chao Zhang, Qingshan Deng, Xiaoping Xu, Jun Qiu, Lihua Qu, Yong Yi
Medicine.2025; 104(6): e41336. CrossRef
Development of an MRI‐Based Comprehensive Model Fusing Clinical, Radiomics and Deep Learning Models for Preoperative Histological Stratification in Intracranial Solitary Fibrous Tumor
Xiaohong Liang, Kaiqiang Tang, Xiaoai Ke, Jian Jiang, Shenglin Li, Caiqiang Xue, Juan Deng, Xianwang Liu, Cheng Yan, Mingzi Gao, Junlin Zhou, Liqin Zhao
Journal of Magnetic Resonance Imaging.2024; 60(2): 523. CrossRef
Meningeal Solitary Fibrous Tumor: A Single-Center Retrospective Cohort Study
Siyer Roohani, Yasemin Alberti, Maximilian Mirwald, Felix Ehret, Carmen Stromberger, Soleiman Fabris Roohani, Katja Bender, Anne Flörcken, Sven Märdian, Daniel Zips, David Kaul, Manish Charan
Sarcoma.2024; 2024: 1. CrossRef
Repeated Radiation Therapy of Recurrent Solitary Fibrous Tumors of the Brain: A Medical Case History Over 20 Years
Anna Carla Piccardo, Sabrina Gurdschinski, Sybille Spieker, Christof Renner, Piotr Czapiewski, Markus Wösle, I. Frank Ciernik
Advances in Radiation Oncology.2024; 9(4): 101426. CrossRef
Intracranial solitary fibrous tumors: Clinical, radiological, and histopathological insights along with review of literature
Adil Aziz Khan, Sana Ahuja, Dipanker Singh Mankotia, Sufian Zaheer
Pathology - Research and Practice.2024; 260: 155456. CrossRef
Central nervous system solitary fibrous tumors: Case series in accordance with the WHO 2021 reclassification. Framework for patient surveillance
V. Matthijs, R. Beckers, C. Vanden Broecke, F. Dedeurwaerdere, J. Van Dorpe, D. Vanhauwaert, G. Hallaert
Acta Neurochirurgica.2024;[Epub] CrossRef
Recurrence of Solitary Fibrous Tumor in the Spinal Cord Following Gross Total and Subtotal Resection: A Case Report of Recurrence 19 Years of Post-total Resection and Systematic Literature Review
Satoka SHIDOH, Kazutoshi HIDA, Yoshitaka ODA, Toru SASAMORI, Prabin SHRESTHA, Jangbo LEE, Satoshi YAMAGUCHI
NMC Case Report Journal.2024; 11: 297. CrossRef
The role of radiotherapy in intracranial hemangiopericytoma/solitary fibrous tumors
Nuri Kaydıhan, Gözde Yazıcı, Petek Erpolat, Serra Kamer, Burak Erdemci, Emine Canyılmaz, Beste Melek Atasoy, Dicle Aslan, Ela Delikgöz Soykut, Enis Özyar, Fatih Demircioğlu, Fazilet Öner Dinçbaş, Meltem Kirli Bolukbas, Ramazan Aksu, Selvi Tabak Dinçer, Ya
Strahlentherapie und Onkologie.2024;[Epub] CrossRef
The Role of Radical Radiotherapy in Sinonasal Myopericytoma: A Case Report and Literature Overview
Anna Merlotti, Stefania Martini, Riccardo Vigna Taglianti, Alessia Reali, Giuseppe Signorini, Silvana Parisi, Francesca De Felice
EMJ Oncology.2023;[Epub] CrossRef
Intracranial Solitary Fibrous Tumour Management: A French Multicentre Retrospective Study
Marine Lottin, Alexandre Escande, Luc Bauchet, Marie Albert-Thananayagam, Maël Barthoulot, Matthieu Peyre, Mathieu Boone, Sonia Zouaoui, Jacques Guyotat, Guillaume Penchet, Johan Pallud, Henry Dufour, Evelyne Emery, Michel Lefranc, Sébastien Freppel, Houm
Cancers.2023; 15(3): 704. CrossRef
Solitary fibrous tumor of the central nervous system invading and penetrating the skull: A case report
Qiyan Lin, Jiabin Zhu, Xiaofeng Zhang
Oncology Letters.2023;[Epub] CrossRef
Impact of extent of resection and postoperative radiotherapy on survival outcomes in intracranial solitary fibrous tumors: a systematic review and meta-analysis
Sae Min Kwon, Min Kyun Na, Kyu-Sun Choi, Tae Ho Lim, Hyungoo Shin, Juncheol Lee, Heekyung Lee, Wonhee Kim, Youngsuk Cho, Jae Guk Kim, Chiwon Ahn, Bo-Hyoung Jang
Neurosurgical Review.2023;[Epub] CrossRef
Radiotherapy for rare primary brain tumors
E. Mesny, P. Lesueur
Cancer/Radiothérapie.2023; 27(6-7): 599. CrossRef
Complete Resection of a Torcular Herophili Hemangiopericytoma without Sinus Reconstruction: A Case Report and Review of the Literature
Salah-Edine Safi, Julie Godfrain, Herbert Rooijakkers, Frederic Collignon, Mario Ganau
Case Reports in Surgery.2023; 2023: 1. CrossRef
Surgical Management of Craniospinal Axis Solitary Fibrous Tumors: A Single-Institution Case Series and Comprehensive Review of the Literature
Anthony J. Piscopo, A. J. Chowdhury, Nahom Teferi, Sarah Lee, Meron Challa, Michael Petronek, Kathryn Eschbacher, Girish Bathla, John M. Buatti, Patrick Hitchon
Neurosurgery.2023;[Epub] CrossRef
Clinical Features, Management, and Prognostic Factors of Intracranial Solitary Fibrous Tumor
Jingdian Liu, Sisi Wu, Kai Zhao, Junwen Wang, Kai Shu, Ting Lei
Frontiers in Oncology.2022;[Epub] CrossRef
Toward Better Understanding and Management of Solitary Fibrous Tumor
Karineh Kazazian, Elizabeth G. Demicco, Marc de Perrot, Dirk Strauss, Carol J. Swallow
Surgical Oncology Clinics of North America.2022; 31(3): 459. CrossRef
Effect of Different Treatments for Intracranial Solitary Fibrous Tumors: Retrospective Analysis of 31 Patients
Qinghua Li, Wenshuai Deng, Peng Sun
World Neurosurgery.2022; 166: e60. CrossRef
Sixteen-Year Follow-Up in a Cavernous Sinus Hemangiopericytoma: Improved Outcomes over Radiotherapy Advances
Beatrice Detti, Lilia Bardoscia, Antonio Rosario Pisani, Salvatore Cozzi, Manuele Roghi, Paolo Mammucci, Angela Sardaro
Brain Sciences.2022; 12(9): 1209. CrossRef
Solitary Fibrous Tumor of the Jugular Foramen: A Case Report and Review of the Histopathologic Classification
Mallory Raymond, Philip Ryan Elvis, Tiffany Baker, William Alexander Vandergrift, Theodore McRackan
Otology & Neurotology.2022; 43(10): e1208. CrossRef
A Comprehensive Review on Solitary Fibrous Tumor: New Insights for New Horizons
Javier Martin-Broto, Jose L. Mondaza-Hernandez, David S. Moura, Nadia Hindi
Cancers.2021; 13(12): 2913. CrossRef
Intradural Extramedullary Solitary Fibrous Tumor of the Thoracic Spinal Cord
Zachary T Olmsted, Joanna Tabor, Omer Doron, Hossein Hosseini, Daniel Schneider, Ross Green, Samuel J Wahl, Daniel M Scuibba, Randy S D'Amico
Cureus.2021;[Epub] CrossRef

8,978 View
350 Download
21 Web of Science
23 Crossref

Concurrent and Adjuvant Temozolomide for Newly Diagnosed Grade III Gliomas without 1p/19q Co-deletion: A Randomized, Open-Label, Phase 2 Study (KNOG-1101 Study): Kihwan Hwang, Tae Min Kim, Chul-Kee Park, Jong Hee Chang, Tae-Young Jung, Jin Hee Kim, Do-Hyun Nam, Se-Hyuk Kim, Heon Yoo, Yong-Kil Hong, Eun-Young Kim, Dong-Eun Lee, Jungnam Joo, Yu Jung Kim, Gheeyoung Choe, Byung Se Choi, Seok-Gu Kang, Jeong Hoon Kim, Chae-Yong Kim; Cancer Res Treat. 2020;52(2):505-515. Published online October 28, 2019; DOI: https://doi.org/10.4143/crt.2019.421

Abstract PDF PubReader ePub

Purpose
We investigated the efficacy of temozolomide during and after radiotherapy in Korean adults with anaplastic gliomas without 1p/19q co-deletion.
Materials and Methods
This was a randomized, open-label, phase 2 study and notably the first multicenter trial for Korean grade III glioma patients. Eligible patients were aged 18 years or older and had newly diagnosed non-co-deleted anaplastic glioma with an Eastern Cooperative Oncology Group performance status of 0-2. Patients were randomized 1:1 to receive radiotherapy alone (60 Gy in 30 fractions of 2 Gy) (control group, n=44) or to receive radiotherapy with concurrent temozolomide (75 mg/m²/day) followed by adjuvant temozolomide (150-200 mg/m²/day for 5 days during six 28-day cycles) (treatment group, n=40). The primary end-point was 2-year progression-free survival (PFS). Seventy patients (83.3%) were available for the analysis of the isocitrate dehydrogenase 1 gene (IDH1) mutation status.
Results
The two-year PFS was 42.2% in the treatment group and 37.2% in the control group. Overall survival (OS) did not reach to significant difference between the groups. In multivariable analysis, age was a significant risk factor for PFS (hazard ratio [HR], 2.08; 95% confidence interval [CI], 1.04 to 4.16). The IDH1 mutation was the only significant prognostic factor for PFS (HR, 0.28; 95% CI, 0.13 to 0.59) and OS (HR, 0.19; 95% CI, 0.07 to 0.50). Adverse events over grade 3 were seen in 16 patients (40.0%) in the treatment group and were reversible.
Conclusion
Concurrent and adjuvant temozolomide in Korean adults with newly diagnosed non-co- deleted anaplastic gliomas showed improved 2-year PFS. The survival benefit of this regimen needs further analysis with long-term follow-up at least more than 10 years.

Citations

Citations to this article as recorded by

Impact of upfront adjuvant chemoradiation on survival in patients with molecularly defined oligodendroglioma: the benefits of PCV over TMZ
Jordina Rincon-Torroella, Maureen Rakovec, Anita L. Kalluri, Kelly Jiang, Carly Weber-Levine, Megan Parker, Divyaansh Raj, Josh Materi, Sadra Sepehri, Abel Ferres, Karisa C. Schreck, Iban Aldecoa, Calixto-Hope G. Lucas, Haris I. Sair, Kristin J. Redmond,
Journal of Neuro-Oncology.2025; 171(1): 35. CrossRef
Multidisciplinary Management of Isocitrate Dehydrogenase–Mutated Gliomas in a Contemporary Molecularly Defined Era
Rupesh Kotecha, David Schiff, Arnab Chakravarti, Jessica L. Fleming, Paul D. Brown, Vinay K. Puduvalli, Michael A. Vogelbaum, Vinai Gondi, Marco Gallus, Hideho Okada, Minesh P. Mehta
Journal of Clinical Oncology.2024; 42(21): 2588. CrossRef
The IDH paradox: Meta-analysis of alkylating chemotherapy in IDH-wild type and -mutant lower grade gliomas
Connor J Kinslow, Soumyajit Roy, Fabio M Iwamoto, Paul D Brown, David M DeStephano, Peter D Canoll, Summer S Qureshi, Matthew Gallito, Michael B Sisti, Jeffrey N Bruce, David P Horowitz, Lisa A Kachnic, Alfred I Neugut, James B Yu, Minesh P Mehta, Simon K
Neuro-Oncology.2024; 26(10): 1839. CrossRef
The Role of Systemic Therapies in the Treatment of Grades 1-4 Gliomas
Jan Stepka, Mariusz Dotka, Maciej Kosiński, Piotr Suchecki, Maciej Hobot, Igor Piotrowski
Cureus.2024;[Epub] CrossRef
Therapy for Diffuse Astrocytic and Oligodendroglial Tumors in Adults: ASCO-SNO Guideline
Nimish A. Mohile, Hans Messersmith, Na Tosha Gatson, Andreas F. Hottinger, Andrew Lassman, Jordan Morton, Douglas Ney, Phioanh Leia Nghiemphu, Adriana Olar, Jeffery Olson, James Perry, Jana Portnow, David Schiff, Anne Shannon, Helen A. Shih, Roy Strowd, M
Journal of Clinical Oncology.2022; 40(4): 403. CrossRef
Therapy for Diffuse Astrocytic and Oligodendroglial Tumors in Adults: ASCO-SNO Guideline
Nimish A Mohile, Hans Messersmith, Na Tosha N Gatson, Andreas F Hottinger, Andrew B Lassman, Jordan Morton, Douglas Ney, Phioanh Leia Nghiemphu, Adriana Olar, Jeffery Olson, James Perry, Jana Portnow, David Schiff, Anne Shannon, Helen A Shih, Roy Strowd,
Neuro-Oncology.2022; 24(3): 358. CrossRef
Executive summary of American Radium Society’s appropriate use criteria for the postoperative management of lower grade gliomas
Martin C. Tom, Michael T. Milano, Samuel T. Chao, Scott G. Soltys, Jonathan P.S. Knisely, Arjun Sahgal, Seema Nagpal, Simon S. Lo, Siavash Jabbari, Tony J.C. Wang, Manmeet S. Ahluwalia, Marian Simonson, Joshua D. Palmer, Melanie Hayden Gephart, Lia M. Hal
Radiotherapy and Oncology.2022; 170: 79. CrossRef
Influence of Concurrent and Adjuvant Temozolomide on Health-Related Quality of Life of Patients with Grade III Gliomas: A Secondary Analysis of a Randomized Clinical Trial (KNOG-1101 Study)
Grace S. Ahn, Kihwan Hwang, Tae Min Kim, Chul Kee Park, Jong Hee Chang, Tae-Young Jung, Jin Hee Kim, Do-Hyun Nam, Se-Hyuk Kim, Heon Yoo, Yong-Kil Hong, Eun-Young Kim, Dong-Eun Lee, Jungnam Joo, Yu Jung Kim, Gheeyoung Choe, Byung Se Choi, Seok-Gu Kang, Jeo
Cancer Research and Treatment.2022; 54(2): 396. CrossRef
The Risk of Heart Disease-Related Death Among Anaplastic Astrocytoma Patients After Chemotherapy: A SEER Population-Based Analysis
Qi Lin, Jia-Hao Bao, Fei Xue, Jia-Jun Qin, Zhen Chen, Zhong-Rong Chen, Chao Li, Yi-Xuan Yan, Jin Fu, Zhao-Li Shen, Xian-Zhen Chen
Frontiers in Oncology.2022;[Epub] CrossRef
Association between a prior cancer history and prognosis in adult patients with high‑grade glioma
Dongjie He, Peiwen Wu, Gaiyan Li, Siying Zhu, Qiming Wang, Qiuju Shao, Hao Chang
Journal of Clinical Neuroscience.2022; 106: 20. CrossRef

9,723 View
635 Download
9 Web of Science
10 Crossref

Treatment Outcome after Fractionated Conformal Radiotherapy for Hepatocellular Carcinoma in Patients with Child-Pugh Classification B in Korea (KROG 16-05): Sun Hyun Bae, Hee Chul Park, Won Sup Yoon, Sang Min Yoon, In-Hye Jung, Ik Jae Lee, Jun Won Kim, Jinsil Seong, Tae Hyun Kim, Taek-Keun Nam, Youngmin Choi, Sun Young Lee, Hong Seok Jang, Dong Soo Lee, Jin Hee Kim; Cancer Res Treat. 2019;51(4):1589-1599. Published online April 10, 2019; DOI: https://doi.org/10.4143/crt.2018.687

Abstract PDF Supplementary Material PubReader ePub

Purpose
There is limited data on radiotherapy (RT) for hepatocellular carcinoma (HCC) in patients with Child-Pugh classification B (CP-B). This study aimed to evaluate the treatment outcomes of fractionated conformal RT in HCC patients with CP-B.
Materials and Methods
We retrospectively reviewed the data of HCC patients with CP-B treated with RT between 2009 and 2014 at 13 institutions in Korea. HCC was diagnosed by the Korea guideline of 2009, and modern RT techniques were applied. Fraction size was ≤ 5 Gy and the biologically effective dose (BED) ≥ 40 Gy10 (α/β = 10 Gy). A total of 184 patients were included in this study.
Results
Initial CP score was seven in 62.0% of patients, eight in 31.0%, and nine in 7.0%. Portal vein tumor thrombosis was present in 66.3% of patients. The BED ranged from 40.4 to 89.6 Gy10 (median, 56.0 Gy10). After RT completion, 48.4% of patients underwent additional treatment. The median overall survival (OS) was 9.4 months. The local progression-free survival and OS rates at 1 year were 58.9% and 39.8%, respectively. In the multivariate analysis, non-classic radiation-induced liver disease (RILD) (p < 0.001) and additional treatment (p < 0.001) were the most significant prognostic factors of OS. Among 132 evaluable patients without progressive disease, 19.7% experienced non-classic RILD. Normal liver volume was the most predictive dosimetric parameter of non-classic RILD.
Conclusion
Fractionated conformal RT showed favorable OS with a moderate risk non-classic RILD. The individual radiotherapy for CP-B could be cautiously applied weighing the survival benefits and the RILD risks.

Citations

Citations to this article as recorded by

Development and validation of a nomogram for radiation-induced hepatic toxicity after intensity modulated radiotherapy for hepatocellular carcinoma: a retrospective study
Qiaoyuan Wu, Yudan Wang, Yuxin Wei, Zhengqiang Yang, Kai Chen, Jianxu Li, Liqing Li, Tingshi Su, Shixiong Liang
Japanese Journal of Clinical Oncology.2024; 54(6): 699. CrossRef
Managing hepatocellular carcinoma across the stages: efficacy and outcomes of stereotactic body radiotherapy
Ahmed Allam Mohamed, Marie-Luise Berres, Philipp Bruners, Sven Arke Lang, Christian Trautwein, Georg Wiltberger, Alexandra Barabasch, Michael Eble
Strahlentherapie und Onkologie.2024; 200(8): 715. CrossRef
Clinical outcomes and safety of external beam radiotherapy with extensive intrahepatic targets for advanced hepatocellular carcinoma: A single institutional clinical experience
Sunmin Park, Chai Hong Rim, Won Sup Yoon
Saudi Journal of Gastroenterology.2024; 30(6): 399. CrossRef
Role of rapid arc-image-guided radiotherapy in hepatocellular carcinoma with portal vein tumor thrombosis: A study from tertiary care center in Punjab, India
Manjinder Singh Sidhu, Ramandeep, Sandhya Sood, Ritu Aggarwal, Kulbir Singh, Divyanshi Sood
Journal of Cancer Research and Therapeutics.2023; 19(3): 639. CrossRef
Non-classic radiation-induced liver disease after intensity-modulated radiotherapy for Child–Pugh grade B patients with locally advanced hepatocellular carcinoma
Jian-Xu Li, Rui-Jun Zhang, Mo-Qin Qiu, Liu-Ying Yan, Mei-Ling He, Mei-Ying Long, Jian-Hong Zhong, Hai-Yan Lu, Hong-Mei Zhou, Bang-De Xiang, Shi-Xiong Liang
Radiation Oncology.2023;[Epub] CrossRef
Long-term characterization of MRI-morphologic alterations after active motion-compensated liver SBRT: a multi-institutional pooled analysis
Constantin Dreher, Gustavo R. Sarria, Georgia Miebach, Christel Weiss, Daniel Buergy, Paulina Wojtal, Anoshirwan A. Tavakoli, David Krug, Hans Oppitz, Frank A. Giordano, Marcus Both, Frank Lohr, Jürgen Dunst, Oliver Blanck, Judit Boda-Heggemann
Acta Oncologica.2023; 62(3): 281. CrossRef
Radiotherapy trend in elderly hepatocellular carcinoma: retrospective analysis of patients diagnosed between 2005 and 2017
Bong Kyung Bae, Jeong Il Yu, Hee Chul Park, Myung Ji Goh, Yong-Han Paik
Radiation Oncology Journal.2023; 41(2): 98. CrossRef
Radiotherapy plus anti-PD1 versus radiotherapy for hepatic toxicity in patients with hepatocellular carcinoma
Rui-Jun Zhang, Hong-Mei Zhou, Hai-Yan Lu, Hong-Ping Yu, Wei-Zhong Tang, Mo-Qin Qiu, Liu-Ying Yan, Mei-Ying Long, Ting-Shi Su, Bang-De Xiang, Mei-Ling He, Xiao-Ting Wang, Shi-Xiong Liang, Jian-Xu Li
Radiation Oncology.2023;[Epub] CrossRef
Low-dose radiotherapy combined with dual PD-L1 and VEGFA blockade elicits antitumor response in hepatocellular carcinoma mediated by activated intratumoral CD8+ exhausted-like T cells
Siqi Li, Kun Li, Kang Wang, Haoyuan Yu, Xiangyang Wang, Mengchen Shi, Zhixing Liang, Zhou Yang, Yongwei Hu, Yang Li, Wei Liu, Hua Li, Shuqun Cheng, Linsen Ye, Yang Yang
Nature Communications.2023;[Epub] CrossRef
Stereotactic ablative radiotherapy for pulmonary oligometastases from primary hepatocellular carcinoma: a multicenter and retrospective analysis (KROG 17-08)
In Young Jo, Hee Chul Park, Eun Seog Kim, Seung-Gu Yeo, Myungsoo Kim, Jinsil Seong, Jun Won Kim, Tae Hyun Kim, Won Sup Yoon, Bae Kwon Jeong, Sung Hwan Kim, Jong Hoon Lee
Japanese Journal of Clinical Oncology.2022; 52(6): 616. CrossRef
Efficacy and feasibility of surgery and external radiotherapy for hepatocellular carcinoma with portal invasion: A meta-analysis
Han Ah Lee, Yeon Seok Seo, In-Soo Shin, Won Sup Yoon, Hye Yoon Lee, Chai Hong Rim
International Journal of Surgery.2022; 104: 106753. CrossRef
Trend Analysis and Prediction of Hepatobiliary Pancreatic Cancer Incidence and Mortality in Korea
Hyeong Min Park, Young-Joo Won, Mee Joo Kang, Sang-Jae Park, Sun-Whe Kim, Kyu-Won Jung, Sung-Sik Han
Journal of Korean Medical Science.2022;[Epub] CrossRef
Radiofrequency ablation and stereotactic body radiotherapy for hepatocellular carcinoma: should they clash or reconcile?
Chai Hong Rim, Hye Yoon Lee, Jung Sun Kim, Hakyoung Kim
International Journal of Radiation Biology.2021; 97(2): 111. CrossRef
Therapeutic Decision Making in Hepatocellular Carcinoma According to Age and Child–Pugh Class: A Nationwide Cohort Analysis in South Korea
Sunmin Park, Chai Hong Rim, Young Kul Jung, Won Sup Yoon, Alessandro Granito
Canadian Journal of Gastroenterology and Hepatology.2021; 2021: 1. CrossRef
Benefits of Local Treatment Including External Radiotherapy for Hepatocellular Carcinoma with Portal Invasion
Han Lee, Sunmin Park, Yeon Seo, Won Yoon, Chai Rim
Biology.2021; 10(4): 326. CrossRef
Phase I Radiation Dose-Escalation Study to Investigate the Dose-Limiting Toxicity of Concurrent Intra-Arterial Chemotherapy for Unresectable Hepatocellular Carcinoma
Yeona Cho, Jun Won Kim, Ja Kyung Kim, Kwan Sik Lee, Jung Il Lee, Hyun Woong Lee, Kwang-Hun Lee, Seung-Moon Joo, Jin Hong Lim, Ik Jae Lee
Cancers.2020; 12(6): 1612. CrossRef
Do Biliary Complications after Proton Beam Therapy for Perihilar Hepatocellular Carcinoma Matter?
Gyu Sang Yoo, Jeong Il Yu, Hee Chul Park, Dongho Hyun, Woo Kyoung Jeong, Ho Yeong Lim, Moon Seok Choi, Sang Yun Ha
Cancers.2020; 12(9): 2395. CrossRef
Combinational Immunotherapy for Hepatocellular Carcinoma: Radiotherapy, Immune Checkpoint Blockade and Beyond
Yun Hua Lee, David Tai, Connie Yip, Su Pin Choo, Valerie Chew
Frontiers in Immunology.2020;[Epub] CrossRef

8,862 View
236 Download
19 Web of Science
18 Crossref

Impact of Regional Nodal Irradiation for Breast Cancer Patients with Supraclavicular and/or Internal Mammary Lymph Node Involvement: A Multicenter, Retrospective Study (KROG 16-14): Kyubo Kim, Yuri Jeong, Kyung Hwan Shin, Jin Ho Kim, Seung Do Ahn, Su Ssan Kim, Chang-Ok Suh, Yong Bae Kim, Doo Ho Choi, Won Park, Jihye Cha, Mison Chun, Dong Soo Lee, Sun Young Lee, Jin Hee Kim, Hae Jin Park, Wonguen Jung; Cancer Res Treat. 2019;51(4):1500-1508. Published online March 15, 2019; DOI: https://doi.org/10.4143/crt.2018.575

Abstract PDF Supplementary Material PubReader ePub

Purpose
The purpose of this study was to evaluate the treatment outcomes of radiotherapy (RT) for breast cancer with ipsilateral supraclavicular (SCL) and/or internal mammary (IMN) lymph node involvement.
Materials and Methods
A total of 353 patients from 11 institutions were included. One hundred and thirty-six patients had SCL involvement, 148 had IMN involvement, and 69 had both. All patients received neoadjuvant systemic therapy followed by breast-conserving surgery or mastectomy, and postoperative RT to whole breast/chest wall. As for regional lymph node irradiation, SCL RT was given to 344 patients, and IMN RT to 236 patients. The median RT dose was 50.4 Gy.
Results
The median follow-up duration was 61 months (range, 7 to 173 months). In-field progression was present in SCL (n=20) and/or IMN (n=7). The 5-year disease-free survival (DFS) and overall survival rates were 57.8% and 75.1%, respectively. On multivariate analysis, both SCL/IMN involvement, number of axillary lymph node ≥ 4, triple-negative subtype, and mastectomy were significant adverse prognosticators for DFS (p=0.022, p=0.001, p=0.001, and p=0.004, respectively). Regarding the impact of regional nodal irradiation, SCL RT dose ≥ 54 Gy was not associated with DFS (5-year rate, 52.9% vs. 50.9%; p=0.696) in SCL-involved patients, and the receipt of IMN RT was not associated with DFS (5-year rate, 56.1% vs. 78.1%; p=0.099) in IMN-involved patients.
Conclusion
Neoadjuvant chemotherapy followed by surgery and postoperative RT achieved an acceptable in-field regional control rate in patients with SCL and/or IMN involvement. However, a higher RT dose to SCL or IMN RT was not associated with the improved DFS in these patients.

Citations

Citations to this article as recorded by

Clinical outcomes after post-operative radiotherapy for breast cancer patients presenting with ipsilateral supraclavicular metastasis: considerations on the cranial border of irradiation field
Xiaofang Wang, Xiaomeng Zhang, Li Zhang, Jin Meng, Wei Shi, Xingxing Chen, Zhaozhi Yang, Xin Mei, Xiaoli Yu, Zhen Zhang, Zhimin Shao, Xiaomao Guo, Jinli Ma
Breast Cancer.2025; 32(1): 144. CrossRef
Outcomes and Trends in Axillary Management of Stage cN3b Breast Cancer Patients
Julia M. Selfridge, Zachary Schrank, Chris B. Agala, David W. Ollila, Kristalyn K. Gallagher, Dana L. Casey, Philip M. Spanheimer
Annals of Surgical Oncology.2025; 32(3): 2070. CrossRef
Internal mammary regional management after neoadjuvant therapy in breast cancer
Zhao Bi, Chun-Hui Zheng, Tong-Yue Ren, Yong-Sheng Wang
International Journal of Surgery.2024;[Epub] CrossRef
Oncological outcomes in patients with residual triple-negative breast cancer after preoperative chemotherapy
Hyunki Park, Haeyoung Kim, Won Park, Won Kyung Cho, Nalee Kim, Tae Gyu Kim, Young-Hyuck Im, Jin Seok Ahn, Yeon Hee Park, Ji-Yeon Kim, Seok Jin Nam, Seok Won Kim, Jeong Eon Lee, Jonghan Yu, Byung Joo Chae, Sei Kyung Lee, Jai-Min Ryu
Radiation Oncology Journal.2024; 42(3): 210. CrossRef
Clinical audit of breast cancer patients treated with helical tomotherapy for irradiation of the internal mammary chain
Garima Shrivastav, Debanjali Datta, Tabassum Wadasadawala, Pallavi Rane, Subhajit Panda, Rima Pathak, Libin Scaria, Revathy Krishnamurthy, Rajiv Sarin
Journal of Radiotherapy in Practice.2023;[Epub] CrossRef
The optimal regional irradiation volume for breast cancer patients: A comprehensive systematic review and network meta-analysis of published studies
Wei-Xiang Qi, Lu Cao, Cheng Xu, Gang Cai, Jiayi Chen
Frontiers in Oncology.2023;[Epub] CrossRef
Contemporary Outcomes After Multimodality Therapy in Patients With Breast Cancer Presenting With Ipsilateral Supraclavicular Node Involvement
Kevin Diao, Lauren M. Andring, Carlos H. Barcenas, Puneet Singh, Huong (Carisa) Le-Petross, Valerie K. Reed, Jay P. Reddy, Elizabeth S. Bloom, Neelofur R. Ahmad, Lauren L. Mayo, George H. Perkins, Melissa P. Mitchell, Kevin T. Nead, Welela Tereffe, Benjam
International Journal of Radiation Oncology*Biology*Physics.2022; 112(1): 66. CrossRef
Locoregional Management and Prognostic Factors in Breast Cancer With Ipsilateral Internal Mammary and Axillary Lymph Node Involvement
Lauren M. Andring, Kevin Diao, Susie Sun, Miral Patel, Gary J. Whitman, Pamela Schlembach, Isadora Arzu, Melissa M. Joyner, Simona F. Shaitelman, Karen Hoffman, Michael C. Stauder, Benjamin D. Smith, Wendy A. Woodward
International Journal of Radiation Oncology*Biology*Physics.2022; 113(3): 552. CrossRef
Yesterday, Today and Tomorrow – Are We Any Closer to Knowing Which Patients Will Benefit from Adjuvant Internal Mammary Nodal Irradiation?
C.A. Johnson, J. Evans
Clinical Oncology.2022; 34(8): 534. CrossRef
Dynamics of circulating tumor DNA during postoperative radiotherapy in patients with residual triple-negative breast cancer following neoadjuvant chemotherapy: a prospective observational study
Haeyoung Kim, Yeon Jeong Kim, Donghyun Park, Woong-Yang Park, Doo Ho Choi, Won Park, Won kyung Cho, Nalee Kim
Breast Cancer Research and Treatment.2021; 189(1): 167. CrossRef
Cervical Lymph Node Involvement above the Supraclavicular Fossa in Breast Cancer: Comparison with Stage IIIC (KROG 18-02)
Jae Sik Kim, Kyubo Kim, Kyung Hwan Shin, Jin Ho Kim, Seung Do Ahn, Su Ssan Kim, Yong Bae Kim, Jee Suk Chang, Doo Ho Choi, Won Park, Tae Hyun Kim, Mison Chun, Jihye Cha, Jin Hee Kim, Dong Soo Lee, Sun Young Lee, Hae Jin Park
Journal of Breast Cancer.2020; 23(2): 194. CrossRef
Aggressive Surgical Excision of Supraclavicular Lymph Node Did Not Improve the Outcomes of Breast Cancer With Supraclavicular Lymph Node Involvement (KROG 16-14)
Kyubo Kim, Su Ssan Kim, Kyung Hwan Shin, Jin Ho Kim, Seung Do Ahn, Doo Ho Choi, Won Park, Sun Young Lee, Mison Chun, Jin Hee Kim, Yong Bae Kim, Jihye Cha, Hae Jin Park, Dong Soo Lee, Wonguen Jung
Clinical Breast Cancer.2020; 20(1): 51. CrossRef
Combined Therapy Can Improve the Outcomes of Breast Cancer with Isolated Supraclavicular Lymph Node Involvement

Tianyi Ma, Yan Mao, Haibo Wang
Cancer Management and Research.2020; Volume 12: 11857. CrossRef

8,636 View
331 Download
16 Web of Science
13 Crossref

Comparison of Breast Conserving Surgery Followed by Radiation Therapy with Mastectomy Alone for Pathologic N1 Breast Cancer Patients in the Era of Anthracycline Plus Taxane-Based Chemotherapy: A Multicenter Retrospective Study (KROG 1418): Gyu Sang Yoo, Won Park, Jeong Il Yu, Doo Ho Choi, Yeon-Joo Kim, Kyung Hwan Shin, Chan Woo Wee, Kyubo Kim, Kyung Ran Park, Yong Bae Kim, Sung Ja Ahn, Jong Hoon Lee, Jin Hee Kim, Mison Chun, Hyung-Sik Lee, Jung Soo Kim, Jihye Cha; Cancer Res Treat. 2019;51(3):1041-1051. Published online November 1, 2018; DOI: https://doi.org/10.4143/crt.2018.424

Abstract PDF PubReader ePub

Purpose
We compared the oncologic outcomes of breast-conserving surgery plus radiation therapy (BCS+RT) and modified radical mastectomy (MRM) under anthracycline plus taxane-based (AT) regimens and investigated the role of adjuvant radiation therapy (RT) in patients with pathologic N1 (pN1) breast cancer treated by mastectomy.
Materials and Methods
We retrospectively reviewed the medical records of 2,011 patients with pN1 breast cancer who underwent BCS+RT or MRM alone at 12 institutions between January 2006 and December 2010. Two-to-one propensity score matching was performed for balances in variables between the groups.
Results
The median follow-up duration for the total cohort was 69 months (range, 1 to 114 months). After propensity score matching, 1,074 patients (676 in the BCS+RT group and 398 in the MRM-alone group) were analyzed finally. The overall survival, disease-free survival, locoregional failure-free survival, and regional failure-free survival (RFFS) curves of the BCS+RT group vs. MRM-alone group were not significantly different. The subgroup analysis revealed that in the group with both lymphovascular invasion (LVI) and histologic grade (HG) III, the BCS+RT showed significantly superior RFFS (p=0.008). Lymphedema (p=0.007) and radiation pneumonitis (p=0.031) occurred more frequently in the BCS+RT group than in the MRM-alone group, significantly.
Conclusion
There are no differences in oncologic outcomes between BCS+RT and MRM-alone groups under the AT chemotherapy regimens for pN1 breast cancer. However, BCS+RT group showed superior RFFS to MRM-alone group in the patients with LVI and HG III. Adjuvant RT might be considerable for pN1 breast cancer patients with LVI and HG III.

Citations

Citations to this article as recorded by

Investigation of the clinical benefits of regular breath-holding training utilizing surface guided radiation therapy technology for patients with left breast cancer
Hongming Li, Zheng Miao, Jie Shen, Jianing Xiao, Zhiwei Yang, Wei Tian, Xiansong Sun, Zhen Zhou, Jing Shen, Jie Qiu
Journal of Radiation Research and Applied Sciences.2025; 18(2): 101393. CrossRef
21-gene recurrence score in predicting the outcome of postoperative radiotherapy in T1-2N1 luminal breast cancer after breast-conserving surgery
Shang-Jin Xie, Run-Jie Wang, San-Gang Wu, Fu-Xing Zhang
The Breast.2024; 74: 103679. CrossRef
Assessing Radiation Effects on Chemo-Treated BT20 and 4T1 Breast Cancer, and Neuroblastoma Cell Lines: A Study of Single and Multiple-Cell Ionization via Infrared Laser Trapping
Mulugeta S. Goangul, Daniel B. Erenso, Ying Gao, Li Chen, Kwame O. Eshun, Gisela Alvarez, Horace T. Crogman
Radiation.2024; 4(1): 85. CrossRef
Overall survival after mastectomy versus breast-conserving surgery with adjuvant radiotherapy for early-stage breast cancer: meta-analysis
Kiran K Rajan, Katherine Fairhurst, Beth Birkbeck, Shonnelly Novintan, Rebecca Wilson, Jelena Savović, Chris Holcombe, Shelley Potter
BJS Open.2024;[Epub] CrossRef
Radiotherapy dosimetry and radiotherapy related complications of immediate implant-based reconstruction after breast cancer surgery
Yu Zhang, Fuxiu Ye, Yun Teng, Jin Zheng, Chunlu Li, Ruilan Ma, Haichen Zhang
Frontiers in Oncology.2023;[Epub] CrossRef
Does Breast-Conserving Surgery with Radiotherapy have a Better Survival than Mastectomy? A Meta-Analysis of More than 1,500,000 Patients
Gabriel De la Cruz Ku, Manish Karamchandani, Diego Chambergo-Michilot, Alexis R. Narvaez-Rojas, Michael Jonczyk, Fortunato S. Príncipe-Meneses, David Posawatz, Salvatore Nardello, Abhishek Chatterjee
Annals of Surgical Oncology.2022; 29(10): 6163. CrossRef
Protocol for the postoperative radiotherapy in N1 breast cancer patients (PORT-N1) trial, a prospective multicenter, randomized, controlled, non-inferiority trial of patients receiving breast-conserving surgery or mastectomy
Tae Hoon Lee, Ji Hyun Chang, Bum-Sup Jang, Jae Sik Kim, Tae Hyun Kim, Won Park, Yong Bae Kim, Su Ssan Kim, Wonshik Han, Han-Byoel Lee, Kyung Hwan Shin
BMC Cancer.2022;[Epub] CrossRef
Risk factors to identify the indication for regional nodal irradiation in T1-2N1M0 breast cancer: A joint analysis of 4,243 real-world cases from two institutions
Guang-Yi Sun, Ge Wen, Yu-Jing Zhang, Yu Tang, Hao Jing, Hui Fang, Jian-Yang Wang, Jiang-Hu Zhang, Xu-Ran Zhao, Si-Ye Chen, Yong-Wen Song, Jing Jin, Yue-Ping Liu, Yuan Tang, Shu-Nan Qi, Ning Li, Bo Chen, Ning-Ning Lu, Ye-Xiong Li, Shu-Lian Wang
Frontiers in Oncology.2022;[Epub] CrossRef
Chemo-treated 4T1 breast cancer cells radiation response measured by single and multiple cell ionization using infrared laser trap
Endris Muhammed, Li Chen, Ying Gao, Daniel Erenso
Scientific Reports.2019;[Epub] CrossRef

9,123 View
317 Download
10 Web of Science
9 Crossref

Dummy Run of Quality Assurance Program before Prospective Study of Hippocampus-Sparing Whole-Brain Radiotherapy and Simultaneous Integrated Boost for Multiple Brain Metastases from Non-small Cell Lung Cancer: Korean Radiation Oncology Group (KROG) 17-06 Study: Eunah Chung, Jae Myoung Noh, Kyu Chan Lee, Jin Hee Kim, Weon Kuu Chung, Yang-Gun Suh, Jung Ae Lee, Ki Ho Seol, Hong Gyun Wu, Yeon Sil Kim, O Kyu Noh, Jae Won Park, Dong Soo Lee, Jihae Lee, Young Suk Kim, Woo-Yoon Park, Min Kyu Kang, Sunmi Jo, Yong Chan Ahn; Cancer Res Treat. 2019;51(3):1001-1010. Published online October 15, 2018; DOI: https://doi.org/10.4143/crt.2018.415

Abstract PDF PubReader ePub

Purpose
Lung Cancer Subcommittee of Korean Radiation Oncology Group (KROG) has recently launched a prospective clinical trial (KROG 17-06) of hippocampus-sparing whole brain radiotherapy (HS-WBRT) with simultaneous integrated boost (SIB) in treating multiple brain metastases from non-small cell lung cancer. In order to improve trial quality, dummy run studies among the participating institutions were designed. This work reported the results of two-step dummy run procedures of the KROG 17-06 study.
Materials and Methods
Two steps tested hippocampus contouring variability and radiation therapy planning compliance. In the first step, the variation of the hippocampus delineation was investigated for two representative cases using the Dice similarity coefficients. In the second step, the participating institutions were requested to generate a HS-WBRT with SIB treatment plan for another representative case. The compliance of the treatment plans to the planning protocol was evaluated.
Results
In the first step, the median Dice similarity coefficients of the hippocampus contours for two other dummy run cases changed from 0.669 (range, 0.073 to 0.712) to 0.690 (range, 0.522 to 0.750) and from 0.291 (range, 0.219 to 0.522) to 0.412 (range, 0.264 to 0.598) after providing the hippocampus contouring feedback. In the second step, with providing additional plan priority and extended dose constraints to the target volumes and normal structures, we observed the improved compliance of the treatment plans to the planning protocol.
Conclusion
The dummy run studies demonstrated the notable inter-institutional variability in delineating the hippocampus and treatment plan generation, which could be decreased through feedback from the trial center.

Citations

Citations to this article as recorded by

Radiotherapy trial quality assurance processes: a systematic review
Chloe Brooks, Elizabeth Miles, Peter J Hoskin
The Lancet Oncology.2024; 25(3): e104. CrossRef
Durvalumab with chemoradiotherapy for limited-stage small-cell lung cancer
Sehhoon Park, Jae Myoung Noh, Yoon-La Choi, Sang Ah Chi, Kyunga Kim, Hyun Ae Jung, Se-Hoon Lee, Jin Seok Ahn, Myung-Ju Ahn, Jong-Mu Sun
European Journal of Cancer.2022; 169: 42. CrossRef
Region-Specific Effects of Fractionated Low-Dose Versus Single-Dose Radiation on Hippocampal Neurogenesis and Neuroinflammation
Zoé Schmal, Claudia E. Rübe
Cancers.2022; 14(22): 5477. CrossRef
Non–coplanar whole brain radiotherapy is an effective modality for parotid sparing
Jaehyeon Park, Jae Won Park, Ji Woon Yea
Yeungnam University Journal of Medicine.2019; 36(1): 36. CrossRef

9,058 View
286 Download
4 Web of Science
4 Crossref

Comparative Effectiveness of Abdominal versus Laparoscopic Radical Hysterectomy for Cervical Cancer in the Postdissemination Era: Jin Hee Kim, Kyungjoo Kim, Seo Jin Park, Jung-Yun Lee, Kidong Kim, Myong Cheol Lim, Jae Weon Kim; Cancer Res Treat. 2019;51(2):788-796. Published online September 11, 2018; DOI: https://doi.org/10.4143/crt.2018.120

Abstract PDF Supplementary Material PubReader ePub

Purpose
Despite the benefits of minimally invasive surgery for cervical cancer, there are a lack of randomized trials comparing laparoscopic radical hysterectomy and abdominal radical hysterectomy. We compared morbidity, cost of care, and survival between abdominal radical hysterectomy and laparoscopic radical hysterectomy for cervical cancer.
Materials and Methods
We used the Korean nationwide database to identify women with cervical cancer who underwent radical hysterectomy from January 1, 2011 to December 31, 2014. Patients who underwent abdominal radical hysterectomy were compared to those who underwent laparoscopic radical hysterectomy. Perioperative morbidity, the use of adjuvant therapy, and survival were evaluated after propensity score balancing.
Results
We identified 6,335 patients, including 3,235 who underwent abdominal radical hysterectomy and 3,100 who underwent laparoscopic radical hysterectomy. The use of laparoscopic radical hysterectomy increased from 46.1% in 2011 to 51.8% in 2014. Patients who were younger, had a more recent year of diagnosis, and were treated in the metropolitan area were more likely to undergo a laparoscopic procedure (p < 0.001). Compared to abdominal radical hysterectomy, laparoscopic radical hysterectomy was associated with lower rates of complication, fewertransfusions, a shorter hospital stay, less adjuvant therapy, and reduced total medical costs (p < 0.001). Laparoscopic surgery was associated with a better overall survival than abdominal operation (hazard ratio, 0.74; 95% confidence interval, 0.64 to 0.85).
Conclusion
In the postdissemination era, laparoscopic radical hysterectomy was associated with more favorable morbidity profiles, a lower cost of care, and comparable survival than abdominal radical hysterectomy.

Citations

Citations to this article as recorded by

Internal Validation of Predictive Models for Recurrence-Free Survival and Risk of Recurrence in Patients with Figo Stages I–IV Cervical Cancer
Jorge Cea García, Francisco Márquez Maraver, M. Carmen Rubio Rodríguez, Laura Ríos-Pena, Inmaculada Rodríguez Jiménez
Indian Journal of Gynecologic Oncology.2024;[Epub] CrossRef
Lymph Node Yield, Positivity Ratio, and Overall Survival in Laparoscopic Versus Open Radical Hysterectomy for Carcinoma Cervix: A Retrospective Analysis
Subbiah Shanmugam, Jagadish Singh, Mohanasundaram Natarajan
Indian Journal of Gynecologic Oncology.2024;[Epub] CrossRef
Research Progress on the Therapeutic Effect of Laparoscopic Surgery without Uterine Ma-nipulator on Cervical Cancer
潇予刘
Advances in Clinical Medicine.2023; 13(08): 13249. CrossRef
Meta-analysis of laparoscopic radical hysterectomy, excluding robotic assisted versus open radical hysterectomy for early stage cervical cancer
Greg Marchand, Ahmed Taher Masoud, Ahmed Abdelsattar, Alexa King, Hollie Ulibarri, Julia Parise, Amanda Arroyo, Catherine Coriell, Sydnee Goetz, Carmen Moir, Atley Moberly, Malini Govindan
Scientific Reports.2023;[Epub] CrossRef
Comparison between laparoscopic and abdominal radical hysterectomy for cervical adenosquamous carcinoma at stage IA2 to IIA2: A multicenter retrospective study
Xiaohui Teng, Shan Kang, Weili Li, Hongmei Ding, Bin Ling, Lin Zhu, Danbo Wang, Jinghe Lang, Ping Liu, Chunlin Chen
Journal of Obstetrics and Gynaecology Research.2023; 49(6): 1592. CrossRef
The sealing effect of magnetic-sealing uterine manipulator in isolated uterus from patients with early-stage cervical cancer: a pre-clinical study
Xue Zhou, Dongxin Liang, Qing Li, Lanbo Zhao, Yadi Bin, Feng Ma, Rongqian Wu, Yi Lv, Qiling Li
Journal of Gynecologic Oncology.2023;[Epub] CrossRef
External Validation of the eCura System for Undifferentiated-Type Early Gastric Cancer with Noncurative Endoscopic Resection
Hyo-Joon Yang, Young-Il Kim, Ji Yong Ahn, Kee Don Choi, Sang Gyun Kim, Seong Woo Jeon, Jie-Hyun Kim, Sung Kwan Shin, Hyuk Lee, Wan Sik Lee, Gwang Ha Kim, Jae Myung Park, Woon Geon Shin, Il Ju Choi
Gut and Liver.2023; 17(4): 537. CrossRef
Internal Validation of a Predictive Model for Overall Survival in Patients with FIGO stages I–IV Cervical Cancer
Jorge Cea García, Francisco Márquez Maraver, Inmaculada Rodríguez Jiménez, Laura Ríos-Pena, M. Carmen Rubio Rodríguez
Indian Journal of Gynecologic Oncology.2023;[Epub] CrossRef
A meta-analysis of survival after minimally invasive radical hysterectomy versus abdominal radical hysterectomy in cervical cancer: center-associated factors matter
Si Sun, Jing Cai, Ruixie Li, Yujia Wang, Jing Zhao, Yuhui Huang, Linjuan Xu, Qiang Yang, Zehua Wang
Archives of Gynecology and Obstetrics.2022; 306(3): 623. CrossRef
Association of preoperative cone biopsy with recurrences after radical hysterectomy
Rüdiger Klapdor, Hermann Hertel, Laura Delebinski, Peter Hillemanns
Archives of Gynecology and Obstetrics.2022; 305(1): 215. CrossRef
Comparison between laparoscopic and abdominal radical hysterectomy for low-risk cervical cancer: a multicentre retrospective study
Zhiqiang Li, Chunlin Chen, Ping Liu, Anwei Lu, Hongwei Zhao, Xuemei Zhan, Hui Duan, Pengfei Li, Weidong Zhao, Jilong Yao, Donglin Li, Haixia Jiang, Mubiao Liu, Xiaonong Bin, Jinghe Lang
Archives of Gynecology and Obstetrics.2022; 305(2): 449. CrossRef
Perioperative morbidity of different operative approaches in early cervical carcinoma: a systematic review and meta-analysis comparing minimally invasive versus open radical hysterectomy
J. Kampers, E. Gerhardt, P. Sibbertsen, T. Flock, H. Hertel, R. Klapdor, M. Jentschke, P. Hillemanns
Archives of Gynecology and Obstetrics.2022; 306(2): 295. CrossRef
Retrospective Analysis of Cervical Cancer Treatment Outcomes: Ten Years of Experience with the Vaginal Assisted Radical Laparoscopic Hysterectomy VARLH
R. Wojdat, E. Malanowska, Harald Krentel
BioMed Research International.2022;[Epub] CrossRef
Comparison of Minimally Invasive Versus Abdominal Radical Hysterectomy for Early-Stage Cervical Cancer: An Updated Meta-Analysis
Mengting Zhang, Wei Dai, Yuexiu Si, Yetan Shi, Xiangyuan Li, Ke Jiang, Jingyi Shen, Liying Ying
Frontiers in Oncology.2022;[Epub] CrossRef
The Impaction of Laparoscopic versus Laparotomy for Lymphovascular Space Invasion of Early Cervical Cancer
Wei Huang, Yina Wang, Fanchun Yang, Ning Luo, Guihai Ai, Yuliang Wu, Zhongping Cheng
Gynecology and Minimally Invasive Therapy.2022; 11(1): 17. CrossRef
Retrospective Comparison of Laparoscopic versus Open Radical Hysterectomy for Early-Stage Cervical Cancer in a Single Tertiary Care Institution from Lithuania between 2009 and 2019
Danuta Vasilevska, Dominika Vasilevska, Andrzej Semczuk, Vilius Rudaitis
Medicina.2022; 58(4): 553. CrossRef
The incidence of postoperative symptomatic lymphocele after pelvic lymphadenectomy between abdominal and laparoscopic approach: a systemic review and meta-analysis
Jong Ha Hwang, Bo Wook Kim
Surgical Endoscopy.2022; 36(10): 7114. CrossRef
Comparison of Survival Outcomes between Minimally Invasive Surgery and Open Radical Hysterectomy in Early-Stage Cervical Cancer
I.-Ning Chen, I.-Te Wang, Hsueh-Yu Mu, J.-Timothy Qiu, Wei-Min Liu, Ching-Wen Chang, Yen-Hsieh Chiu
Cancers.2022; 14(9): 2117. CrossRef
Comparison of outcomes between abdominal, minimally invasive and combined vaginal-laparoscopic hysterectomy in patients with stage IAI/IA2 cervical cancer: 4C (Canadian Cervical Cancer Collaborative) study
Sabrina Piedimonte, Gregory R. Pond, Marie Plante, Gregg Nelson, Janice Kwon, Alon Altman, Tomer Feigenberg, Laurie Elit, Susie Lau, Jeanelle Sabourin, Karla Willows, Christa Aubrey, Ji-Hyun Jang, Ly-Ann Teo-Fortin, Norah Cockburn, Nora-Beth Saunders, Sar
Gynecologic Oncology.2022; 166(2): 230. CrossRef
The MEMORY Study: MulticentEr study of Minimally invasive surgery versus Open Radical hYsterectomy in the management of early-stage cervical cancer: Survival outcomes
Mario M. Leitao, Qin C. Zhou, Benny Brandt, Alexia Iasonos, Vasileios Sioulas, Katherine Lavigne Mager, Mark Shahin, Shaina Bruce, Destin R. Black, Carrie G. Kay, Meeli Gandhi, Maira Qayyum, Jennifer Scalici, Nathaniel L. Jones, Rajesh Paladugu, Jubilee B
Gynecologic Oncology.2022; 166(3): 417. CrossRef
New Insights in the Diagnosis of Rare Adenocarcinoma Variants of the Cervix—Case Report and Review of Literature
Cristina Secosan, Oana Balint, Aurora Ilian, Lavinia Balan, Ligia Balulescu, Andrei Motoc, Delia Zahoi, Dorin Grigoras, Laurentiu Pirtea
Healthcare.2022; 10(8): 1410. CrossRef
Learning curve could affect oncologic outcome of minimally invasive radical hysterectomy for cervical cancer
Seongmin Kim, Kyung Jin Min, Sanghoon Lee, Jin Hwa Hong, Jae Yun Song, Jae Kwan Lee, Nak Woo Lee
Asian Journal of Surgery.2021; 44(1): 174. CrossRef
Risk factors of lymph node metastasis after non-curative endoscopic resection of undifferentiated-type early gastric cancer
Hyo-Joon Yang, Jae-Young Jang, Sang Gyun Kim, Ji Yong Ahn, Su Youn Nam, Jie-Hyun Kim, Byung-Hoon Min, Wan-Sik Lee, Bong Eun Lee, Moon Kyung Joo, Jae Myung Park, Woon Geon Shin, Hang Lak Lee, Tae-Geun Gweon, Moo In Park, Jeongmin Choi, Chung Hyun Tae, Youn
Gastric Cancer.2021; 24(1): 168. CrossRef
Clinical outcomes of endoscopic resection for undifferentiated intramucosal early gastric cancer larger than 2 cm
Hyo-Joon Yang, Su Youn Nam, Byung-Hoon Min, Ji Yong Ahn, Jae-Young Jang, Jung Kim, Jie-Hyun Kim, Wan-Sik Lee, Bong Eun Lee, Moon Kyung Joo, Jae Myung Park, Woon Geon Shin, Hang Lak Lee, Tae-Geun Gweon, Moo In Park, Jeongmin Choi, Chung Hyun Tae, Young-Il
Gastric Cancer.2021; 24(2): 435. CrossRef
Conditional relative survival of cervical cancer: a Korean National Cancer Registry Study
Dong Wook Shin, Jaeman Bae, Johyun Ha, Kyu-Won Jung
Journal of Gynecologic Oncology.2021;[Epub] CrossRef
Accuracy of preoperative cross-sectional imaging in cervical cancer patients undergoing primary radical surgery
S. Allison Staley, Katherine R. Tucker, Paola A. Gehrig, Leslie H. Clark
Gynecologic Oncology.2021; 160(2): 384. CrossRef
Comparison of survival outcomes between laparoscopic and abdominal radical hysterectomy for early-stage cervical cancer: A French multicentric study
François Zaccarini, Anna Santy, Yohann Dabi, Vincent Lavoue, Xavier Carcopino, Sofiane Bendifallah, Amélie Benbara, Pierre Collinet, Geoffroy Canlorbe, Emilie Raimond, Olivier Graesslin, Lobna Ouldamer, Emile Daraï, Cyrille Huchon, François Golfier, Cyril
Journal of Gynecology Obstetrics and Human Reproduction.2021; 50(2): 102046. CrossRef
Oncological outcomes of laparoscopic radical hysterectomy versus radical abdominal hysterectomy in patients with early-stage cervical cancer: a multicenter analysis
Juliana Rodriguez, Jose Alejandro Rauh-Hain, James Saenz, David Ortiz Isla, Gabriel Jaime Rendon Pereira, Diego Odetto, Fabio Martinelli, Vladimir Villoslada, Ignacio Zapardiel, Lina Maria Trujillo, Milagros Perez, Marcela Hernandez, Jose Martin Saadi, Fr
International Journal of Gynecological Cancer.2021; 31(4): 504. CrossRef
Minimally Invasive Radical Hysterectomy for Cervical Cancer: A Systematic Review and Meta-analysis
Anna Jo Bodurtha Smith, Tiffany Nicole Jones, Diana Miao, Amanda Nickles Fader
Journal of Minimally Invasive Gynecology.2021; 28(3): 544. CrossRef
Comparison of oncological outcomes and major complications between laparoscopic radical hysterectomy and abdominal radical hysterectomy for stage IB1 cervical cancer with a tumour size less than 2 cm
Zhiqiang Li, Chunlin Chen, Ping Liu, Hui Duan, Mubiao Liu, Yan Xu, Pengfei Li, Wenling Zhang, Haixia Jiang, Xiaonong Bin, Jinghe Lang
European Journal of Surgical Oncology.2021; 47(8): 2125. CrossRef
Cervical Cancer Surgery
Fan Chun Yang, Wei Huang, Weihong Yang, Jie Liu, Guihai Ai, Ning Luo, Jing Guo, Peng Teng Chua, Zhongping Cheng
Gynecology and Minimally Invasive Therapy.2021; 10(2): 75. CrossRef
Protective operative techniques in radical hysterectomy in early cervical carcinoma and their influence on disease-free and overall survival: a systematic review and meta-analysis of risk groups
Johanna Kampers, E. Gerhardt, P. Sibbertsen, T. Flock, R. Klapdor, H. Hertel, M. Jentschke, P. Hillemanns
Archives of Gynecology and Obstetrics.2021; 304(3): 577. CrossRef
The incidence of urologic complications requiring urologic procedure in radical hysterectomy and difference between abdominal radical hysterectomy and laparoscopic radical hysterectomy
Hyeongsu Kim, Ho Jin Jeong, Bo Wook Kim, Jong Ha Hwang
Journal of Gynecologic Oncology.2021;[Epub] CrossRef
Long-term Outcomes of Undifferentiated-Type Early Gastric Cancer with Positive Horizontal Margins after Endoscopic Resection
Hyo-Joon Yang, Wan-Sik Lee, Bong Eun Lee, Ji Yong Ahn, Jae-Young Jang, Joo Hyun Lim, Su Youn Nam, Jie-Hyun Kim, Byung-Hoon Min, Moon Kyung Joo, Jae Myung Park, Woon Geon Shin, Hang Lak Lee, Tae-Geun Gweon, Moo In Park, Jeongmin Choi, Chung Hyun Tae, Young
Gut and Liver.2021; 15(5): 723. CrossRef
Laparoscopic radical hysterectomy has higher risk of perioperative urologic complication than abdominal radical hysterectomy: a meta-analysis of 38 studies
Jong Ha Hwang, Bo Wook Kim
Surgical Endoscopy.2020; 34(4): 1509. CrossRef
Effect of laparoscopic versus abdominal radical hysterectomy on major surgical complications in women with stage IA-IIB cervical cancer in China, 2004–2015
Cong Liang, Ping Liu, Zhumei Cui, Zhiqing Liang, Xiaonong Bin, Jinghe Lang, Chunlin Chen
Gynecologic Oncology.2020; 156(1): 115. CrossRef
Surgical Management of Early Cervical Cancer: When Is Laparoscopic Appropriate?
Stefano Greggi, Gennaro Casella, Felice Scala, Francesca Falcone, Serena Visconti, Cono Scaffa
Current Oncology Reports.2020;[Epub] CrossRef
Minimally invasive surgery versus laparotomy for radical hysterectomy in the management of early-stage cervical cancer: Survival outcomes
Benny Brandt, Vasileios Sioulas, Derman Basaran, Theresa Kuhn, Katherine LaVigne, Ginger J. Gardner, Yukio Sonoda, Dennis S. Chi, Kara C. Long Roche, Jennifer J. Mueller, Elizabeth L. Jewell, Vance A. Broach, Oliver Zivanovic, Nadeem R. Abu-Rustum, Mario
Gynecologic Oncology.2020; 156(3): 591. CrossRef
Changing treatment landscape for early cervical cancer: outcomes reported with minimally invasive surgery compared with an open approach
Alexander Melamed, Pedro T. Ramirez
Current Opinion in Obstetrics & Gynecology.2020; 32(1): 22. CrossRef
Survival After Minimally Invasive vs Open Radical Hysterectomy for Early-Stage Cervical Cancer
Roni Nitecki, Pedro T. Ramirez, Michael Frumovitz, Kate J. Krause, Ana I. Tergas, Jason D. Wright, J. Alejandro Rauh-Hain, Alexander Melamed
JAMA Oncology.2020; 6(7): 1019. CrossRef
Comparison of laparoscopic versus open radical hysterectomy in patients with early-stage cervical cancer: a multicenter study in China
Ting wen yi Hu, Yue Huang, Na Li, Dan Nie, Zhengyu Li
International Journal of Gynecological Cancer.2020; 30(8): 1143. CrossRef
Laparoscopic versus open radical hysterectomy in women with early stage cervical cancer: A systematic review and meta-analysis
Tanitra Tantitamit, Kuan-Gen Huang, Chyi-Long Lee
Taiwanese Journal of Obstetrics and Gynecology.2020; 59(4): 481. CrossRef
Primary conization overcomes the risk of developing local recurrence following laparoscopic radical hysterectomy in early stage cervical cancer
Giorgio Bogani, Antonino Ditto, Valentina Chiappa, Ciro Pinelli, Cristina Sonetto, Francesco Raspagliesi
International Journal of Gynecology & Obstetrics.2020; 151(1): 43. CrossRef
Survival After Minimally Invasive vs. Open Radical Hysterectomy for Cervical Cancer: A Meta-Analysis
Yizi Wang, Bo Li, Fang Ren, Zixuan Song, Ling Ouyang, Kuiran Liu
Frontiers in Oncology.2020;[Epub] CrossRef
Laparoscopic regional radical hysterectomy showed promising clinical outcomes in early-stage cervical cancer
Weihong Yang, Rong Chen, Caixia Li, Li Li, Ning Luo, Zhongping Cheng
Gynecology and Minimally Invasive Therapy.2020; 9(4): 220. CrossRef
A Retrospective Comparison of the Outcomes of Laparoscopic and Open Radical Hysterectomy for Early and Advanced Cancer of the Cervix, in the Post-LACC Era
Subbiah Shanmugam, Sujay Susikar, Syed Afroze Hussain, T. Bharanidharan, Rajiv Michael
Indian Journal of Gynecologic Oncology.2020;[Epub] CrossRef
Comparison of survival outcomes between minimally invasive surgery and conventional open surgery for radical hysterectomy as primary treatment in patients with stage IB1–IIA2 cervical cancer
Se Ik Kim, Jae Hyun Cho, Aeran Seol, Young Im Kim, Maria Lee, Hee Seung Kim, Hyun Hoon Chung, Jae-Weon Kim, Noh Hyun Park, Yong-Sang Song
Gynecologic Oncology.2019; 153(1): 3. CrossRef
Minimally-Invasive Radical Hysterectomy for Cancer of the Cervix: The Perspective of the Society of Gynecologic Oncology of Canada (GOC)
James R. Bentley
Journal of Obstetrics and Gynaecology Canada.2019; 41(2): 143. CrossRef
Hystérectomie radicale à effraction minimale pour le traitement d'un cancer du col de l'utérus : point de vue de la GOC
James R. Bentley
Journal of Obstetrics and Gynaecology Canada.2019; 41(2): 146. CrossRef
Laparoscopic radical hysterectomy with transvaginal closure of vaginal cuff – a multicenter analysis
Christhardt Köhler, Hermann Hertel, Jörg Herrmann, Simone Marnitz, Peter Mallmann, Giovanni Favero, Andrea Plaikner, Peter Martus, Mieczyslaw Gajda, Achim Schneider
International Journal of Gynecological Cancer.2019; 29(5): 845. CrossRef
After the Laparoscopic Approach to Cervical Cancer (LACC) trial: Korean Society of Gynecologic Oncology (KSGO) survey
Miseon Kim, Yong Beom Kim, Jae-Weon Kim
Journal of Gynecologic Oncology.2019;[Epub] CrossRef
Impact of laparoscopic radical hysterectomy on survival outcome in patients with FIGO stage IB cervical cancer: A matching study of two institutional hospitals in Korea
Se Ik Kim, Maria Lee, Sungyoung Lee, Dong Hoon Suh, Hee Seung Kim, Kidong Kim, Hyun Hoon Chung, Jae Hong No, Jae-Weon Kim, Noh Hyun Park, Yong-Sang Song, Yong Beom Kim
Gynecologic Oncology.2019; 155(1): 75. CrossRef

11,819 View
496 Download
53 Web of Science
52 Crossref

The Effect of Hospital Case Volume on Clinical Outcomes in Patients with Nasopharyngeal Carcinoma: A Multi-institutional Retrospective Analysis (KROG-1106): Boram Ha, Kwan Ho Cho, Sung Ho Moon, Chang-Geol Lee, Ki Chang Keum, Yeon-Sil Kim, Hong-Gyun Wu, Jin Ho Kim, Yong Chan Ahn, Dongryul Oh, Jae Myoung Noh, Jong Hoon Lee, Sung Hwan Kim, Won Taek Kim, Young-Taek Oh, Min Kyu Kang, Jin Hee Kim, Ji-Yoon Kim, Moon-June Cho, Chul Seoung Kay, Jin Hwa Choi; Cancer Res Treat. 2019;51(1):12-23. Published online February 5, 2018; DOI: https://doi.org/10.4143/crt.2017.273

Abstract PDF Supplementary Material PubReader ePub

Purpose
The purpose of this study was to investigate the effect of hospital case volume on clinical outcomes in patients with nasopharyngeal carcinoma (NPC).
Materials and Methods
Data on 1,073 patients with cT1-4N0-3M0 NPC were collected from a multi-institutional retrospective database (KROG 11-06). All patients received definitive radiotherapy (RT) either with three-dimensional-conformal RT (3D-CRT) (n=576) or intensity-modulated RT (IMRT) (n=497). The patients were divided into two groups treated at high volume institution (HVI) (n=750) and low volume institution (LVI) (n=323), defined as patient volume ≥ 10 (median, 13; range, 10 to 18) and < 10 patients per year (median, 3; range, 2 to 6), respectively. Endpoints were overall survival (OS) and loco-regional progression-free survival (LRPFS).
Results
At a median follow-up of 56.7 months, the outcomes were significantly better in those treated at HVI than at LVI. For the 614 patients of propensity score-matched cohort, 5-year OS and LRPFS were consistently higher in the HVI group than in the LVI group (OS: 78.4% vs. 62.7%, p < 0.001; LRPFS: 86.2% vs. 65.8%, p < 0.001, respectively). According to RT modality, significant difference in 5-year OS was observed in patients receiving 3D-CRT (78.7% for HVI vs. 58.9% for LVI, p < 0.001) and not in those receiving IMRT (77.3% for HVI vs. 75.5% for LVI, p=0.170).
Conclusion
A significant relationship was observed between HVI and LVI for the clinical outcomes of patients with NPC. However, the difference in outcome becomes insignificant in the IMRT era, probably due to the standardization of practice by education.

Citations

Citations to this article as recorded by

Accumulated Dose Deviation of Rotational and Residual Setup Errors on Nasopharyngeal Carcinoma Using MIM Treated by Helical Tomotherapy
Wenyan Yao, Jiang Hu, Peixun Xu, Mengxue He, Yongwen Fang, Mingzhi Liu, Zongtai Li, Huilang He, Hui Liu, Wenzhao Sun, Senkui Xu
Technology in Cancer Research & Treatment.2023;[Epub] CrossRef
Systematic Review and Meta-analysis of the Association Between Radiation Therapy Treatment Volume and Patient Outcomes
Jerry Ye Aung Kyaw, Alice Rendall, Erin F. Gillespie, Tom Roques, Laurence Court, Yolande Lievens, Alison C. Tree, Chris Frampton, Ajay Aggarwal
International Journal of Radiation Oncology*Biology*Physics.2023; 117(5): 1063. CrossRef
The Influence of Hospital Volume on the Outcomes of Nasopharyngeal, Sinonasal, and Skull-Base Tumors: A Systematic Review of the Literature
Stephanie Flukes, Rahul K. Sharma, Shivangi Lohia, Marc A. Cohen
Journal of Neurological Surgery Part B: Skull Base.2022; 83(03): 270. CrossRef
A Comprehensive Analysis of Treatment Management and Survival Outcomes in Nasopharyngeal Carcinoma
Khodayar Goshtasbi, Brandon M. Lehrich, Jack L. Birkenbeuel, Arash Abiri, Jeremy P. Harris, Edward C. Kuan
Otolaryngology–Head and Neck Surgery.2021; 165(1): 93. CrossRef
Hospital volume and physician volume in association with survival in patients with nasopharyngeal cancer after radiation therapy
Tzu-Yu Lai, Chiu-Mei Yeh, Yu-Wen Hu, Chia-Jen Liu
Radiotherapy and Oncology.2020; 151: 190. CrossRef

10,290 View
215 Download
5 Web of Science
5 Crossref

Breast Conservation Therapy Versus Mastectomy in Patients with T1-2N1 Triple-Negative Breast Cancer: Pooled Analysis of KROG 14-18 and 14-23: Kyubo Kim, Hae Jin Park, Kyung Hwan Shin, Jin Ho Kim, Doo Ho Choi, Won Park, Seung Do Ahn, Su Ssan Kim, Dae Yong Kim, Tae Hyun Kim, Jin Hee Kim, Jiyoung Kim; Cancer Res Treat. 2018;50(4):1316-1323. Published online January 8, 2018; DOI: https://doi.org/10.4143/crt.2017.575

Abstract PDF PubReader ePub

Purpose
The aim of this study is to compare the treatment outcomes of breast conserving surgery (BCS) plus radiotherapy (RT) versus mastectomy for patients with pT1-2N1 triple-negative breast cancer (TNBC).
Materials and Methods
Using two multicenter retrospective studies on breast cancer, a pooled analysis was performed among 320 patients with pT1-2N1 TNBC. All patients who underwent BCS (n=212) receivedwhole breast RTwith orwithoutregional nodal RT,while nonewho underwent mastectomy (n=108)received it. All patients received taxane-based adjuvant chemotherapy. The median follow-up periods were 65 months in the BCS+RT group, and 74 months in the mastectomy group.
Results
The median age of all patients was 48 years (range, 24 to 70 years). Mastectomy group had more patients with multiple tumors (p < 0.001), no lymphovascular invasion (p=0.001), higher number of involved lymph node (p=0.028), and higher nodal ratio ≥ 0.2 (p=0.037). Other characteristics were not significantly different between the two groups. The 5-year locoregionalrecurrence-free, disease-free, and overall survivalrates of BCS+RT group versus mastectomy group were 94.6% versus 87.7%, 89.5% versus 80.4%, and 95.0% versus 87.8%, respectively, and the differences were statistically significant after adjusting for covariates (p=0.010, p=0.006, and p=0.005, respectively).
Conclusion
In pT1-2N1 TNBC, breast conservation therapy achieved better locoregional recurrencefree, disease-free, and overall survival rates compared with mastectomy.

Citations

Citations to this article as recorded by

Breast conserving surgery combined with radiation therapy offers improved survival over mastectomy in early-stage breast cancer
Elizaveta Vasilyeva, Alan Nichol, Brendan Bakos, Anise Barton, Michelle Goecke, Elaine Lam, Erin Martin, Caroline Lohrisch, Elaine McKevitt
The American Journal of Surgery.2024; 231: 70. CrossRef
Oncoplastic Breast Conservation for Central Tumors: Definition, Classification, and the Analysis of Single Institution Experience
Andrii Zhygulin, Artem Fedosov
Plastic and Reconstructive Surgery - Global Open.2024; 12(5): e5789. CrossRef
Treatment Outcomes after Postoperative Radiotherapy in Triple-Negative Breast Cancer: Multi-Institutional Retrospective Study (KROG 17-05)
Jin Kim, Sang Byun, Myeongsoo Kim, Kyung Shin, Dong Kim, Han Lee, Tae Kim, Yeon Kim, Yong Kim, Jee Chang, Kyubo Kim, Sun Lee
Journal of Personalized Medicine.2024; 14(9): 941. CrossRef
Recent Advances in Targeted Nanocarriers for the Management of Triple Negative Breast Cancer
Rajesh Pradhan, Anuradha Dey, Rajeev Taliyan, Anu Puri, Sanskruti Kharavtekar, Sunil Kumar Dubey
Pharmaceutics.2023; 15(1): 246. CrossRef
Breast-Conserving Therapy is Associated with Improved Survival Without an Increased Risk of Locoregional Recurrence Compared with Mastectomy in Both Clinically Node-Positive and Node-Negative Breast Cancer Patients
Elizaveta Vasilyeva, Jeremy Hamm, Alan Nichol, Kathryn V. Isaac, Amy Bazzarelli, Carl Brown, Caroline Lohrisch, Elaine McKevitt
Annals of Surgical Oncology.2023; 30(11): 6413. CrossRef
Postmastectomy Radiation Therapy in Patients With Minimally Involved Lymph Nodes: A Review of the Current Data and Future Directions
Bum-Sup Jang, Kyung Hwan Shin
Journal of Breast Cancer.2022; 25(1): 1. CrossRef
A Review of Current treatment for Triple-Negative Breast Cancer (TNBC)
Wahyuni Wahyuni, Ajeng Diantini, Mohammad Ghozali, Sahidin I
Research Journal of Pharmacy and Technology.2022; : 409. CrossRef
Long non-coding RNA MRPS30 divergent transcript can be detected in the cytoplasm of triple-negative breast cancer cells and is targeted by microRNA-130b
Dongtao Wang, Qiang Song, Tianyong Zhao, Fang Wang, Yang Yu, Jing Qi, Pengfei Lyu, Xiangyang Duan
Bioengineered.2022; 13(3): 5954. CrossRef
Breast-conserving surgery versus mastectomy for older women with triple-negative breast cancer: population-based study
Waruiru Mburu, Shalini Kulasingam, James S Hodges, Beth A Virnig
Journal of Comparative Effectiveness Research.2022; 11(13): 953. CrossRef
Determining prognostic factors and optimal surgical intervention for early-onset triple-negative breast cancer
Yi-Zi Zheng, Yan Liu, Zhen-Han Deng, Guo-Wen Liu, Ni Xie
Frontiers in Oncology.2022;[Epub] CrossRef
Postoperative Radiotherapy Contributes to the Survival Benefit of Breast-Conserving Therapy over Mastectomy
Chu-Ying Chen, Si-Yue Zheng, Gang Cai, Cheng Xu, Rong Cai, Min Li, Kun-Wei Shen, Xiao-Song Chen, Dan Ou, Wei-Xiang Qi, Lu Cao, Jia-Yi Chen, Weiren Luo
Journal of Oncology.2022; 2022: 1. CrossRef
Значення локорегіонарної терапії у хворих на тричі негативний рак грудної залози (огляд літератури)
M.V. Pavlushenko, R.V. Liubota, R.I. Vereshchako, O.S. Zotov, M.F. Anikusko, I.I. Liubota
Practical oncology.2022; 5(1): 23. CrossRef
Breast conservation therapy confers survival and distant recurrence advantage over mastectomy for stage II Triple Negative Breast cancer
Rebekah Macfie, Cynthia Aks, Kathryn Panwala, Nathalie Johnson, Jennifer Garreau
The American Journal of Surgery.2021; 221(4): 809. CrossRef
Outcomes after breast-conserving surgery or mastectomy in patients with triple-negative breast cancer: meta-analysis
A Fancellu, N Houssami, V Sanna, A Porcu, C Ninniri, M L Marinovich
British Journal of Surgery.2021; 108(7): 760. CrossRef
Are the Outcomes of Breast Conservation Surgery Inferior to Those of Mastectomy in Patients with Stage II-IIIA Triple-Negative Breast Cancer?
Seungju Lee, Hyun Yul Kim, Youn Joo Jung, Hyun-June Paik, Dong-Il Kim, Chang Shin Jung, Seok-Kyung Kang, Jee Yeon Kim, Seokwon Lee, Youngtae Bae
Journal of Breast Disease.2021; 9(2): 77. CrossRef
Thrombin generation predicts early recurrence in breast cancer patients
Marina Marchetti, Cinzia Giaccherini, Giovanna Masci, Cristina Verzeroli, Laura Russo, Luigi Celio, Roberta Sarmiento, Sara Gamba, Carmen J. Tartari, Erika Diani, Alfonso Vignoli, Paolo Malighetti, Daniele Spinelli, Nicole M. Kuderer, Federico Nichetti, M
Journal of Thrombosis and Haemostasis.2020; 18(9): 2220. CrossRef
Molecular Investigation on a Triple Negative Breast Cancer Xenograft Model Exposed to Proton Beams
Francesco P. Cammarata, Giusi I. Forte, Giuseppe Broggi, Valentina Bravatà, Luigi Minafra, Pietro Pisciotta, Marco Calvaruso, Roberta Tringali, Barbara Tomasello, Filippo Torrisi, Giada Petringa, Giuseppe A. P. Cirrone, Giacomo Cuttone, Rosaria Acquaviva,
International Journal of Molecular Sciences.2020; 21(17): 6337. CrossRef
Radiotherapy plays an important role in improving the survival outcome in patients with T1–2N1M0 breast cancer – a joint analysis of 4262 real world cases from two institutions
Guang-Yi Sun, Ge Wen, Yu-Jing Zhang, Yu Tang, Hao Jing, Jian-Yang Wang, Jiang-Hu Zhang, Yong Yang, Xu-Ran Zhao, Si-Ye Chen, Jing Jin, Yong-Wen Song, Yue-Ping Liu, Hui Fang, Hua Ren, Yuan Tang, Shu-Nan Qi, Ning Li, Bo Chen, Ning-Ning Lu, Shu-Lian Wang, Ye-
BMC Cancer.2020;[Epub] CrossRef
Mastectomy or Breast-Conserving Therapy for Early Breast Cancer in Real-Life Clinical Practice: Outcome Comparison of 7565 Cases
Stefanie Corradini, Daniel Reitz, Montserrat Pazos, Stephan Schönecker, Michael Braun, Nadia Harbeck, Christiane Matuschek, Edwin Bölke, Ute Ganswindt, Filippo Alongi, Maximilian Niyazi, Claus Belka
Cancers.2019; 11(2): 160. CrossRef
Are breast conservation treatment rates optimized for Asian women with symptomatic malignancies?
Mona P. C. Tan, Yih Yiow Sitoh
ANZ Journal of Surgery.2019; 89(5): 529. CrossRef

9,273 View
222 Download
16 Web of Science
20 Crossref

The Prognostic Impact of the Number of Metastatic Lymph Nodes and a New Prognostic Scoring System for Recurrence in Early-Stage Cervical Cancer with High Risk Factors: A Multicenter Cohort Study (KROG 15-04): Jeanny Kwon, Keun-Young Eom, Young Seok Kim, Won Park, Mison Chun, Jihae Lee, Yong Bae Kim, Won Sup Yoon, Jin Hee Kim, Jin Hwa Choi, Sei Kyung Chang, Bae Kwon Jeong, Seok Ho Lee, Jihye Cha; Cancer Res Treat. 2018;50(3):964-974. Published online October 24, 2017; DOI: https://doi.org/10.4143/crt.2017.346

Abstract PDF Supplementary Material PubReader ePub

Purpose
We aimed to assess prognostic value of metastatic pelvic lymph node (mPLN) in early-stage cervical cancer treated with radical surgery followed by postoperative chemoradiotherapy. Also, we sought to define a high-risk group using prognosticators for recurrence.
Materials and Methods
A multicenter retrospective study was conducted using the data from 13 Korean institutions from 2000 to 2010. A total of 249 IB-IIA patients with high-risk factors were included. We evaluated distant metastasis-free survival (DMFS) and disease-free survival (DFS) in relation to clinicopathologic factors including pNstage, number of mPLN, lymph node (LN)ratio (number of positive LN/number of harvested LN), and log odds of mPLNs (log(number of positive LN+0.5/number of negative LN+0.5)).
Results
In univariate analysis, histology (squamous cell carcinoma [SqCC] vs. others), lymphovascular invasion (LVI), number of mPLNs (≤ 3 vs. > 3), LN ratio (≤ 17% vs. > 17%), and log odds of mPLNs (≤ ‒0.58 vs. > ‒0.58) were significant prognosticators for DMFS and DFS. Resection margin involvement only affected DFS. No significant survival difference was observed between pN0 patients and patients with 1-3 mPLNs. Multivariate analysis revealed that mPLN > 3, LVI, and non-SqCC were unfavorable index for both DMFS (p < 0.001, p=0.020, and p=0.031, respectively) and DFS (p < 0.001, p=0.017, and p=0.001, respectively). A scoring system using these three factors predicts risk of recurrence with relatively high concordance index (DMFS, 0.69; DFS, 0.71).
Conclusion
mPLN > 3 in early-stage cervical cancer affects DMFS and DFS. A scoring system using mPLNs > 3, LVI, and non-SqCC could stratify risk groups of recurrence in surgically resected early-stage cervix cancer with high-risk factors.

Citations

Citations to this article as recorded by

Should all cervical cancer patients with positive lymph node receive definitive radiotherapy: a population-based comparative study
Yang Wang, Xingyu Liu, Jing Liu, Liying Liu, Yue Ma
Archives of Gynecology and Obstetrics.2025; 311(1): 123. CrossRef
Current Paradigm and Future Directions in the Management of Nodal Disease in Locally Advanced Cervical Cancer
Elki Sze-Nga Cheung, Philip Yuguang Wu
Cancers.2025; 17(2): 202. CrossRef
Spectral computed tomography in the assessment of metastatic lymph nodes in cervical cancer patients treated with definitive radiotherapy: a single-center, prospective study
Zheng Zeng, Yining Chen, Yuliang Sun, Bing Zhou, Haoran Xu, Lei He, Ke Hu, Jie Qiu, Fuquan Zhang, Junfang Yan
Clinical & Experimental Metastasis.2025;[Epub] CrossRef
Significance of tumor size and number of positive nodes in patients with FIGO 2018 stage IIIC1 cervical cancer
Michihide Maeda, Seiji Mabuchi, Mina Sakata, Satoki Deguchi, Reisa Kakubari, Shinya Matsuzaki, Tsuyoshi Hisa, Shoji Kamiura
Japanese Journal of Clinical Oncology.2024; 54(2): 146. CrossRef
Internal Validation of Predictive Models for Recurrence-Free Survival and Risk of Recurrence in Patients with Figo Stages I–IV Cervical Cancer
Jorge Cea García, Francisco Márquez Maraver, M. Carmen Rubio Rodríguez, Laura Ríos-Pena, Inmaculada Rodríguez Jiménez
Indian Journal of Gynecologic Oncology.2024;[Epub] CrossRef
Prediction of recurrence-related factors for patients with early-stage cervical cancer following radical hysterectomy and adjuvant radiotherapy
Gui-Fen Ma, Gen-Lai Lin, Si-Tong Wang, Ya-Yu Huang, Chun-Li Xiao, Jing Sun, Ting-Yan Shi, Li-Bing Xiang
BMC Women's Health.2024;[Epub] CrossRef
Based on 3D-PDU and clinical characteristics nomogram for prediction of lymph node metastasis and lymph-vascular space invasion of early cervical cancer preoperatively
Shuang Dong, Yan-Qing Peng, Ya-Nan Feng, Xiao-Ying Li, Li-Ping Gong, Shuang Zhang, Xiao-Shan Du, Li-Tao Sun
BMC Women's Health.2024;[Epub] CrossRef
Predictive value of number of metastatic lymph nodes and lymph node ratio for prognosis of patients with FIGO 2018 stage IIICp cervical cancer: a multi-center retrospective study
Yanna Ye, Rui Lian, Zhiqiang Li, Xiaolin Chen, Yahong Huang, Jilong Yao, Anwei Lu, Jinghe Lang, Ping Liu, Chunlin Chen
BMC Cancer.2024;[Epub] CrossRef
Prognostic Factors for Cervical Cancer in Asian Populations: A Scoping Review of Research From 2013 to 2023
Syed S Abrar, Seoparjoo Azmel Mohd Isa, Suhaily Mohd Hairon, Najib M Yaacob, Mohd Pazudin Ismail
Cureus.2024;[Epub] CrossRef
New Classification of Tumor Microvessels and the Risk of Regional Metastasis in Squamous Cell and Glandular Cancers
Marina Senchukova
American Journal of Clinical and Experimental Medicine.2024; 12(5): 61. CrossRef
Analysis of prognostic factors for cervical mucinous adenocarcinoma and establishment and validation a nomogram: a SEER-based study
Yiping Hao, Qingqing Liu, Ruowen Li, Zhonghao Mao, Nan Jiang, Bingyu Wang, Wenjing Zhang, Baoxia Cui
Journal of Obstetrics and Gynaecology.2023;[Epub] CrossRef
Validation of the 2018 FIGO Staging System for Predicting the Prognosis of Patients With Stage IIIC Cervical Cancer
Xingtao Long, Misi He, Lingling Yang, Dongling Zou, Dong Wang, Yuemei Chen, Qi Zhou
Clinical Medicine Insights: Oncology.2023;[Epub] CrossRef
Development of novel tracers for sentinel node identification in cervical cancer
Keisuke Kodama, Chuya Tateishi, Tsuyoshi Oda, Lin Cui, Kazutaka Kuramoto, Hideaki Yahata, Kaoru Okugawa, Shoji Maenohara, Hiroshi Yagi, Masafumi Yasunaga, Ichiro Onoyama, Kazuo Asanoma, Takeshi Mori, Yoshiki Katayama, Kiyoko Kato
Cancer Science.2023; 114(11): 4216. CrossRef
Preoperative prediction of cervical cancer survival using a high-resolution MRI-based radiomics nomogram
Jia Li, Hao Zhou, Xiaofei Lu, Yiren Wang, Haowen Pang, Daniel Cesar, Aiai Liu, Ping Zhou
BMC Medical Imaging.2023;[Epub] CrossRef
Abdominal Radical Hysterectomy as an Alternative Treatment Option for Patients with Cervical Cancer without Access to Radiotherapy Facilities
Yanna Ye, Zhiqiang Li, Biliang Chen, Shan Kang, Bin Ling, Li Wang, Jilong Yao, Jinghe Lan, Ping Liu, Chunlin Chen
Clinical and Experimental Obstetrics & Gynecology.2023;[Epub] CrossRef
Canine anal sac gland carcinoma with regional lymph node metastases treated with sacculectomy and lymphadenectomy: Outcome and possible prognostic factors
Jean‐Benoit Tanis, Angharad B. Simlett‐Moss, Malgorzata Ossowksa, Thomas W. Maddox, James Guillem, Cristobal Lopez‐Jimenez, Gerry Polton, Rachel Burrow, Riccardo Finotello
Veterinary and Comparative Oncology.2022; 20(1): 276. CrossRef
The prognostic value of the number of positive lymph nodes and the lymph node ratio in early‐stage cervical cancer
Ester P. Olthof, Constantijne H. Mom, Malou L. H. Snijders, Hans H. B. Wenzel, Jacobus van der Velden, Maaike A. van der Aa
Acta Obstetricia et Gynecologica Scandinavica.2022; 101(5): 550. CrossRef
Development and Validation of Novel Nomograms to Predict the Overall Survival and Cancer-Specific Survival of Cervical Cancer Patients With Lymph Node Metastasis
Jianying Yi, Zhili Liu, Lu Wang, Xingxin Zhang, Lili Pi, Chunlei Zhou, Hong Mu
Frontiers in Oncology.2022;[Epub] CrossRef
Treatment Strategies and Prognostic Factors of 2018 FIGO Stage IIIC Cervical Cancer: A Review
Fengying Qin, Huiting Pang, Tao Yu, Yahong Luo, Yue Dong
Technology in Cancer Research & Treatment.2022;[Epub] CrossRef
Tumoral Morphologic Features From Cervical Biopsies That Are Predictive of a Negligible Risk for Nodal Metastasis and Tumor Recurrence in Usual-type Cervical Adenocarcinomas
Yue Wang, Ruby Jean Chang, Rong-Zhen Luo, Jing Yu, Xiaofei Zhang, Xianghong Yang, M.R. Quddus, Li Li, Wentao Yang, Aijun Liu, Qingping Jiang, Ruijiao Zhao, Huiting Zhu, Feng Zhou, Yiying Wang, Xiujie Sheng, Li-Li Liu, Yan-Lin Wen, Natalie Banet, C.J. Sung
American Journal of Surgical Pathology.2022; 46(5): 713. CrossRef
Significance of the Number and the Location of Metastatic Lymph Nodes in Locally Recurrent or Persistent Cervical Cancer Patients Treated with Salvage Hysterectomy plus Lymphadenectomy
Seiji Mabuchi, Naoko Komura, Michiko Kodama, Michihide Maeda, Yuri Matsumoto, Shoji Kamiura
Current Oncology.2022; 29(7): 4856. CrossRef
Development and validation of a nomogram for predicting pelvic lymph node metastasis and prognosis in patients with cervical cancer
Mengting Wang, Min Ma, Liju Yang, Chengtong Liang
Frontiers in Oncology.2022;[Epub] CrossRef
High expression of PYK2 is associated with poor prognosis and cancer progression in early-stage cervical carcinoma
Can Zhang, Xinghua Zhu, Yong Li, Jia Shao, Haibo Xu, Lei Chen, Youli Dan, Hua Jin, Aiqin He
Medicine.2022; 101(41): e31178. CrossRef
Whether individualized dose escalation should be recommended for lymph nodes with different sizes in the definitive radiotherapy of cervical cancer?
Xiaojuan Lv, Huiting Rao, Tao Feng, Chufan Wu, Hanmei Lou
Radiation Oncology.2022;[Epub] CrossRef
Prognostic value of lymph node ratio in cervical cancer: A meta-analysis
Haixia Cui, Yuan Huang, Weibo Wen, Xiangdan Li, Dongyuan Xu, Lan Liu
Medicine.2022; 101(42): e30745. CrossRef
The Impact of Revised FIGO 2018 Staging System on Survival Outcomes in Patients with Carcinoma Cervix
Sharanya Sathish, Geeta Acharaya, Kiran Kulkarni, Gayatri Ravikumar
Indian Journal of Gynecologic Oncology.2022;[Epub] CrossRef
Lymph Node Ratio Is a Strong Prognostic Factor in Patients with Early-Stage Cervical Cancer Undergoing Minimally Invasive Radical Hysterectomy
Se Ik Kim, Tae Hun Kim, Maria Lee, Hee Seung Kim, Hyun Hoon Chung, Taek Sang Lee, Hye Won Jeon, Jae-Weon Kim, Noh Hyun Park, Yong-Sang Song
Yonsei Medical Journal.2021; 62(3): 231. CrossRef
Recurrence pattern and prognostic factors for survival in cervical cancer with lymph node metastasis
Cigdem Kilic, Gunsu Kimyon Comert, Caner Cakir, Dilek Yuksel, Bahadır Codal, Fatih Kilic, Osman Turkmen, Alper Karalok, Ozlem Moraloglu Tekin, Nurettin Boran, Taner Turan
Journal of Obstetrics and Gynaecology Research.2021; 47(6): 2175. CrossRef
Risk factors for nodal failure after radiochemotherapy and image guided brachytherapy in locally advanced cervical cancer: An EMBRACE analysis
Max Peters, Astrid A.C. de Leeuw, Christel N. Nomden, Kari Tanderup, Kathrin Kirchheiner, Jacob C. Lindegaard, Christian Kirisits, Christine Haie-Meder, Alina Sturdza, Lars Fokdal, Umesh Mahantshetty, Peter Hoskin, Barbara Segedin, Kjersti Bruheim, Bhavan
Radiotherapy and Oncology.2021; 163: 150. CrossRef
Prognostic Value of Lymph Node Characteristics in Patients with Cervical Cancer Treated with Radical Hysterectomy
Yoon Hee Lee, Gun Oh Chong, Su Jeong Kim, Ja Hyun Hwang, Jong Mi Kim, Nora Jee-Young Park, Dae Gy Hong
Cancer Management and Research.2021; Volume 13: 8137. CrossRef
The Combination of T Stage and the Number of Pathologic Lymph Nodes Provides Better Prognostic Discrimination in Early-Stage Cervical Cancer With Lymph Node Involvement
Yongrui Bai, Ling Rong, Bin Hu, Xiumei Ma, Jiahui Wang, Haiyan Chen
Frontiers in Oncology.2021;[Epub] CrossRef
The prognostic value of lymph node ratio in stage IIIC cervical cancer patients triaged to primary treatment by radical hysterectomy with systematic pelvic and para-aortic lymphadenectomy
Koray Aslan, Mehmet Mutlu Meydanli, Murat Oz, Yusuf Aytac Tohma, Ali Haberal, Ali Ayhan
Journal of Gynecologic Oncology.2020;[Epub] CrossRef
Predictive value of preoperative serum squamous cell carcinoma antigen (SCC–Ag) level on tumor recurrence in cervical squamous cell carcinoma patients treated with radical surgery: A single-institution study
Qinhao Guo, Jun Zhu, Yong Wu, Hao Wen, Lingfang Xia, Xiaohua Wu, Xingzhu Ju
European Journal of Surgical Oncology.2020; 46(1): 131. CrossRef
Effects of preoperative radiotherapy or chemoradiotherapy on postoperative pathological outcome of cervical cancer——from the large database of 46,313 cases of cervical cancer in China
Weili Li, Ping Liu, Weidong Zhao, Zhaohong Yin, Zhong Lin, Xiaonong Bin, Jinghe Lang, Chunlin Chen
European Journal of Surgical Oncology.2020; 46(1): 148. CrossRef
DSG2 expression is correlated with poor prognosis and promotes early-stage cervical cancer
Shuhang Qin, Yuandong Liao, Qiqiao Du, Wei Wang, Jiaming Huang, Pan Liu, Chunliang Shang, Tianyu Liu, Meng Xia, Shuzhong Yao
Cancer Cell International.2020;[Epub] CrossRef
Should the Number of Metastatic Pelvic Lymph Nodes Be Integrated into the 2018 Figo Staging Classification of Early Stage Cervical Cancer?
Luigi Pedone Anchora, Vittoria Carbone, Valerio Gallotta, Francesco Fanfani, Francesco Cosentino, Luigi Carlo Turco, Camilla Fedele, Nicolò Bizzarri, Giovanni Scambia, Gabriella Ferrandina
Cancers.2020; 12(6): 1552. CrossRef
UGT1A1 polymorphism has a prognostic effect in patients with stage IB or II uterine cervical cancer and one or no metastatic pelvic nodes receiving irinotecan chemotherapy: a retrospective study
Hideki Matsuoka, Ryusuke Murakami, Kaoru Abiko, Ken Yamaguchi, Akihito Horie, Junzo Hamanishi, Tsukasa Baba, Masaki Mandai
BMC Cancer.2020;[Epub] CrossRef
Validation of the 2018 FIGO Classification for Cervical Cancer: Lymphovascular Space Invasion Should Be Considered in IB1 Stage
Vincent Balaya, Benedetta Guani, Laurent Magaud, Hélène Bonsang-Kitzis, Charlotte Ngô, Patrice Mathevet, Fabrice Lécuru
Cancers.2020; 12(12): 3554. CrossRef
Burden of lymphatic disease predicts efficacy of adjuvant radiation and chemotherapy in FIGO 2018 stage IIICp cervical cancer
Giorgio Bogani, Daniele Vinti, Ferdinando Murgia, Valentina Chiappa, Umberto Leone Roberti Maggiore, Fabio Martinelli, Antonino Ditto, Francesco Raspagliesi
International Journal of Gynecological Cancer.2019; 29(9): 1355. CrossRef
Prognostic factors for and pattern of lymph-node involvement in patients with operable cervical cancer
P. Widschwendter, W. Janni, C. Scholz, A. De Gregorio, N. De Gregorio, T W P Friedl
Archives of Gynecology and Obstetrics.2019; 300(6): 1709. CrossRef
Postoperative chemotherapy for node-positive cervical cancer: Results of a multicenter phase II trial (JGOG1067)
Maki Matoda, Nobuhiro Takeshima, Hirofumi Michimae, Takashi Iwata, Harushige Yokota, Yutaka Torii, Yorito Yamamoto, Kazuhiro Takehara, Shin Nishio, Hirokuni Takano, Mika Mizuno, Yoshiyuki Takahashi, Yuji Takei, Tetsuya Hasegawa, Mikio Mikami, Takayuki Eno
Gynecologic Oncology.2018; 149(3): 513. CrossRef

10,620 View
339 Download
49 Web of Science
41 Crossref

Prognostic Impact of Elective Supraclavicular Nodal Irradiation for Patients with N1 Breast Cancer after Lumpectomy and Anthracycline Plus Taxane-Based Chemotherapy (KROG 1418): A Multicenter Case-Controlled Study: Haeyoung Kim, Won Park, Jeong Il Yu, Doo Ho Choi, Seung Jae Huh, Yeon-Joo Kim, Eun Sook Lee, Keun Seok Lee, Han-Sung Kang, In Hae Park, Kyung Hwan Shin, Chan Woo Wee, Kyubo Kim, Kyung Ran Park, Yong Bae Kim, Sung Ja Ahn, Jong Hoon Lee, Jin Hee Kim, Mison Chun, Hyung-Sik Lee, Jung Soo Kim, Jihye Cha; Cancer Res Treat. 2017;49(4):970-980. Published online January 4, 2017; DOI: https://doi.org/10.4143/crt.2016.382

Abstract PDF Supplementary Material PubReader ePub

Purpose
This study was conducted to evaluate the impact of supraclavicular lymph node radiotherapy (SCNRT) on N1 breast cancer patients receiving post-lumpectomy whole-breast irradiation (WBI) and anthracycline plus taxane-based (AT) chemotherapy.
Materials and Methods
We performed a case-control analysis to compare the outcomes of WBI and WBI plus SCNRT (WBI+SCNRT). Among 1,147 patients with N1 breast cancer who received post-lumpectomy radiotherapy and AT-based chemotherapy in 12 hospitals, 542 were selected after propensity score matching. Patterns of failure, disease-free survival (DFS), distant metastasis-free survival (DMFS), and treatment-related toxicity were compared between groups.
Results
A total of 41 patients (7.6%) were found to have recurrence. Supraclavicular lymph node (SCN) failure was detected in three patients, two in WBI and one in WBI+SCNRT. All SCN failures were found simultaneously with distant metastasis. There was no significant difference in patterns of failure or survival between groups. The 5-year DFS and DMFS for patients with WBI and WBI+SCNRT were 94.4% versus 92.6% (p=0.50) and 95.1% versus 94.5% (p=0.99), respectively. The rates of lymphedema and radiation pneumonitis were significantly higher in the WBI+SCNRT than in the WBI.
Conclusion
We did not find a benefit of SCNRT for N1 breast cancer patients receiving AT-based chemotherapy.

Citations

Citations to this article as recorded by

Patient-Reported Outcomes Between Whole-Breast Plus Regional Irradiation and Whole-Breast Irradiation Only in pN1 Breast Cancer After Breast-Conserving Surgery and Taxane-Based Chemotherapy: A Randomized Phase 3 Clinical Trial (KROG 17-01)
Nalee Kim, Won Park, Haeyoung Kim, Won Kyung Cho, Sung Ja Ahn, Mi Young Kim, Shin-Hyung Park, Ik Jae Lee, Inbong Ha, Jin Hee Kim, Tae Hyun Kim, Kyu Chan Lee, Hyung-Sik Lee, Tae Gyu Kim, Kyung Hwan Shin, Jong Hoon Lee, Jinhong Jung, Oyeon Cho, Yong Bae Kim
International Journal of Radiation Oncology*Biology*Physics.2025; 121(2): 341. CrossRef
De-escalation of regional nodal irradiation fields in pT1-2N1 breast cancer patients after breast conserving surgery: retrospective real-world clinical experience
Ji Hyun Hong, Jin-Ho Song, Kyu-Hye Choi, Shin Woo Kim, Woo-Chan Park, Jieun Lee, Ahwon Lee, Jun Kang, Byung-Ock Choi
Frontiers in Oncology.2025;[Epub] CrossRef
The optimal regional irradiation volume for breast cancer patients: A comprehensive systematic review and network meta-analysis of published studies
Wei-Xiang Qi, Lu Cao, Cheng Xu, Gang Cai, Jiayi Chen
Frontiers in Oncology.2023;[Epub] CrossRef
Protocol for the postoperative radiotherapy in N1 breast cancer patients (PORT-N1) trial, a prospective multicenter, randomized, controlled, non-inferiority trial of patients receiving breast-conserving surgery or mastectomy
Tae Hoon Lee, Ji Hyun Chang, Bum-Sup Jang, Jae Sik Kim, Tae Hyun Kim, Won Park, Yong Bae Kim, Su Ssan Kim, Wonshik Han, Han-Byoel Lee, Kyung Hwan Shin
BMC Cancer.2022;[Epub] CrossRef
What Is High-risk Breast Cancer With Pathologically Negative Lymph Nodes for Regional Recurrence?
Sang-Won Kim, Won Kyung Cho, Doo Ho Choi, Haeyoung Kim, Oyeon Cho, Won Park, Mison Chun
International Journal of Radiation Oncology*Biology*Physics.2021; 111(4): 992. CrossRef
Regional nodal irradiation in pT1-2N1 breast cancer patients treated with breast-conserving surgery and whole breast irradiation
Shin-Hyung Park, Jae-Chul Kim
Radiation Oncology Journal.2020; 38(1): 44. CrossRef
Prediction of nodal staging in breast cancer patients with 1-2 sentinel nodes in the Z0011 era
Fabio Corsi, Luca Sorrentino, Sara Albasini, Daniela Bossi, Carlo Morasso, Laura Villani, Marta Truffi
Medicine.2020; 99(35): e21721. CrossRef
Locoregional recurrence patterns in women with breast cancer who have not undergone post-mastectomy radiotherapy
Xuran Zhao, Yu Tang, Shulian Wang, Yong Yang, Hui Fang, Jianyang Wang, Hao Jing, Jianghu Zhang, Guangyi Sun, Siye Chen, Jing Jin, Yongwen Song, Yueping Liu, Bo Chen, Shunan Qi, Ning Li, Yuan Tang, Ningning Lu, Hua Ren, Yexiong Li
Radiation Oncology.2020;[Epub] CrossRef
Comparison of Dose Distribution in Regional Lymph Nodes in Whole-Breast Radiotherapy vs. Whole-Breast Plus Regional Lymph Node Irradiation: An In Silico Planning Study in Participating Institutions of the Phase III Randomized Trial (KROG 1701)
Haeyoung Kim, Heejung Kim, Won Park, Jong Yun Baek, Sung Ja Ahn, Mi Young Kim, Shin-Hyung Park, Ik Jae Lee, Inbong Ha, Jin Hee Kim, Tae Hyun Kim, Kyu Chan Lee, Hyung-Sik Lee, Tae Gyu Kim, Jin Ho Kim, Jong Hoon Lee, Jinhong Jung, Oyeon Cho, Jee Suk Chang,
Cancers.2020; 12(11): 3261. CrossRef
Clinical Significance of Lymph-Node Ratio in Determining Supraclavicular Lymph-Node Radiation Therapy in pN1 Breast Cancer Patients Who Received Breast-Conserving Treatment (KROG 14-18): A Multicenter Study
Jaeho Kim, Won Park, Jin Kim, Doo Choi, Yeon-Joo Kim, Eun Lee, Kyung Shin, Jin Kim, Kyubo Kim, Yong Kim, Sung-Ja Ahn, Jong Lee, Mison Chun, Hyung-Sik Lee, Jung Kim, Jihye Cha
Cancers.2019; 11(5): 680. CrossRef
Breast Conservation Therapy Versus Mastectomy in Patients with T1-2N1 Triple-Negative Breast Cancer: Pooled Analysis of KROG 14-18 and 14-23
Kyubo Kim, Hae Jin Park, Kyung Hwan Shin, Jin Ho Kim, Doo Ho Choi, Won Park, Seung Do Ahn, Su Ssan Kim, Dae Yong Kim, Tae Hyun Kim, Jin Hee Kim, Jiyoung Kim
Cancer Research and Treatment.2018; 50(4): 1316. CrossRef

10,675 View
319 Download
10 Web of Science
11 Crossref

Postmastectomy Radiotherapy in Patients with pT1-2N1 Breast Cancer Treated with Taxane-Based Chemotherapy: A Retrospective Multicenter Analysis (KROG 1418): Yeon-Joo Kim, Won Park, Boram Ha, Boram Park, Jungnam Joo, Tae Hyun Kim, In Hae Park, Keun Seok Lee, Eun Sook Lee, Kyung Hwan Shin, Haeyoung Kim, Jeong Il Yu, Doo Ho Choi, Seung Jae Huh, Chan Woo Wee, Kyubo Kim, Kyung Ran Park, Yong Bae Kim, Sung Ja Ahn, Jong Hoon Lee, Jin Hee Kim, Mison Chun, Hyung-Sik Lee, Jung Soo Kim, Jihye Cha; Cancer Res Treat. 2017;49(4):927-936. Published online December 26, 2016; DOI: https://doi.org/10.4143/crt.2016.508

Abstract PDF Supplementary Material PubReader ePub

Purpose
The purpose of this study was to evaluate the impact of postmastectomy radiotherapy (PMRT) on loco-regional recurrence-free survival (LRRFS), disease-free survival (DFS), and overall survival (OS) in pT1-2N1 patients treated with taxane-based chemotherapy.
Materials and Methods
We retrospectively reviewed the medical data of pathological N1 patients who were treated with modified radical mastectomy and adjuvant taxane-based chemotherapy in 12 hospitals between January 2006 and December 2010.
Results
We identified 714 consecutive patients. The median follow-up duration was 69 months (range, 1 to 114 months) and the 5-year LRRFS, DFS, and OS rates were 97%, 94%, and 98%, respectively, in patients who received PMRT (PMRT [+]). The corresponding figures were 96%, 90%, and 96%, respectively, in patients who did not receive PMRT (PMRT [–]). PMRT had no significant impact on survival. Upon multivariable analysis, only the histological grade (HG) was statistically significant as a prognostic factor for LRRFS and DFS. In a subgroup analysis of HG 3 patients, PMRT (+) showed better DFS (p=0.081).
Conclusion
PMRT had no significant impact on LRRFS, DFS, or OS in pT1-2N1 patients treated with taxane-based chemotherapy. PMRT showed a marginal benefit for DFS in HG 3 patients. Randomized studies are needed to confirm the benefit of PMRT in high risk patients, such as those with HG 3.

Citations

Citations to this article as recorded by

Does Post-Mastectomy Radiotherapy Confer Survival Benefits on Patients With 1-3 Clinically Positive Lymph Nodes Rendered Pathologically Negative After Neoadjuvant Systemic Chemotherapy: Consensus from A Pooled Analysis?
Munaser Alamoodi
European Journal of Breast Health.2024; 20(2): 81. CrossRef
Effect of postmastectomy radiotherapy on T1-2N1M0 triple-negative breast cancer
Lin-Yu Xia, Wei-Yun Xu, Yan Zhao, Sudeep Gupta
PLOS ONE.2022; 17(6): e0270528. CrossRef
Suggestion for the omission of post-mastectomy chest wall radiation therapy in patients who underwent skin-sparing/nipple-sparing mastectomy
Nalee Kim, Won Park, Won Kyung Cho, Hae Young Kim, Doo Ho Choi, Seok Jin Nam, Seok Won Kim, Jeong Eon Lee, Jonghan Yu, Byung Joo Chae, Se Kyung Lee, Jai Min Ryu, Goo-Hyun Mun, Jai-Kyong Pyon, Byung-Joon Jeon
The Breast.2022; 66: 54. CrossRef
Post-mastectomy radiation therapy in breast cancer patients with 1–3 positive lymph nodes: No one size fits all
Majd Kayali, Joseph Abi Jaoude, Arafat Tfayli, Nagi El Saghir, Philip Poortmans, Youssef H. Zeidan
Critical Reviews in Oncology/Hematology.2020; 147: 102880. CrossRef
The survival benefit of postmastectomy radiotherapy for breast cancer patients with T1-2N1 disease according to molecular subtype
Jinli Wei, Yizhou Jiang, Zhimin Shao
The Breast.2020; 51: 40. CrossRef
The effect of postmastectomy radiotherapy in node-positive triple-negative breast cancer
Lei Zhang, Ru Tang, Jia-Peng Deng, Wen-Wen Zhang, Huan-Xin Lin, San-Gang Wu, Zhen-Yu He
BMC Cancer.2020;[Epub] CrossRef
Comparison of Breast Conserving Surgery Followed by Radiation Therapy with Mastectomy Alone for Pathologic N1 Breast Cancer Patients in the Era of Anthracycline Plus Taxane-Based Chemotherapy: A Multicenter Retrospective Study (KROG 1418)
Gyu Sang Yoo, Won Park, Jeong Il Yu, Doo Ho Choi, Yeon-Joo Kim, Kyung Hwan Shin, Chan Woo Wee, Kyubo Kim, Kyung Ran Park, Yong Bae Kim, Sung Ja Ahn, Jong Hoon Lee, Jin Hee Kim, Mison Chun, Hyung-Sik Lee, Jung Soo Kim, Jihye Cha
Cancer Research and Treatment.2019; 51(3): 1041. CrossRef
Effect of postmastectomy radiotherapy on triple-negative breast cancer with T1-2 and 1-3 positive axillary lymph nodes: a population-based study using the SEER 18 database
Jie Zhang, Xiao-Xiao Wang, Jun-Yu Lian, Chuan-Gui Song
Oncotarget.2019; 10(50): 5245. CrossRef
Local and regional recurrence following mastectomy in breast cancer patients with 1–3 positive nodes: implications for postmastectomy radiotherapy volume
Shin-Hyung Park, Jeeyeon Lee, Jeong Eun Lee, Min Kyu Kang, Mi Young Kim, Ho Yong Park, Jin Hyang Jung, Yee Soo Chae, Soo Jung Lee, Jae-Chul Kim
Radiation Oncology Journal.2018; 36(4): 285. CrossRef

11,328 View
346 Download
9 Web of Science
9 Crossref

Survey of the Patterns of Using Stereotactic Ablative Radiotherapy for Early-Stage Non-small Cell Lung Cancer in Korea: Sanghyuk Song, Ji Hyun Chang, Hak Jae Kim, Yeon Sil Kim, Jin Hee Kim, Yong Chan Ahn, Jae-Sung Kim, Si Yeol Song, Sung Ho Moon, Moon June Cho, Seon Min Youn; Cancer Res Treat. 2017;49(3):688-694. Published online October 31, 2016; DOI: https://doi.org/10.4143/crt.2016.219

Abstract PDF Supplementary Material PubReader ePub

Purpose
Stereotactic ablative radiotherapy (SABR) is an effective emerging technique for early-stage non-small cell lung cancer (NSCLC). We investigated the current practice of SABR for early-stage NSCLC in Korea.
Materials and Methods
We conducted a nationwide survey of SABR for NSCLC by sending e-mails to all board-certified members of the Korean Society for Radiation Oncology. The survey included 23 questions focusing on the technical aspects of SABR and 18 questions seeking the participants’ opinions on specific clinical scenarios in the use of SABR for early-stage NSCLC. Overall, 79 radiation oncologists at 61/85 specialist hospitals in Korea (71.8%) responded to the survey.
Results
SABR was used at 33 institutions (54%) to treat NSCLC. Regarding technical aspects, the most common planning methods were the rotational intensity-modulated technique (59%) and the static intensity-modulated technique (49%). Respiratory motion was managed by gating (54%) or abdominal compression (51%), and 86% of the planning scans were obtained using 4-dimensional computed tomography. In the clinical scenarios, the most commonly chosen fractionation schedule for peripherally located T1 NSCLC was 60 Gy in four fractions. For centrally located tumors and T2 NSCLC, the oncologists tended to avoid SABR for radiotherapy, and extended the fractionation schedule.
Conclusion
The results of our survey indicated that SABR is increasingly being used to treat NSCLC in Korea. However, there were wide variations in the technical protocols and fractionation schedules of SABR for early-stage NSCLC among institutions. Standardization of SABR is necessary before implementing nationwide, multicenter, randomized studies.

Citations

Citations to this article as recorded by

Guidelines for safe practice of stereotactic body (ablative) radiation therapy: RANZCR 2023 update
Howard Yu‐hao Liu, Nicholas Hardcastle, Michael Bailey, Shankar Siva, Anna Seeley, Tamara Barry, Jeremy Booth, Louis Lao, Michelle Roach, Stacey Buxton, David Thwaites, Matthew Foote
Journal of Medical Imaging and Radiation Oncology.2024; 68(2): 217. CrossRef
Technical Giants But Biologic Infants: Defining a More Sophisticated Role for Local Therapy in Metastatic Disease
Sophia C. Kamran, David Palma, Matthew S. Katz, Anthony L. Zietman
Seminars in Radiation Oncology.2021; 31(3): 200. CrossRef
MiR-223-3p regulates cell viability, migration, invasion, and apoptosis of non-small cell lung cancer cells by targeting RHOB
Shufang Li, Yuping Feng, Yuxia Huang, Yu Liu, Yanxi Wang, Yan Liang, Hui Zeng, Hong Qu, Ling Wei
Open Life Sciences.2020; 15(1): 389. CrossRef

10,073 View
235 Download
3 Web of Science
3 Crossref

Incorporating Risk Factors to Identify the Indication of Post-mastectomy Radiotherapy in N1 Breast Cancer Treated with Optimal Systemic Therapy: A Multicenter Analysis in Korea (KROG 14-23): Hae Jin Park, Kyung Hwan Shin, Jin Ho Kim, Seung Do Ahn, Ja Young Kim, Won Park, Yong Bae Kim, Yeon-joo Kim, Jin Hee Kim, Kyubo Kim, Kyung Ran Park, Hyun Soo Shin, Bae Kwon Jeong, Sun Young Lee, Suzy Kim; Cancer Res Treat. 2017;49(3):739-747. Published online October 19, 2016; DOI: https://doi.org/10.4143/crt.2016.405

Abstract PDF Supplementary Material PubReader ePub

Purpose
In a recent meta-analysis, post-mastectomy radiotherapy (PMRT) reduced any first recurrence (AFR) and improved survival in N1 and N2 patients. We investigated risk factors for AFR in N1 after optimal systemic therapy without PMRT, to define a subgroup of patients who may benefit from PMRT.
Materials and Methods
One thousand three hundred eighty-two pT1-2N1M0 breast cancer patients treated with mastectomy without PMRT between 2005 and 2010 were retrospectively analyzed. Only 0.6% had no systemic therapy.
Results
After a median follow-up of 5.9 years, there were 173 AFR (53 loco-regional recurrence [LRR] without distant metastases [DM], 38 LRR with DM, and 82 DM without LRR). The 5-year LRR and AFR rates were 6.1% and 12.0%, respectively. Multivariate analysis revealed that close resection margin (p=0.001) was the only independent risk factor for LRR. Multivariate analysis for AFR revealed that age < 35 years (p=0.025), T2 stage (p=0.004), high tumor grade (p=0.032), close resection margin (p=0.035), and triple-negative biological subtype (p=0.031) were independent risk factors. Two or three positive lymph nodes (p=0.078) were considered a marginally significant factor. When stratified by these six factors, the 5-year LRR rates were 3.6% with 0-1 (n=606), 7.5% with 2-3 (n=655), and 12.7% with 4-6 (n=93) risk factors. The 5-year AFR rates were 7.1% with 0-1, 15.0% with 2-3, and 24.5% with 4-6 risk factors.
Conclusion
Patients with pT1-2N1M0 breast cancer who underwent mastectomy and optimal systemic therapy showed excellent loco-regional control and disease control. The patients with four or more risk factors may benefit from PMRT, and those with two or three risk factors merit consideration of PMRT.

Citations

Citations to this article as recorded by

Clinical treatment score Post-5 Years (CTS5) predicts the benefit of postmastectomy radiotherapy in patients with T1-2N1 luminal breast cancer
Ke Liu, Guan-Qiao Li, Si-Qi Li, Xue-Qin Chen, San-Gang Wu
The Breast.2025; 79: 103873. CrossRef
Who can benefit from postmastectomy radiotherapy among HR+/HER2- T1-2 N1M0 breast cancer patients? An explainable machine learning mortality prediction based approach
Long Jin, Qifan Zhao, Shenbo Fu, Yuan Zhang, Shuhan Wu, Xiao Li, Fei Cao
Frontiers in Endocrinology.2024;[Epub] CrossRef
Assessment of Postmastectomy Radiation Therapy Receipt by Age and Association With Outcomes in Women With Breast Cancer
Carolina E. Fasola, Elaina Graham, Wei Sha, Courtney R. Schepel, Sally J. Trufan, Anna Hecksher, Richard L. White, Lejla Hadzikadic-Gusic
Clinical Breast Cancer.2024; 24(5): e396. CrossRef
The significance of risk stratification through nomogram-based assessment in determining postmastectomy radiotherapy for patients diagnosed with pT1 − 2N1M0 breast cancer
Chao Wei, Jie Kong, Huina Han, Xue Wang, Zimeng Gao, Danyang Wang, Andu Zhang, Jun Zhang, Zhikun Liu
Radiation Oncology.2024;[Epub] CrossRef
Development and validation of nomograms for predicting survival outcomes in patients with T1-2N1 breast cancer to identify those who could not benefit from postmastectomy radiotherapy
Hongyu Pu, Yunbo Luo, Linxing Zhang, Xin Li, Fangwei Li, Jingtai Chen, Shuangqiang Qian, Yunhui Tang, Xiaobo Zhao, Lingmi Hou, Yanchun Gao
Frontiers in Oncology.2023;[Epub] CrossRef
Postmastectomy radiotherapy in patients with T1-2N1 breast cancer: a single center experience and a meta-analysis
Meng Luo, Yao Jin, Chunjing Xu, Huihui Chen, Kun Zhang, Qiang Chen, Chencan Jin, Jinglu Lu, Jing Wang, Jia Huang, Hao Deng, Weili Jin, Shu Zheng, Yiding Chen, Jiaojiao Zhou
Journal of Cancer Research and Clinical Oncology.2023; 149(12): 9979. CrossRef
Developing prompts from large language model for extracting clinical information from pathology and ultrasound reports in breast cancer
Hyeon Seok Choi, Jun Yeong Song, Kyung Hwan Shin, Ji Hyun Chang, Bum-Sup Jang
Radiation Oncology Journal.2023; 41(3): 209. CrossRef
The Role of Post-Mastectomy Radiotherapy in T1-2N1 Breast Cancer Patients: Propensity Score Matched Analysis
Kangpyo Kim, Won Park, Haeyoung Kim, Won Kyung Cho, Nalee Kim, Seok Jin Nam, Seok Won Kim, Jeong Eon Lee, Jonghan Yu, Byung Joo Chae, Se Kyung Lee, Jai Min Ryu
Cancers.2023; 15(22): 5473. CrossRef
Immediate breast reconstruction has no impact on the oncologic outcomes of patients treated with post-mastectomy radiation therapy: a comparative analysis based on propensity score matching
Nalee Kim, Haeyoung Kim, Won Park, Doo Ho Choi, Won Kyung Cho, Seok Jin Nam, Jeong Eon Lee, Seok Won Kim, Jonghan Yu, Sei Kyung Lee, Byung-Joon Jeon, Jai Kyong Pyon, Goo-Hyun Mun, Tae Gyu Kim
Breast Cancer Research and Treatment.2022; 192(1): 101. CrossRef
Postmastectomy Radiation Therapy in Patients With Minimally Involved Lymph Nodes: A Review of the Current Data and Future Directions
Bum-Sup Jang, Kyung Hwan Shin
Journal of Breast Cancer.2022; 25(1): 1. CrossRef
Practical Model to Optimize the Strategy of Adjuvant Postmastectomy Radiotherapy in T1-2N1 Breast Cancer With Modern Systemic Therapy
Fei-Fei Xu, Lu Cao, Cheng Xu, Gang Cai, Shu-Bei Wang, Wei-Xiang Qi, Jia-Yi Chen
Frontiers in Oncology.2022;[Epub] CrossRef
Influence of age as a continuous variable on the prognosis of patients with pT1-2N1 breast cancer
Xu-Ran Zhao, Yu Tang, Hong-Fen Wu, Qi-Shuai Guo, Yu-Jing Zhang, Mei Shi, Jing Cheng, Hong-Mei Wang, Min Liu, Chang-Ying Ma, Ge Wen, Xiao-hu Wang, Hui Fang, Hao Jing, Yong-Wen Song, Jing Jin, Yue-Ping Liu, Bo Chen, Shu-Nan Qi, Ning Li, Yuan Tang, Ning-Ning
The Breast.2022; 66: 136. CrossRef
Suggestion for the omission of post-mastectomy chest wall radiation therapy in patients who underwent skin-sparing/nipple-sparing mastectomy
Nalee Kim, Won Park, Won Kyung Cho, Hae Young Kim, Doo Ho Choi, Seok Jin Nam, Seok Won Kim, Jeong Eon Lee, Jonghan Yu, Byung Joo Chae, Se Kyung Lee, Jai Min Ryu, Goo-Hyun Mun, Jai-Kyong Pyon, Byung-Joon Jeon
The Breast.2022; 66: 54. CrossRef
Protocol for the postoperative radiotherapy in N1 breast cancer patients (PORT-N1) trial, a prospective multicenter, randomized, controlled, non-inferiority trial of patients receiving breast-conserving surgery or mastectomy
Tae Hoon Lee, Ji Hyun Chang, Bum-Sup Jang, Jae Sik Kim, Tae Hyun Kim, Won Park, Yong Bae Kim, Su Ssan Kim, Wonshik Han, Han-Byoel Lee, Kyung Hwan Shin
BMC Cancer.2022;[Epub] CrossRef
Risk factors to identify the indication for regional nodal irradiation in T1-2N1M0 breast cancer: A joint analysis of 4,243 real-world cases from two institutions
Guang-Yi Sun, Ge Wen, Yu-Jing Zhang, Yu Tang, Hao Jing, Hui Fang, Jian-Yang Wang, Jiang-Hu Zhang, Xu-Ran Zhao, Si-Ye Chen, Yong-Wen Song, Jing Jin, Yue-Ping Liu, Yuan Tang, Shu-Nan Qi, Ning Li, Bo Chen, Ning-Ning Lu, Ye-Xiong Li, Shu-Lian Wang
Frontiers in Oncology.2022;[Epub] CrossRef
Prognostic factors for breast cancer patients with T1–2 tumors and 1–3 positive lymph nodes and the role of postmastectomy radiotherapy in these patients
Jia-ming Zhao, Qi An, Chao-nan Sun, Yu-bing Li, Zi-lan Qin, Hong Guo, Xue Zeng, Yao-tian Zhang, Lin-lin Wei, Ning Han, Shi-chen Sun, Na Zhang
Breast Cancer.2021; 28(2): 298. CrossRef
A Prognostic Risk Stratification Model to Identify Potential Population Benefiting From Postmastectomy Radiotherapy in T1–2 Breast Cancer With 1–3 Positive Axillary Lymph Nodes
Niuniu Hou, Juliang Zhang, Lu Yang, Ying Wu, Zhe Wang, Mingkun Zhang, Li Yang, Guangdong Hou, Jianfeng Wu, Yidi Wang, Bingyao Dong, Lili Guo, Mei Shi, Rui Ling
Frontiers in Oncology.2021;[Epub] CrossRef
Mastectomy alone for pT1-2 pN0-1 breast cancer patients: when postmastectomy radiotherapy is indicated
Maria Cristina Leonardi, Ida Rosalia Scognamiglio, Patrick Maisonneuve, Samantha Dicuonzo, Damaris Patricia Rojas, Maria Alessia Zerella, Anna Morra, Marianna Alessandra Gerardi, Mattia Zaffaroni, Alessandra De Scalzi, Antonia Girardi, Francesca Magnoni,
Breast Cancer Research and Treatment.2021; 188(2): 511. CrossRef
Impact of clinical-pathological factors on locoregional recurrence in mastectomy patients with T1-2N1 breast cancer: who can omit adjuvant radiotherapy?
Xiaofang Wang, Li Zhang, Xiaomeng Zhang, Jurui Luo, Xuanyi Wang, Xingxing Chen, Zhaozhi Yang, Xin Mei, Xiaoli Yu, Zhen Zhang, Xiaomao Guo, Zhimin Shao, Jinli Ma
Breast Cancer Research and Treatment.2021; 190(2): 277. CrossRef
Evaluation of the 8th edition of the American joint committee on cancer’s pathological staging system in prognosis assessment and treatment decision making for stage T1-2N1 breast cancer after mastectomy
San-Gang Wu, Jun Wang, Chen-Lu Lian, Jian Lei, Li Hua, Qin Lin, Yong-Xiong Chen, Zhen-Yu He
The Breast.2020; 51: 2. CrossRef
Nomogram predicting survival as a selection criterion for postmastectomy radiotherapy in patients with T1 to T2 breast cancer with 1 to 3 positive lymph nodes
Yu Tang, Yu-Jing Zhang, Na Zhang, Mei Shi, Ge Wen, Jing Cheng, Hong-Mei Wang, Min Liu, Xiao-Hu Wang, Qi-Shuai Guo, Hong-Fen Wu, Chang-Ying Ma, Jing Jin, Yue-Ping Liu, Yong-Wen Song, Hui Fang, Hua Ren, Shu-Lian Wang, Ye-Xiong Li
Cancer.2020; 126(S16): 3857. CrossRef
Effectiveness of the AJCC 8th edition staging system for selecting patients with T1–2N1 breast cancer for post-mastectomy radiotherapy: a joint analysis of 1986 patients from two institutions
Shulian Wang, Ge Wen, Yu Tang, Yong Yang, Hao Jing, Jianyang Wang, Jianghu Zhang, Xuran Zhao, Guangyi Sun, Jing Jin, Yongwen Song, Yueping Liu, Hui Fang, Yujing Zhang, Yexiong Li
BMC Cancer.2020;[Epub] CrossRef
Postmastectomy radiotherapy in T1-2 patients with one to three positive lymph nodes – Past, present and future
Filip Kaššák, Christine Rossier, Cristina Picardi, Jacques Bernier
The Breast.2019; 48: 73. CrossRef
Chest wall recurrence in pT1-2N0-1 breast cancer patients after mastectomy without radiotherapy
Ji Hyun Chang, Kyung Hwan Shin, Seung Do Ahn, Hae Jin Park, Eui Kyu Chie, Jin Ho Kim, Su Ssan Kim, Yong Bae Kim, Won Park, Yeon-Joo Kim, Hyun Soo Shin, Jin Hee Kim, Sun Young Lee, Kyubo Kim, Kyung Ran Park, Bae Kwon Jeong, Ja Young Kim, Suzy Kim
Breast Cancer Research and Treatment.2018; 169(3): 507. CrossRef
Evaluation of the Benefit of Radiotherapy in Patients with Occult Breast Cancer: A Population-Based Analysis of the SEER Database
Byoung Hyuck Kim, Jeanny Kwon, Kyubo Kim
Cancer Research and Treatment.2018; 50(2): 551. CrossRef
Breast Conservation Therapy Versus Mastectomy in Patients with T1-2N1 Triple-Negative Breast Cancer: Pooled Analysis of KROG 14-18 and 14-23
Kyubo Kim, Hae Jin Park, Kyung Hwan Shin, Jin Ho Kim, Doo Ho Choi, Won Park, Seung Do Ahn, Su Ssan Kim, Dae Yong Kim, Tae Hyun Kim, Jin Hee Kim, Jiyoung Kim
Cancer Research and Treatment.2018; 50(4): 1316. CrossRef
Meeting Highlights: The Second Consensus Conference for Breast Cancer Treatment in Korea
Seeyoun Lee, In Hae Park, Seho Park, Joohyuk Sohn, Joon Jeong, Sung Gwe Ahn, Ik Jae Lee, Hae Kyung Lee, Seung Ah Lee, Won Park, Kyung-Hun Lee, Sung-Won Kim, Sang-Ah Han, Kyung Hae Jung, Byung Ho Son
Journal of Breast Cancer.2017; 20(3): 228. CrossRef
Predicting loco-regional recurrence risk in T1, T2 breast cancer with 1–3 positive axillary nodes postmastectomy: Development of a predictive nomogram
T Wadasadawala, S Kannan, S Gudi, A Rishi, A Budrukkar, V Parmar, T Shet, S Desai, S Gupta, R Badwe, R Sarin
Indian Journal of Cancer.2017; 54(1): 352. CrossRef

11,573 View
354 Download
28 Web of Science
28 Crossref

Concurrent Chemoradiotherapy with Temozolomide Followed by Adjuvant Temozolomide for Newly Diagnosed Glioblastoma Patients: A Retrospective Multicenter Observation Study in Korea: Byung Sup Kim, Ho Jun Seol, Do-Hyun Nam, Chul-Kee Park, Il Han Kim, Tae Min Kim, Jeong Hoon Kim, Young Hyun Cho, Sang Min Yoon, Jong Hee Chang, Seok-Gu Kang, Eui Hyun Kim, Chang-Ok Suh, Tae-Young Jung, Kyung-Hwa Lee, Chae-Yong Kim, In Ah Kim, Chang-Ki Hong, Heon Yoo, Jin Hee Kim, Shin-Hyuk Kang, Min Kyu Kang, Eun-Young Kim, Sun-Hwan Kim, Dong-Sup Chung, Sun-Chul Hwang, Joon-Ho Song, Sung Jin Cho, Sun-Il Lee, Youn-Soo Lee, Kook-Jin Ahn, Se Hoon Kim, Do Hun Lim, Ho-Shin Gwak, Se-Hoon Lee, Yong-Kil Hong; Cancer Res Treat. 2017;49(1):193-203. Published online June 27, 2016; DOI: https://doi.org/10.4143/crt.2015.473

Abstract PDF PubReader ePub

Purpose
The purpose of this study was to investigate the feasibility and survival benefits of combined treatment with radiotherapy and adjuvant temozolomide (TMZ) in a Korean sample.
Materials and Methods
A total of 750 Korean patients with histologically confirmed glioblastoma multiforme, who received concurrent chemoradiotherapy with TMZ (CCRT) and adjuvant TMZ from January 2006 until June 2011, were analyzed retrospectively.
Results
After the first operation, a gross total resection (GTR), subtotal resection (STR), partial resection (PR), biopsy alone were achieved in 388 (51.7%), 159 (21.2%), 96 (12.8%), and 107 (14.3%) patients,respectively. The methylation status of O⁶-methylguanine-DNA methyltransferase (MGMT) was reviewed retrospectively in 217 patients. The median follow-up period was 16.3 months and the median overall survival (OS) was 17.5 months. The actuarial survival rates at the 1-, 3-, and 5-year OS were 72.1%, 21.0%, and 9.0%, respectively. The median progression-free survival (PFS) was 10.1 months, and the actuarial PFS at 1-, 3-, and 5-year PFS were 42.2%, 13.0%, and 7.8%, respectively. The patients who received GTR showed a significantly longer OS and PFS than those who received STR, PR, or biopsy alone, regardless of the methylation status of the MGMT promoter. Patients with a methylated MGMT promoter also showed a significantly longer OS and PFS than those with an unmethylated MGMT promoter. Patients who received more than six cycles of adjuvant TMZ had a longer OS and PFS than those who received six or fewer cycles. Hematologic toxicity of grade 3 or 4 was observed in 8.4% of patients during the CCRT period and in 10.2% during the adjuvant TMZ period.
Conclusion
Patients treated with CCRT followed by adjuvant TMZ had more favorable survival rates and tolerable toxicity than those who did not undergo this treatment.

Citations

Citations to this article as recorded by

Efficacy and safety of carmustine wafers, followed by radiation, temozolomide, and bevacizumab therapy, for newly diagnosed glioblastoma with maximal resection
Masayuki Kanamori, Ichiyo Shibahara, Yoshiteru Shimoda, Yukinori Akiyama, Takaaki Beppu, Shigeo Ohba, Toshiyuki Enomoto, Takahiro Ono, Yuta Mitobe, Mitsuto Hanihara, Yohei Mineharu, Joji Ishida, Kenichiro Asano, Yasuyuki Yoshida, Manabu Natsumeda, Sadahir
International Journal of Clinical Oncology.2025; 30(1): 51. CrossRef
Letter to the Editor Regarding Cerebral Blood Flow Role in Delineating Treatment Effect from True Tumor Progression in Glioblastoma Multiforme
Inibehe Ime Okon, Tolulope Judah Gbayisomore, Samuel Berchi Kankam, Mohammad Jalloh
World Neurosurgery.2024; 186: 269. CrossRef
NTRK-fused central nervous system tumours: clinicopathological and genetic insights and response to TRK inhibitors
Eric Eunshik Kim, Chul-Kee Park, Seung-Ki Kim, Ji Hoon Phi, Sun Ha Paek, Jung Yoon Choi, Hyoung Jin Kang, Joo Ho Lee, Jae Kyung Won, Hongseok Yun, Sung-Hye Park
Acta Neuropathologica Communications.2024;[Epub] CrossRef
The Korean Society for Neuro-Oncology (KSNO) Guideline for the Management of Brain Tumor Patients During the Crisis Period: A Consensus Recommendation Using the Delphi Method (Version 2023.1)
Min-Sung Kim, Se-Il Go, Chan Woo Wee, Min Ho Lee, Seok-Gu Kang, Kyeong-O Go, Sae Min Kwon, Woohyun Kim, Yun-Sik Dho, Sung-Hye Park, Youngbeom Seo, Sang Woo Song, Stephen Ahn, Hyuk-Jin Oh, Hong In Yoon, Sea-Won Lee, Joo Ho Lee, Kyung Rae Cho, Jung Won Choi
Brain Tumor Research and Treatment.2023; 11(2): 123. CrossRef
Lymphoproliferative disorder during temozolomide therapy; a representative case of a formidable complication and management challenges
Daisuke Sato, Hirokazu Takami, Shunsaku Takayanagi, Kazuki Taoka, Mariko Tanaka, Reiko Matsuura, Shota Tanaka, Nobuhito Saito
BMC Neurology.2023;[Epub] CrossRef
Glioma angiogenesis is boosted by ELK3 activating the HIF-1$$alpha$$/VEGF-A signaling axis
Mou Yueyang, Hu Yaqin, Xue Guolian, Zhao Wenjian, Jiao Yang, Li Chen, Cao Haiyan, Chao Min, Deng Jianping, Dai Penggao, Zhu Hongli, Wang Liang
BMC Cancer.2023;[Epub] CrossRef
Levetiracetam as a sensitizer of concurrent chemoradiotherapy in newly diagnosed glioblastoma: An open‐label phase 2 study
Kihwan Hwang, Junhyung Kim, Seok‐Gu Kang, Tae‐Young Jung, Jeong Hoon Kim, Se‐Hyuk Kim, Shin‐Hyuk Kang, Yong‐Kil Hong, Tae Min Kim, Yu Jung Kim, Byung Se Choi, Jong Hee Chang, Chae‐Yong Kim
Cancer Medicine.2022; 11(2): 371. CrossRef
Prognostic Value and Risk Factors of Treatment-Related Lymphopenia in Malignant Glioma Patients Treated With Chemoradiotherapy: A Systematic Review and Meta-Analysis
Yongchao Zhang, Shichao Chen, Hualei Chen, Shanshan Chen, Zhen Li, Enshan Feng, Wei Li
Frontiers in Neurology.2022;[Epub] CrossRef
PrACTiC: A Predictive Algorithm for Chemoradiotherapy-Induced Cytopenia in Glioblastoma Patients
Alireza Amouheidari, Zahra Alirezaei, Stefan Rauh, Masoud Hassanpour, Ozkan Kanat
Journal of Oncology.2022; 2022: 1. CrossRef
Relapsing High—Grade Glioma from Peritumoral Zone: Critical Review of Radiotherapy Treatment Options
Maria Chiara Lo Greco, Roberto Milazzotto, Rocco Luca Emanuele Liardo, Grazia Acquaviva, Madalina La Rocca, Roberto Altieri, Francesco Certo, Giuseppe Maria Barbagallo, Antonio Basile, Pietro Valerio Foti, Stefano Palmucci, Stefano Pergolizzi, Antonio Pon
Brain Sciences.2022; 12(4): 416. CrossRef
Effect of Choline Alphoscerate on the Survival of Glioblastoma Patients: A Retrospective, Single-Center Study
Yeong Jin Kim, Tae-Kyu Lee, Myung-Giun Noh, Tae-Young Jung, In-Young Kim, Shin Jung, Kyung-Hwa Lee, Kyung-Sub Moon
Journal of Clinical Medicine.2022; 11(20): 6052. CrossRef
Evaluating survival in subjects with astrocytic brain tumors by dynamic susceptibility-weighted perfusion MR imaging
Matthew L. White, Yan Zhang, Syed A. Jaffar Kazmi, Michele Aizenberg, Nicole Shonka, Fang Yu, Adams Kusi Appiah, Michael C. Burger
PLOS ONE.2021; 16(1): e0244275. CrossRef
Prognostic value of test(s) for O6-methylguanine–DNA methyltransferase (MGMT) promoter methylation for predicting overall survival in people with glioblastoma treated with temozolomide
Alexandra McAleenan, Claire Kelly, Francesca Spiga, Ashleigh Kernohan, Hung-Yuan Cheng, Sarah Dawson, Lena Schmidt, Tomos Robinson, Sebastian Brandner, Claire L Faulkner, Christopher Wragg, Sarah Jefferies, Amy Howell, Luke Vale, Julian P T Higgins, Kathr
Cochrane Database of Systematic Reviews.2021;[Epub] CrossRef
Mixed malignant glioblastoma and schwannoma in spinal cord with metachronous ependymoma: A case report
Mostafa Farzin, Mohamadreza Hajiabadi, Mohammad Rahmani, Kasra Kolahdouzan
Clinical Case Reports.2021;[Epub] CrossRef
Treatment patterns and outcomes for patients with newly diagnosed glioblastoma multiforme: a retrospective cohort study
Srinivas Annavarapu, Anagha Gogate, Trang Pham, Kalatu Davies, Prianka Singh, Nicholas Robert
CNS Oncology.2021;[Epub] CrossRef
A Systematic Review and Meta-Analysis on the Number of Adjuvant Temozolomide Cycles in Newly Diagnosed Glioblastoma
Fahimeh Attarian, Farzad Taghizadeh-Hesary, Azar Fanipakdel, Seyed Alireza Javadinia, Pejman Porouhan, Babak PeyroShabany, Danial Fazilat-Panah
Frontiers in Oncology.2021;[Epub] CrossRef
Tumor treating fields plus temozolomide for newly diagnosed glioblastoma: a sub-group analysis of Korean patients in the EF-14 phase 3 trial
Chae-Yong Kim, Sun Ha Paek, Do-hyun Nam, Jong-Hee Chang, Yong-Kil Hong, Jeong Hoon Kim, Oh Lyong Kim, Se-Hyuk Kim
Journal of Neuro-Oncology.2020; 146(3): 399. CrossRef
Risk Factors for Cognitive Impairment in High-Grade Glioma Patients Treated with Postoperative Radiochemotherapy
Qiang Wang, Fengxia Xiao, Fei Qi, Xiaopeng Song, Yonghua Yu
Cancer Research and Treatment.2020; 52(2): 586. CrossRef
Immunotherapy for gliomas: shedding light on progress in preclinical and clinical development
Maria B. Garcia-Fabiani, Maria Ventosa, Andrea Comba, Marianela Candolfi, Alejandro J. Nicola Candia, Mahmoud S. Alghamri, Padma Kadiyala, Stephen Carney, Syed M. Faisal, Anna Schwendeman, James J. Moon, Lindsay Scheetz, Joerg Lahann, Ava Mauser, Pedro R.
Expert Opinion on Investigational Drugs.2020; 29(7): 659. CrossRef
Long Intergenic Non-Protein Coding RNA 1094 Promotes Initiation and Progression of Glioblastoma by Promoting microRNA-577-Regulated Stabilization of Brain-Derived Neurotrophic Factor

Xiaoyan Dong, Xiuxin Fu, Miao Yu, Zengfen Li
Cancer Management and Research.2020; Volume 12: 5619. CrossRef
SNHG7 Facilitates Glioblastoma Progression by Functioning as a Molecular Sponge for MicroRNA-449b-5p and Thereby Increasing MYCN Expression
Yaogang Chen, Shaoyong Yuan, Tieying Ning, Huiqing Xu, Bo Guan
Technology in Cancer Research & Treatment.2020;[Epub] CrossRef
Combined effects of niclosamide and temozolomide against human glioblastoma tumorspheres
Hyeong-Cheol Oh, Jin-Kyoung Shim, Junseong Park, Ji-Hyun Lee, Ran Joo Choi, Nam Hee Kim, Hyun Sil Kim, Ju Hyung Moon, Eui Hyun Kim, Jong Hee Chang, Jong In Yook, Seok-Gu Kang
Journal of Cancer Research and Clinical Oncology.2020; 146(11): 2817. CrossRef
Clinical Characteristics of High-Grade Glioma with Primary Leptomeningeal Seeding at Initial Diagnosis in a Single Center Study
Ji-Eyon Kwon, Kihwan Hwang, Kyeong-O Go, Chan Woo Wee, In Ah Kim, Yu Jung Kim, Gheeyoung Choe, Byung Se Choi, Jung Ho Han, Chae-Yong Kim
Brain Tumor Research and Treatment.2020; 8(2): 77. CrossRef
A Longitudinal Study of Lipid Peroxidation and Symptom Clusters in Patients With Brain Cancers
Sanghee Kim
Nursing Research.2018; 67(5): 387. CrossRef
Dynamic Susceptibility Contrast (DSC) Perfusion MR in the Prediction of Long-Term Survival of Glioblastomas (GBM): Correlation with MGMT Promoter Methylation and 1p/19q Deletions
Yong Wonn Kwon, Won-Jin Moon, Mina Park, Hong Gee Roh, Young Cho Koh, Sang Woo Song, Jin Woo Choi
Investigative Magnetic Resonance Imaging.2018; 22(3): 158. CrossRef
Notch1ablation radiosensitizes glioblastoma cells
Na Han, Guangyuan Hu, Lei Shi, Guoxian Long, Lin Yang, Qingsong Xi, Qiuyun Guo, Jianhua Wang, Zhen Dong, Mengxian Zhang
Oncotarget.2017; 8(50): 88059. CrossRef
Impact of epidemiological characteristics of supratentorial gliomas in adults brought about by the 2016 world health organization classification of tumors of the central nervous system
Haihui Jiang, Yong Cui, Junmei Wang, Song Lin
Oncotarget.2017; 8(12): 20354. CrossRef

16,080 View
314 Download
24 Web of Science
27 Crossref

Clinical Practice Patterns of Radiotherapy in Patients with Hepatocellular Carcinoma: A Korean Radiation Oncology Group Study (KROG 14-07): Hyejung Cha, Hee Chul Park, Jeong Il Yu, Tae Hyun Kim, Taek-Keun Nam, Sang Min Yoon, Won Sup Yoon, Jun Won Kim, Mi Sook Kim, Hong Seok Jang, Youngmin Choi, Jin Hee Kim, Chul Seung Kay, Inkyung Jung, Jinsil Seong; Cancer Res Treat. 2017;49(1):61-69. Published online June 13, 2016; DOI: https://doi.org/10.4143/crt.2016.097

Abstract PDF PubReader ePub

Purpose
The aim of this study was to examine patterns of radiotherapy (RT) in Korean patients with hepatocellular carcinoma (HCC) according to the evolving guideline for HCC established by the Korean Liver Cancer Study Group-National Cancer Center (KLCSG-NCC).
Materials and Methods
We reviewed 765 patients with HCC who were treated with RT between January 2011 and December 2012 in 12 institutions.
Results
The median follow-up period was 13.3 months (range, 0.2 to 51.7 months). Compared with previous data between 2004 and 2005, the use of RT as a first treatment has increased (9.0% vs. 40.8%). Increased application of intensity-modulated RT resulted in an increase in radiation dose (fractional dose, 1.8 Gy vs. 2.5 Gy; biologically effective dose, 53.1 Gy₁₀ vs. 56.3 Gy₁₀). Median overall survival was 16.2 months, which is longer than that reported in previous data (12 months). In subgroup analysis, treatments were significantly different according to stage (p < 0.001). Stereotactic body RT was used in patients with early HCC, and most patients with advanced stage were treated with three-dimensional conformal RT.
Conclusion
Based on the evolving KLCSG-NCC practice guideline for HCC, clinical practice patterns of RT have changed. Although RT is still used mainly in advanced HCC, the number of patients with good performance status who were treated with RT as a first treatment has increased. This change in practice patterns could result in improvement in overall survival.

Citations

Citations to this article as recorded by

Complications After Exosome Treatment for Aesthetic Skin Rejuvenation
William J. Nahm, Sukruthi Thunga, Jane Yoo
Dermatological Reviews.2024;[Epub] CrossRef
2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma

Journal of Liver Cancer.2023; 23(1): 1. CrossRef
2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma

Clinical and Molecular Hepatology.2022; 28(4): 583. CrossRef
2022 KLCA-NCC Korea Practice Guidelines for the Management of Hepatocellular Carcinoma

Korean Journal of Radiology.2022; 23(12): 1126. CrossRef
Multi-Institutional Retrospective Study of Radiotherapy for Hepatocellular Carcinoma in the Caudate Lobe
Sung Uk Lee, Sang Min Yoon, Jason Chia-Hsien Cheng, Tae Hyun Kim, Bo Hyun Kim, Jin-hong Park, Jinhong Jung, Chiao-Ling Tsai, Yun Chiang, Joong-Won Park
Frontiers in Oncology.2021;[Epub] CrossRef
Patterns of definitive radiotherapy practice for cervical cancer in South Korea: a survey endorsed by the Korean Radiation Oncology Group (KROG 20-06)
Nalee Kim, Won Park
Journal of Gynecologic Oncology.2021;[Epub] CrossRef
Indications of external radiotherapy for hepatocellular carcinoma from updated clinical guidelines: Diverse global viewpoints
Sunmin Park, Won Sup Yoon, Chai Hong Rim
World Journal of Gastroenterology.2020; 26(4): 393. CrossRef
Optimizing radiotherapy with immune checkpoint blockade in hepatocellular carcinoma
Changhoon Choi, Gyu Sang Yoo, Won Kyung Cho, Hee Chul Park
World Journal of Gastroenterology.2019; 25(20): 2416. CrossRef
2018 Korean Liver Cancer Association–National Cancer Center Korea Practice Guidelines for the Management of Hepatocellular Carcinoma
KLCA Korean Liver Cancer Association, NCC National Cancer Center
Gut and Liver.2019; 13(3): 227. CrossRef
2018 Korean Liver Cancer Association–National Cancer Center Korea Practice Guidelines for the Management of Hepatocellular Carcinoma

Korean Journal of Radiology.2019; 20(7): 1042. CrossRef
Treatment Outcome after Fractionated Conformal Radiotherapy for Hepatocellular Carcinoma in Patients with Child-Pugh Classification B in Korea (KROG 16-05)
Sun Hyun Bae, Hee Chul Park, Won Sup Yoon, Sang Min Yoon, In-Hye Jung, Ik Jae Lee, Jun Won Kim, Jinsil Seong, Tae Hyun Kim, Taek-Keun Nam, Youngmin Choi, Sun Young Lee, Hong Seok Jang, Dong Soo Lee, Jin Hee Kim
Cancer Research and Treatment.2019; 51(4): 1589. CrossRef
EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma
Peter R. Galle, Alejandro Forner, Josep M. Llovet, Vincenzo Mazzaferro, Fabio Piscaglia, Jean-Luc Raoul, Peter Schirmacher, Valérie Vilgrain
Journal of Hepatology.2018; 69(1): 182. CrossRef

11,355 View
279 Download
14 Web of Science
12 Crossref

Adjuvant Treatment after Surgery in Stage IIIA Endometrial Adenocarcinoma: Mee Sun Yoon, Seung Jae Huh, Hak Jae Kim, Young Seok Kim, Yong Bae Kim, Joo-Young Kim, Jong-Hoon Lee, Hun Jung Kim, Jihye Cha, Jin Hee Kim, Juree Kim, Won Sup Yoon, Jin Hwa Choi, Mison Chun, Youngmin Choi, Kang Kyoo Lee, Myungsoo Kim, Jae-Uk Jeong, Sei Kyung Chang, Won Park; Cancer Res Treat. 2016;48(3):1074-1083. Published online October 29, 2015; DOI: https://doi.org/10.4143/crt.2015.356

Abstract PDF PubReader ePub

Purpose
We evaluated the role of adjuvant therapy in stage IIIA endometrioid adenocarcinoma patients who underwent surgery followed by radiotherapy (RT) alone or chemoradiotherapy (CTRT) according to risk group. Materials and Methods A multicenter retrospective study was conducted including patients with surgical stage IIIA endometrial cancertreated by radical surgery and adjuvant RT or CTRT. Disease-free survival (DFS) and overall survival (OS) were analyzed.
Results
Ninety-three patients with stage IIIA disease were identified. Nineteen patients (20.4%) experienced recurrence, mostly distant metastasis (17.2%). Combined CTRT did not affect DFS (74.1% vs. 82.4%, p=0.130) or OS (96.3% vs. 91.9%, p=0.262) in stage IIIA disease compared with RT alone. Patients with age ≥ 60 years, grade G2/3, and lymphovascular space involvement had a significantly worse DFS and those variables were defined as risk factors. The high-risk group showed a significant reduction in 5-year DFS (≥ 2 risk factors) (49.0% vs. 88.0%, p < 0.001) compared with the low-risk group (< 2). Multivariate analysis confirmed that more than one risk factor was the only predictor of worse DFS (hazard ratio, 5.45; 95% confidence interval, 2.12 to 13.98; p < 0.001). Of patients with no risk factors, a subset treated with RT alone showed an excellent 5-year DFS and OS (93.8% and 100%, respectively). Conclusion We identified a low-risk subset of stage IIIA endometrioid adenocarcinoma patients who might be reasonable candidates for adjuvant RT alone. Further randomized studies are needed to determine which subset might benefit from combined CTRT.

Citations

Citations to this article as recorded by

Practice patterns and survival in FIGO 2009 stage 3B endometrial cancer
Jessica Jou, Lindsey Charo, Marianne Hom-Tedla, Katherine Coakley, Pratibha Binder, Cheryl Saenz, Ramez N. Eskander, Michael McHale, Steven Plaxe
Gynecologic Oncology.2021; 163(2): 299. CrossRef
Treatment strategies for endometrial cancer: current practice and perspective
Yeh C. Lee, Stephanie Lheureux, Amit M. Oza
Current Opinion in Obstetrics & Gynecology.2017; 29(1): 47. CrossRef

14,309 View
126 Download
3 Web of Science
2 Crossref

A Survey of Stereotactic Body Radiotherapy in Korea: Sun Hyun Bae, Mi-Sook Kim, Won Il Jang, Chul-Seung Kay, Woochul Kim, Eun Seog Kim, Jin Ho Kim, Jin Hee Kim, Kwang Mo Yang, Kyu Chan Lee, A Ram Chang, Sunmi Jo; Cancer Res Treat. 2015;47(3):379-386. Published online November 24, 2014; DOI: https://doi.org/10.4143/crt.2014.021

Abstract PDF PubReader ePub

Purpose
The purpose of this study is to investigate the current status of stereotactic body radiotherapy (SBRT) in Korea. A nationwide survey was conducted by the Korean Stereotactic Radiosurgery Group of the Korean Society for Radiation Oncology (KROG 13-13).
Materials and Methods
SBRT was defined as radiotherapy with delivery of a high dose of radiation to an extracranial lesion in ≤ 4 fractions. A 16-questionnaire survey was sent by e-mail to the chief of radiation oncology at 85 institutions in June 2013.
Results
All institutions (100%) responded to this survey. Of these, 38 institutions (45%) have used SBRT and 47 institutions (55%) have not used SBRT. Regarding the treatment site, the lung (92%) and liver (76%) were the two most common sites. The most common schedules were 60 Gy/4 fractions for non-small cell lung cancer, 48 Gy/4 fractions for lung metastases, 60 Gy/3 fractions for hepatocellular carcinoma, and 45 Gy/3 fractions or 40 Gy/4 fractions for liver metastases. Four-dimensional computed tomography (CT) was the most common method for planning CT (74%). During planning CT, the most common method of immobilization was the use of an alpha cradle/vacuum-lock (42%).
Conclusion
Based on this survey, conduct of further prospective studies will be needed in order to determine the appropriate prescribed doses and to standardize the practice of SBRT.

Citations

Citations to this article as recorded by

Five-Day Spacing of Two Fractionated Ablative Radiotherapies Enhances Antitumor Immunity
Hyunkyung Kim, Eunju Lee, Haeun Cho, Eunji Kim, Won Il Jang, Kwangmo Yang, Yoon-Jin Lee, Tae-Jin Kim, Mi-Sook Kim
International Journal of Radiation Oncology*Biology*Physics.2024; 118(2): 498. CrossRef
Patterns of quality assurance and treatment planning for stereotactic body radiation therapy in India – A survey
Smriti Sharma, Ritu Raj Upreti, Rajesh A. Kinhikar, G. Sahani, P. K. Dash Sharma
Journal of Cancer Research and Therapeutics.2024; 20(6): 1752. CrossRef
Measuring dose in lung identifies peripheral tumour dose inaccuracy in SBRT audit
Maddison Shaw, Jessica Lye, Andrew Alves, Joerg Lehmann, Masoumeh Sanagou, Moshi Geso, Rhonda Brown
Physica Medica.2023; 112: 102632. CrossRef
Stereotactic radiotherapy for hepatocellular carcinoma: Expanding the multidisciplinary armamentarium
Mihir D Shanker, Howard Y Liu, Yoo Young Lee, Katherine A Stuart, Elizabeth E Powell, Alan Wigg, David I Pryor
Journal of Gastroenterology and Hepatology.2021; 36(4): 873. CrossRef
A national survey on technology and quality assurance for stereotactic body radiation therapy
Carmelo Marino, Cristina Garibaldi, Ivan Veronese, Claudia Carbonini, Serenella Russo, Michele Stasi, Pietro Mancosu
Physica Medica.2019; 65: 6. CrossRef
Clinical Practice Patterns of Radiotherapy in Patients with Hepatocellular Carcinoma: A Korean Radiation Oncology Group Study (KROG 14-07)
Hyejung Cha, Hee Chul Park, Jeong Il Yu, Tae Hyun Kim, Taek-Keun Nam, Sang Min Yoon, Won Sup Yoon, Jun Won Kim, Mi Sook Kim, Hong Seok Jang, Youngmin Choi, Jin Hee Kim, Chul Seung Kay, Inkyung Jung, Jinsil Seong
Cancer Research and Treatment.2017; 49(1): 61. CrossRef
Application of stereotactic body radiation therapy to cancer liver metastasis
Si-Yuan Zhang, Guang-Ying Zhu, Gong Li, Yi-Bao Zhang, Jian-Hao Geng
Cancer Letters.2016; 379(2): 225. CrossRef
Practical patterns for stereotactic body radiotherapy to hepatocellular carcinoma in Korea: a survey of the Korean Stereotactic Radiosurgery Group
Sun Hyun Bae, Mi-Sook Kim, Won Il Jang, Chul-Seung Kay, Woochul Kim, Eun Seog Kim, Jin Ho Kim, Jin Hee Kim, Kwang Mo Yang, Kyu Chan Lee, A Ram Chang, Sunmi Jo
Japanese Journal of Clinical Oncology.2016; 46(4): 363. CrossRef
Radiotherapy in the multidisciplinary treatment of liver cancer: a survey on behalf of the Italian Association of Radiation Oncology
Francesco Dionisi, Alessia Guarneri, Veronica Dell’Acqua, Mariacristina Leonardi, Rita Niespolo, Gabriella Macchia, Tiziana Comito, Maurizio Amichetti, Pierfrancesco Franco, Savino Cilla, Luciana Caravatta, Filippo Alongi, Giovanna Mantello
La radiologia medica.2016; 121(9): 735. CrossRef

13,774 View
101 Download
11 Web of Science
9 Crossref

Is Prophylactic Irradiation to Para-aortic Lymph Nodes in Locally Advanced Cervical Cancer Necessary?: Seung Gyu Park, Jin Hee Kim, Young Kee Oh, Sang Jun Byun, Mi Young Kim, Sang Hoon Kwon, Ok Bae Kim; Cancer Res Treat. 2014;46(4):374-382. Published online July 21, 2014; DOI: https://doi.org/10.4143/crt.2013.084

Abstract PDF PubReader ePub

Purpose
This study evaluated the efficacy of extended field irradiation (EFI) in patients with locally advanced cervical cancer without para-aortic nodal involvement.
Materials and Methods
A total of 203 patients with locally advanced cervical cancer (International Federation of Gynecology and Obstetrics [FIGO] stage, IB2-IIIB) treated with radiotherapy at Keimyung University Dongsan Medical Center from 1996 to 2010 were retrospectively analyzed. The median patient age was 59 years (range, 29 to 83 years). None of the patients had para-aortic node metastases. Of the 203 patients, 88 underwent EFI and 115 underwent irradiation of the pelvis only. Concurrent chemoradiotherapy (CCRT) was administered to 133 patients. EFI field was used for treatment of 26 patients who received radiotherapy alone and 62 who received CCRT.
Results
The median follow-up period was 60 months. The 2- and 5-year overall survival (OS) rates were 87.8% and 73.5%, respectively, and the 2- and 5-year disease-free survival rates were 81.7% and 75.0%, respectively, however, no survival differences were observed between the two treatment field groups. EFI tended to increase OS in the radiotherapy alone group, but not in the CCRT group.
Conclusion
These findings suggest that EFI does not have a significant effect in patients with locally advanced cervical cancer, especially in patients receiving CCRT. Conduct of additional studies will be required in order to confirm these findings.

Citations

Citations to this article as recorded by

Clinical analysis of prophylactic para-aortic intensity-modulated radiation in cervical cancer
G. Jin, K. Li, S. Niu, S. Liu, Q. Zhang, X. Fan
Clinical Radiology.2023; 78(2): e77. CrossRef
Combined modality management of advanced cervical cancer including novel sensitizers
Michelle Tseng, Natalie YL Ngoi, David SP Tan, Pearl SY Tong
International Journal of Gynecological Cancer.2022; 32(3): 246. CrossRef
The best postoperative adjuvant therapy for patients with early stage cervical adenosquamous carcinoma
Yawen Liu, Haiyan Tu, Lingling Zhang, Meiling Zhong, Yanan Wang, Ling Li, Xiaojun Xiang
BMC Women's Health.2022;[Epub] CrossRef
The impact of para-aortic lymph node irradiation on disease-free survival in patients with cervical cancer: A systematic review and meta-analysis
Leslie J.H. Bukkems, Ina M. Jürgenliemk-Schulz, Femke van der Leij, Max Peters, Cornelis G. Gerestein, Ronald P. Zweemer, Peter S.N. van Rossum
Clinical and Translational Radiation Oncology.2022; 35: 97. CrossRef
Clinical impact of extended field radiation therapy in Stage III carcinoma cervix versus conventional field techniques
Prateek Daga, H. S. Kumar, Neeti Sharma, Shankar Lal Jakhar, Kamlesh Kumar Harsh, Saroj Dhaka
Journal of Cancer Research and Therapeutics.2022; 18(4): 1083. CrossRef
Patterns of definitive radiotherapy practice for cervical cancer in South Korea: a survey endorsed by the Korean Radiation Oncology Group (KROG 20-06)
Nalee Kim, Won Park
Journal of Gynecologic Oncology.2021;[Epub] CrossRef
Risk factors for nodal failure after radiochemotherapy and image guided brachytherapy in locally advanced cervical cancer: An EMBRACE analysis
Max Peters, Astrid A.C. de Leeuw, Christel N. Nomden, Kari Tanderup, Kathrin Kirchheiner, Jacob C. Lindegaard, Christian Kirisits, Christine Haie-Meder, Alina Sturdza, Lars Fokdal, Umesh Mahantshetty, Peter Hoskin, Barbara Segedin, Kjersti Bruheim, Bhavan
Radiotherapy and Oncology.2021; 163: 150. CrossRef
Higher Dose to Organs at Risk: The Unintended Consequences of Intravenous Contrast Use in Computed Tomography Simulation for Cervical Cancer
Dunhuang Wang, Bo Yang, Weiping Wang, Xiaoliang Liu, Yongguang Liang, Shuai Sun, Jiabin Ma, Bing Zhou, Ke Hu, Fuquan Zhang
Practical Radiation Oncology.2021; 11(6): 534. CrossRef
Lymphocytopenia and Radiotherapy Treatment Volumes in the Time of COVID-19
N. Joseph, A. Choudhury
Clinical Oncology.2020; 32(7): 420. CrossRef
Prophylactic Extended-Field Irradiation in Patients With Cervical Cancer: A Literature Review
Weiping Wang, Yuncan Zhou, Dunhuang Wang, Ke Hu, Fuquan Zhang
Frontiers in Oncology.2020;[Epub] CrossRef
Nomogram for predicting para-aortic lymph node metastases in patients with cervical cancer
Weiping Wang, Xiaoliang Liu, Qingyu Meng, Fuquan Zhang, Ke Hu
Archives of Gynecology and Obstetrics.2018; 298(2): 381. CrossRef
Prophylactic Extended-Field Irradiation for Patients With Cervical Cancer Treated With Concurrent Chemoradiotherapy: A Propensity-Score Matching Analysis
Weiping Wang, Xiaoliang Liu, Qingyu Meng, Fuquan Zhang, Ke Hu
International Journal of Gynecologic Cancer.2018; 28(8): 1584. CrossRef
The role of para-aortic nodal irradiation in cervical cancer
Adela Poitevin Chacón, Jessica Chavez-Nogueda, Rubí Ramos-Prudencio, Michelle Aline Villavicencio-Queijeiro, Francisco Lozano-Ruiz
Reports of Practical Oncology & Radiotherapy.2018; 23(6): 540. CrossRef
Management of Para-aortic Lymph Node Disease in Patients With Cervical Cancer What Is the Best Approach?
Marcelo Vailati Negrao, Julianne Maria da Silva Lima, Samantha Cabral Severino Silva, Maria Del Pilar Estevez Diz, Vanessa da Costa Miranda
International Journal of Gynecological Cancer.2017; 27(3): 543. CrossRef
Prophylactic extended-field irradiation with concurrent chemotherapy for pelvic lymph node-positive cervical cancer
Jinju Oh, Ki Ho Seol, Hyun Joo Lee, Youn Seok Choi, Ji Y. Park, Jin Young Bae
Radiation Oncology Journal.2017; 35(4): 349. CrossRef
Impact of primary para-aortic lymphadenectomy on distant failure in locally advanced cervical cancer patients treated in the era of image-guided adaptive brachytherapy
Cyrus Chargari, Renaud Mazeron, Ariane Dunant, Sébastien Gouy, Claire Petit, Pierre Maroun, Catherine Uzan, Pierre Annede, Enrica Bentivegna, Corinne Balleyguier, Catherine Genestie, Patricia Pautier, Alexandra Leary, Catherine Lhomme, Eric Deutsch, Phili
Clinical & Experimental Metastasis.2016; 33(8): 775. CrossRef
Optimal Extent of Prophylactic Irradiation of Paraaortic Lymph Nodes in Patients with Uterine Cervical Cancer
Jinhyun Choi, Hong In Yoon, Jeongshim Lee, Ki Chang Keum, Gwi Eon Kim, Yong Bae Kim, Ruby John Anto
PLOS ONE.2015; 10(12): e0145158. CrossRef

13,354 View
110 Download
17 Crossref

Multicenter Validation Study of a Prognostic Index for Portal Vein Tumor Thrombosis in Hepatocellular Carcinoma: Jeong Il Yu, Sang Min Yoon, Hee Chul Park, Jong Hoon Kim, Tae Hyun Kim, Joong-Won Park, Jinsil Seong, Ik Jae Lee, Hong Seok Jang, Chul Seung Kay, Chul Yong Kim, Eui Kyu Chie, Jin Hee Kim, Mi-Sook Kim, Young Min Choi; Cancer Res Treat. 2014;46(4):348-357. Published online July 16, 2014; DOI: https://doi.org/10.4143/crt.2013.142

Abstract PDF PubReader ePub

Purpose
We previously reported on a staging system and prognostic index (PITH) for portal vein tumor thrombosis (PVTT) in hepatocellular carcinoma (HCC) patients treated with radiotherapy (RT) at a single institution. The aim of this study is to validate the PITH staging system using data from patients at other institutions and to compare it with other published staging systems. Materials and Methods A total of 994 HCC patients with PVTT who were treated with RT between 1998 and 2011 by the Korean Radiation Oncology Group were analyzed retrospectively. All patients were staged using the Cancer of the Liver Italian Program (CLIP), Japanese Integrated Staging (JIS), Okuda, and PITH staging systems, and survival data were analyzed. The likelihood ratio, Akaike information criteria (AIC), time-dependent receiver operating characteristics, and prediction error curve analysis were used to determine discriminatory ability for comparison of staging systems. Results The median survival was 9.2 months. Compared with the other staging systems, the PITH score gave the highest values for likelihood ratio and lowest AIC values, demonstrating that PITH may be a better prognostic model. Although the values were not significant and differences were not exceptional, the PITH score showed slightly better performance with respect to time-dependent area under curve and integrated Brier score of prediction error curve. Conclusion The PITH staging system was validated in this multicenter retrospective study and showed better stratification ability in HCC patients with PVTT than other systems.

Citations

Citations to this article as recorded by

Efficacy and safety of radiotherapy combined with atezolizumab plus bevacizumab in treating hepatocellular carcinoma with portal vein tumour thrombus: a study protocol
Kang Wang, Hong-Ming Yu, Yan-Jun Xiang, Yu-Qiang Cheng, Qian-Zhi Ni, Wei-Xing Guo, Jie Shi, Shuang Feng, Jian Zhai, Shu-Qun Cheng
BMJ Open.2022; 12(12): e064688. CrossRef
Comparison of Transcatheter Arterial Chemoembolization-Radiofrequency Ablation and Transcatheter Arterial Chemoembolization Alone for Advanced Hepatocellular Carcinoma with Macrovascular Invasion Using Propensity Score Analysis: A Retrospective Cohort Stu
Yao Liu, Yuxin Li, Fangyuan Gao, Qun Zhang, Xue Yang, Bingbing Zhu, Shuaishuai Niu, Yunyi Huang, Ying Hu, Wei Li, Xianbo Wang
Journal of Oncology.2020; 2020: 1. CrossRef
2018 Korean Liver Cancer Association–National Cancer Center Korea Practice Guidelines for the Management of Hepatocellular Carcinoma
KLCA Korean Liver Cancer Association, NCC National Cancer Center
Gut and Liver.2019; 13(3): 227. CrossRef
2018 Korean Liver Cancer Association–National Cancer Center Korea Practice Guidelines for the Management of Hepatocellular Carcinoma

Korean Journal of Radiology.2019; 20(7): 1042. CrossRef
Outcome of transarterial chemoembolization in Egyptian patients with hepatocellular carcinoma and branch portal vein thrombosis
H. Abdella, M. K. Shaker, Iman Fawzy Montasser, M. Sobhi, H. Aly, A. Sayed, S. Saleh, A. El Dorry
Indian Journal of Gastroenterology.2018; 37(2): 127. CrossRef
Strategic application of radiotherapy for hepatocellular carcinoma
Seo Hee Choi, Jinsil Seong
Clinical and Molecular Hepatology.2018; 24(2): 114. CrossRef
Proton therapy for hepatocellular carcinoma: Current knowledges and future perspectives
Gyu Sang Yoo, Jeong Il Yu, Hee Chul Park
World Journal of Gastroenterology.2018; 24(28): 3090. CrossRef
Radiotherapy as valid modality for hepatocellular carcinoma with portal vein tumor thrombosis
Jeong Il Yu, Hee Chul Park
World Journal of Gastroenterology.2016; 22(30): 6851. CrossRef
Radiotherapy for liver tumors
Florence K Keane, Shyam K Tanguturi, Andrew X Zhu, Laura A Dawson, Theodore S Hong
Hepatic Oncology.2015; 2(2): 133. CrossRef
New perspectives on the management of hepatocellular carcinoma with portal vein thrombosis
Hyun Young Woo, Jeong Heo
Clinical and Molecular Hepatology.2015; 21(2): 115. CrossRef
Current management of hepatocellular carcinoma: An Eastern perspective
Hyung Joon Yim
World Journal of Gastroenterology.2015; 21(13): 3826. CrossRef
Portal vein thrombosis: What is new?
María del Carmen Manzano-Robleda, Beatriz Barranco-Fragoso, Misael Uribe, Nahum Méndez-Sánchez
Annals of Hepatology.2015; 14(1): 20. CrossRef

14,225 View
72 Download
12 Web of Science
12 Crossref

Outcome of Local Excision Following Preoperative Chemoradiotherapy for Clinically T2 Distal Rectal Cancer: A Multicenter Retrospective Study (KROG 12-06): Jae Myoung Noh, Won Park, Jae-Sung Kim, Woong Sub Koom, Jin Hee Kim, Doo Ho Choi, Hee Chul Park; Cancer Res Treat. 2014;46(3):243-249. Published online July 15, 2014; DOI: https://doi.org/10.4143/crt.2014.46.3.243

Abstract PDF PubReader ePub

Purpose
The aim of this study was to examine the clinical implications of a pathologically complete response after neoadjuvant chemoradiotherapy (CRT) followed by local excision for patients with cT2 rectal cancer who refused radical surgery. Materials and Methods Seventeen patients with cT2 primary rectal cancer within 6 cm from the anal verge who received neoadjuvant CRT and local excision because of patient refusal of radical surgery or poor performance status were included. Two patients had clinical involvement of a regional lymph node. Preoperative radiotherapy was delivered to the whole pelvis at a dose of 44 to 50.4 Gy in 22 to 28 fractions. All patients underwent transanal excision and eight patients (47%) received postoperative chemotherapy. Results Ten patients (59%) achieved ypT0. At a median follow-up period of 75 months (range, 22 to 126 months), four (24%) patients developed recurrence (two locoregional and two distant). The 5-year disease-free survival of all patients was 82%, and was higher in patients with ypT0 (90%) than in patients with ypT1-2 (69%, p=0.1643). Decreased disease-free survival was also observed in patients receiving capecitabine compared with 5-fluorouracil (54% vs. 100%, p=0.0298). Conclusion Local excision could be a feasible alternative to radical surgery in patients with ypT0 after neoadjuvant CRT for cT2 distal rectal cancer without further radical surgery.

Citations

Citations to this article as recorded by

Towards personalized treatment of T2N0 rectal cancer: A systematic review of long‐term oncological outcomes of neoadjuvant therapy followed by local excision
Roberto Peltrini, Nicola Imperatore, Maria Michela Di Nuzzo, Gianluca Pellino
Journal of Gastroenterology and Hepatology.2022; 37(8): 1426. CrossRef
Preoperative concurrent chemoradiotherapy MRI characteristics favouring pathologic complete response in patients with rectal cancer: Usefulness of MR T2‐stage as an ancillary finding for predicting pathologic complete response
Hyeon Jin Lee, Woo‐Suk Chung, Ji hae An, Jung Hoon Kim
Journal of Medical Imaging and Radiation Oncology.2021; 65(2): 166. CrossRef
MR prediction of pathologic complete response and early-stage rectal cancer after neoadjuvant chemoradiation in patients with clinical T1/T2 rectal cancer for organ saving strategy
Heejin Bae, Nieun Seo, Kyunghwa Han, Woong Sub Koom, Myeong-Jin Kim, Nam Kyu Kim, Joon Seok Lim
Medicine.2020; 99(42): e22746. CrossRef
Does total regression of primary rectal cancer after preoperative chemoradiotherapy represent “no tumor” status?
Seong-A Jeong, In Ja Park, Seung Mo Hong, Jun Woo Bong, Hye Yoon Choi, Ji Hyun Seo, Hyong Eun Kim, Seok-Byung Lim, Chang Sik Yu, Jin Cheon Kim
Annals of Surgical Treatment and Research.2019; 96(2): 78. CrossRef
Neoadjuvant chemoradiation followed by transanal local excision for T2 rectal cancer confers equivalent survival benefit as traditional transabdominal resection
Oliver K. Jawitz, Mohamed A. Adam, Megan C. Turner, Brian F. Gilmore, John Migaly
Surgery.2019; 165(6): 1193. CrossRef
Status for clinically complete remission rectal cancer after concomitant chemo-radiotherapy in Taiwan
Geng-Ping Lin, Kuan-Der Lee, Jeng-Yi Wang, Jinn-Shiun Chen, Chun-Ju Chiang, Chien-Yuh Yeh
Asian Journal of Surgery.2018; 41(3): 203. CrossRef
Watch-and-Wait as a Therapeutic Strategy in Rectal Cancer
Laurence Bernier, Svetlana Balyasnikova, Diana Tait, Gina Brown
Current Colorectal Cancer Reports.2018; 14(2): 37. CrossRef
Total Mesorectal Excision Versus Local Excision After Preoperative Chemoradiotherapy in Rectal Cancer With Lymph Node Metastasis: A Propensity Score–Matched Analysis
Young Seob Shin, Jin-hong Park, Sang Min Yoon, Jin Cheon Kim, Chang Sik Yu, Seok-Byung Lim, In Ja Park, Tae Won Kim, Yong Sang Hong, Kyu-pyo Kim, Eun Kyung Choi, Seung Do Ahn, Sang-Wook Lee, Jong Hoon Kim
International Journal of Radiation Oncology*Biology*Physics.2018; 101(3): 630. CrossRef
Are We Predicting Disease Progress of the Rectal Cancer Patients without Surgery after Neoadjuvant Chemoradiotherapy?
Bo Young Oh, Jung Wook Huh, Woo Yong Lee, Yoon Ah Park, Yong Beom Cho, Seong Hyeon Yun, Hee Cheol Kim, Ho-Kyung Chun
Cancer Research and Treatment.2018; 50(3): 634. CrossRef
Local Excision Techniques for Rectal Cancer After Neoadjuvant Chemoradiotherapy: What Are We Doing?
Fraser McLean Smith, Abdul Ahad, Rodrigo Oliva Perez, John Marks, Krzysztof Bujko, Richard J. Heald
Diseases of the Colon & Rectum.2017; 60(2): 228. CrossRef
Transanal Minimally Invasive Surgery: Review of Indications and Outcomes from 75 Consecutive Patients
Deborah S. Keller, Reena N. Tahilramani, Juan R. Flores-Gonzalez, Ali Mahmood, Eric M. Haas
Journal of the American College of Surgeons.2016; 222(5): 814. CrossRef
Lymphknotenmetastasen beim ypT1/2-Rektumkarzinom nach neoadjuvanter Radiochemotherapie
T. Sprenger, H. Rothe, T. Beissbarth, L.-C. Conradi, A. Kauffels, K. Homayounfar, C. L. Behnes, C. Rödel, T. Liersch, M. Ghadimi
Der Chirurg.2016; 87(7): 593. CrossRef
Oncologic Safety of Local Excision Compared With Total Mesorectal Excision for ypT0-T1 Rectal Cancer
Sung Min Jung, Chang Sik Yu, In Ja Park, Tae Won Kim, Jong Hoon Kim, Yong Sik Yoon, Seok-Byung Lim, Jin Cheon Kim
Medicine.2016; 95(20): e3718. CrossRef
A Systematic Review of Local Excision After Neoadjuvant Therapy for Rectal Cancer: Are ypT0 Tumors the Limit?
Sally Hallam, David E. Messenger, Michael G. Thomas
Diseases of the Colon & Rectum.2016; 59(10): 984. CrossRef
Preoperative chemoradiotherapy followed by local excision in clinical T2N0 rectal cancer
Young Seob Shin, Yong sik Yoon, Seok-Byung Lim, Chang Sik Yu, Tae Won Kim, Heung Moon Chang, Jin-hong Park, Seung Do Ahn, Sang-Wook Lee, Eun Kyung Choi, Jin Cheon Kim, Jong Hoon Kim
Radiation Oncology Journal.2016; 34(3): 177. CrossRef
Why the Conventional Parks Transanal Excision for Early Stage Rectal Cancer Should Be Abandoned
Sam Atallah, Deborah Keller
Diseases of the Colon & Rectum.2015; 58(12): 1211. CrossRef
Influence of Preoperative Chemoradiotherapy on the Surgical Strategy According to the Clinical T Stage of Patients With Rectal Cancer
In Ja Park, Jong Lyul Lee, Yong Sik Yoon, Chan Wook Kim, Seok-Byung Lim, Jong Seok Lee, Seong Ho Park, Jin Hong Park, Jong Hoon Kim, Chang Sik Yu, Jin Cheon Kim
Medicine.2015; 94(52): e2377. CrossRef
Implications for selecting local excision in locally advanced rectal cancer after preoperative chemoradiation
Juefeng Wan, Kaitai Liu, Ji Zhu, Guichao Li, Zhen Zhang
Oncotarget.2015; 6(13): 11714. CrossRef
Prediction of pathologic staging with magnetic resonance imaging after preoperative chemoradiotherapy in rectal cancer: Pooled analysis of KROG 10-01 and 11-02
Jong Hoon Lee, Hong Seok Jang, Jun-Gi Kim, Myung Ah Lee, Dae Yong Kim, Tae Hyun Kim, Jae Hwan Oh, Sung Chan Park, Sun Young Kim, Ji Yeon Baek, Hee Chul Park, Hee Cheol Kim, Taek-Keun Nam, Eui Kyu Chie, Ji-Han Jung, Seong Taek Oh
Radiotherapy and Oncology.2014; 113(1): 18. CrossRef

12,875 View
75 Download
20 Web of Science
19 Crossref

Interval between Surgery and Radiation Therapy Is an Important Prognostic Factor in Treatment of Rectal Cancer: Jin Hee Kim, Sang Jun Byun, Seung Gyu Park, Young Kee Oh, Seong Kyu Baek; Cancer Res Treat. 2012;44(3):187-194. Published online September 30, 2012; DOI: https://doi.org/10.4143/crt.2012.44.3.187

Abstract PDF PubReader ePub

PURPOSE
The purpose of this study is to evaluate survival and prognostic factors for rectal cancer, including interval between surgery and radiation therapy after surgery, radiation therapy, and chemotherapy.
MATERIALS AND METHODS
We conducted a retrospective study of 153 patients with rectal cancer who were treated with surgery, radiotherapy with/without chemotherapy at Keimyung University Dongsan Medical Center from January, 1988 to December, 2005. The study included 89 males and 64 females, with a median age of 56 years (range, 23 to 81 years). Tumor, node and metastasis (TNM) was I in 23 patients, II in 39, and III in 91. Radiation therapy was performed on pelvic fields using a median dose of 54 Gy five days per week, 1.8 Gy once per day. Ninety two patients were treated with radiotherapy, 43 with concurrent chemo-radiation therapy and 18 with sequential therapy after surgery. The median follow-up period was 52 months (range, 4 to 272 months). The interval between surgery and radiation was 1-25 weeks (median, 5 weeks).
RESULTS
Two-year and five-year overall survival rate was 64.7% and 46.4%, respectively. Two-year and five-year disease-free-survival (DFS) rate was 58.6% and 43.1%, respectively. Median DFS was 39 months. Loco-regional failure was evident in 10.5% of patients, 8.4% had distant metastasis, and 9.2% had both. In multivariate analysis, TNM stage and interval between surgery and radiation therapy (< or =5 weeks vs. >5 weeks; 95% confidence interval, 1.276 to 2.877; hazard ratio, 1.916; p=0.002) were significant prognostic factors of DFS.
CONCLUSION
Survival rates for rectal cancer after surgery, chemotherapy, and radiation therapy were similar to those reported in previous studies. Starting radiation therapy as soon as possible after surgery, especially within the first five weeks after surgery, is suggested.

Citations

Citations to this article as recorded by

Integration of O2-economised tumour-targeted photosensitive magnetic nanomaterials in the diagnosis and therapy of gastric cancer
JinRong Situ, Yingying Yang, Lingle Zhang, Hongzhang Yan, Yingsheng Cheng
RSC Advances.2024; 14(14): 9920. CrossRef
Deeper insights into long-term survival heterogeneity of pancreatic ductal adenocarcinoma (PDAC) patients using integrative individual- and group-level transcriptome network analyses
Archana Bhardwaj, Claire Josse, Daniel Van Daele, Christophe Poulet, Marcela Chavez, Ingrid Struman, Kristel Van Steen
Scientific Reports.2022;[Epub] CrossRef
Gallic acid suppresses the progression of triple-negative breast cancer HCC1806 cells via modulating PI3K/AKT/EGFR and MAPK signaling pathways
Si Lin, Hui-Zhen Qin, Ze-Yu Li, Hua Zhu, Li Long, Li-Ba Xu
Frontiers in Pharmacology.2022;[Epub] CrossRef
MSCs-engineered biomimetic PMAA nanomedicines for multiple bioimaging-guided and photothermal-enhanced radiotherapy of NSCLC
Yipengchen Yin, Yongjing Li, Sheng Wang, Ziliang Dong, Chao Liang, Jiaxin Sun, Changchun Wang, Rong Chai, Weiwei Fei, Jianping Zhang, Ming Qi, Liangzhu Feng, Qin Zhang
Journal of Nanobiotechnology.2021;[Epub] CrossRef
Modification of inorganic porous materials as gene vectors: an overview
Feng Guo Liu, Li Zhi Zhao, Ning An, Dong Shen Tong, Wei Hua Yu, Chun Hui Zhou
Journal of Porous Materials.2015; 22(4): 927. CrossRef

11,092 View
55 Download
5 Crossref

First
Prev
Page of 2
Next
Last

Search